id	sid	tid	token	lemma	pos
fnp-3395	1	1	sars	sar	NOUN
fnp-3395	1	2	-	-	PUNCT
fnp-3395	1	3	cov-2	cov-2	PART
fnp-3395	1	4	vaccination	vaccination	NOUN
fnp-3395	1	5	induced	induce	VERB
fnp-3395	1	6	cerebral	cerebral	ADJ
fnp-3395	1	7	venous	venous	ADJ
fnp-3395	1	8	sinus	sinus	NOUN
fnp-3395	1	9	thrombosis	thrombosis	NOUN
fnp-3395	1	10	:	:	PUNCT
fnp-3395	1	11	do	do	AUX
fnp-3395	1	12	megakaryocytes	megakaryocyte	NOUN
fnp-3395	1	13	,	,	PUNCT
fnp-3395	1	14	platelets	platelet	NOUN
fnp-3395	1	15	and	and	CCONJ
fnp-3395	1	16	lipid	lipid	NOUN
fnp-3395	1	17	mediators	mediator	NOUN
fnp-3395	1	18	make	make	VERB
fnp-3395	1	19	up	up	ADP
fnp-3395	1	20	the	the	DET
fnp-3395	1	21	orchestra	orchestra	NOUN
fnp-3395	1	22	?	?	PUNCT
fnp-3395	2	1	feel	feel	VERB
fnp-3395	2	2	free	free	ADJ
fnp-3395	2	3	to	to	PART
fnp-3395	2	4	add	add	VERB
fnp-3395	2	5	comments	comment	NOUN
fnp-3395	2	6	by	by	ADP
fnp-3395	2	7	clicking	click	VERB
fnp-3395	2	8	these	these	DET
fnp-3395	2	9	icons	icon	NOUN
fnp-3395	2	10	on	on	ADP
fnp-3395	2	11	the	the	DET
fnp-3395	2	12	sidebar	sidebar	NOUN
fnp-3395	2	13	free	free	ADJ
fnp-3395	2	14	neuropathology	neuropathology	NOUN
fnp-3395	2	15	2:18	2:18	NUM
fnp-3395	2	16	(	(	PUNCT
fnp-3395	2	17	2021	2021	NUM
fnp-3395	2	18	)	)	PUNCT
fnp-3395	2	19	opinion	opinion	NOUN
fnp-3395	2	20	piece	piece	NOUN
fnp-3395	2	21	sars	sar	NOUN
fnp-3395	2	22	-	-	PUNCT
fnp-3395	2	23	cov-2	cov-2	PART
fnp-3395	2	24	vaccination	vaccination	NOUN
fnp-3395	2	25	induced	induce	VERB
fnp-3395	2	26	cerebral	cerebral	ADJ
fnp-3395	2	27	venous	venous	ADJ
fnp-3395	2	28	sinus	sinus	NOUN
fnp-3395	2	29	thrombosis	thrombosis	NOUN
fnp-3395	2	30	:	:	PUNCT
fnp-3395	2	31	do	do	AUX
fnp-3395	2	32	megakaryocytes	megakaryocyte	NOUN
fnp-3395	2	33	,	,	PUNCT
fnp-3395	2	34	platelets	platelet	NOUN
fnp-3395	2	35	and	and	CCONJ
fnp-3395	2	36	lipid	lipid	NOUN
fnp-3395	2	37	mediators	mediator	NOUN
fnp-3395	2	38	make	make	VERB
fnp-3395	2	39	up	up	ADP
fnp-3395	2	40	the	the	DET
fnp-3395	2	41	orchestra	orchestra	NOUN
fnp-3395	2	42	?	?	PUNCT
fnp-3395	3	1	kate	kate	PROPN
fnp-3395	3	2	chander	chander	PROPN
fnp-3395	3	3	chiang1	chiang1	PROPN
fnp-3395	3	4	,	,	PUNCT
fnp-3395	3	5	ravi	ravi	PROPN
fnp-3395	3	6	raghavan2	raghavan2	PROPN
fnp-3395	3	7	,	,	PUNCT
fnp-3395	3	8	ajay	ajay	PROPN
fnp-3395	3	9	gupta1,3	gupta1,3	PROPN
fnp-3395	3	10	1	1	NUM
fnp-3395	3	11	kare	kare	PROPN
fnp-3395	3	12	biosciences	bioscience	NOUN
fnp-3395	3	13	,	,	PUNCT
fnp-3395	3	14	orange	orange	PROPN
fnp-3395	3	15	,	,	PUNCT
fnp-3395	3	16	ca	ca	NOUN
fnp-3395	3	17	92869	92869	NUM
fnp-3395	3	18	,	,	PUNCT
fnp-3395	3	19	usa	usa	PROPN
fnp-3395	3	20	2	2	NUM
fnp-3395	3	21	department	department	NOUN
fnp-3395	3	22	of	of	ADP
fnp-3395	3	23	pathology	pathology	PROPN
fnp-3395	3	24	,	,	PUNCT
fnp-3395	3	25	loma	loma	PROPN
fnp-3395	3	26	linda	linda	PROPN
fnp-3395	3	27	university	university	PROPN
fnp-3395	3	28	medical	medical	ADJ
fnp-3395	3	29	center	center	NOUN
fnp-3395	3	30	,	,	PUNCT
fnp-3395	3	31	loma	loma	PROPN
fnp-3395	3	32	linda	linda	PROPN
fnp-3395	3	33	,	,	PUNCT
fnp-3395	3	34	ca	ca	PROPN
fnp-3395	3	35	92354	92354	NUM
fnp-3395	3	36	,	,	PUNCT
fnp-3395	3	37	usa	usa	PROPN
fnp-3395	3	38	3	3	NUM
fnp-3395	3	39	department	department	NOUN
fnp-3395	3	40	of	of	ADP
fnp-3395	3	41	medicine	medicine	NOUN
fnp-3395	3	42	,	,	PUNCT
fnp-3395	3	43	university	university	PROPN
fnp-3395	3	44	of	of	ADP
fnp-3395	3	45	california	california	PROPN
fnp-3395	3	46	irvine	irvine	PROPN
fnp-3395	3	47	(	(	PUNCT
fnp-3395	3	48	uci	uci	PROPN
fnp-3395	3	49	)	)	PUNCT
fnp-3395	3	50	school	school	NOUN
fnp-3395	3	51	of	of	ADP
fnp-3395	3	52	medicine	medicine	NOUN
fnp-3395	3	53	,	,	PUNCT
fnp-3395	3	54	orange	orange	PROPN
fnp-3395	3	55	,	,	PUNCT
fnp-3395	3	56	ca	ca	NOUN
fnp-3395	3	57	92868	92868	NUM
fnp-3395	3	58	,	,	PUNCT
fnp-3395	3	59	usa	usa	PROPN
fnp-3395	3	60	corresponding	corresponding	PROPN
fnp-3395	3	61	author	author	NOUN
fnp-3395	3	62	:	:	PUNCT
fnp-3395	3	63	ajay	ajay	PROPN
fnp-3395	3	64	gupta	gupta	PROPN
fnp-3395	3	65	·	·	PUNCT
fnp-3395	3	66	division	division	NOUN
fnp-3395	3	67	of	of	ADP
fnp-3395	3	68	nephrology	nephrology	NOUN
fnp-3395	3	69	,	,	PUNCT
fnp-3395	3	70	hypertension	hypertension	NOUN
fnp-3395	3	71	and	and	CCONJ
fnp-3395	3	72	kidney	kidney	NOUN
fnp-3395	3	73	transplantation	transplantation	NOUN
fnp-3395	3	74	·	·	PUNCT
fnp-3395	3	75	university	university	NOUN
fnp-3395	3	76	of	of	ADP
fnp-3395	3	77	california	california	PROPN
fnp-3395	3	78	irvine	irvine	PROPN
fnp-3395	3	79	(	(	PUNCT
fnp-3395	3	80	uci	uci	PROPN
fnp-3395	3	81	)	)	PUNCT
fnp-3395	3	82	school	school	NOUN
fnp-3395	3	83	of	of	ADP
fnp-3395	3	84	medicine	medicine	NOUN
fnp-3395	3	85	·	·	PUNCT
fnp-3395	4	1	orange	orange	PROPN
fnp-3395	4	2	,	,	PUNCT
fnp-3395	4	3	ca	can	AUX
fnp-3395	4	4	92868	92868	NUM
fnp-3395	4	5	·	·	PUNCT
fnp-3395	4	6	usa	usa	PROPN
fnp-3395	4	7	ajayg1@hs.uci.edu	ajayg1@hs.uci.edu	PROPN
fnp-3395	4	8	submitted	submit	VERB
fnp-3395	4	9	:	:	PUNCT
fnp-3395	4	10	6	6	NUM
fnp-3395	4	11	june	june	PROPN
fnp-3395	4	12	2021	2021	NUM
fnp-3395	4	13	accepted	accept	VERB
fnp-3395	4	14	:	:	PUNCT
fnp-3395	4	15	1	1	NUM
fnp-3395	4	16	july	july	PROPN
fnp-3395	4	17	2021	2021	NUM
fnp-3395	4	18	copyedited	copyedit	VERB
fnp-3395	4	19	by	by	ADP
fnp-3395	4	20	:	:	PUNCT
fnp-3395	4	21	biswarathan	biswarathan	PROPN
fnp-3395	4	22	ramani	ramani	PROPN
fnp-3395	4	23	published	publish	VERB
fnp-3395	4	24	:	:	PUNCT
fnp-3395	5	1	7	7	NUM
fnp-3395	5	2	july	july	PROPN
fnp-3395	5	3	2021	2021	NUM
fnp-3395	5	4	https://doi.org/10.17879/freeneuropathology-2021-3395	https://doi.org/10.17879/freeneuropathology-2021-3395	PROPN
fnp-3395	5	5	keywords	keyword	NOUN
fnp-3395	5	6	:	:	PUNCT
fnp-3395	5	7	sars	sar	NOUN
fnp-3395	5	8	-	-	PUNCT
fnp-3395	5	9	cov-2	cov-2	NOUN
fnp-3395	5	10	,	,	PUNCT
fnp-3395	5	11	covid-19	covid-19	PROPN
fnp-3395	5	12	,	,	PUNCT
fnp-3395	5	13	vaccine	vaccine	NOUN
fnp-3395	5	14	,	,	PUNCT
fnp-3395	5	15	thrombosis	thrombosis	NOUN
fnp-3395	5	16	,	,	PUNCT
fnp-3395	5	17	cerebral	cerebral	ADJ
fnp-3395	5	18	venous	venous	ADJ
fnp-3395	5	19	sinus	sinus	NOUN
fnp-3395	5	20	thrombosis	thrombosis	NOUN
fnp-3395	5	21	,	,	PUNCT
fnp-3395	5	22	aspirin	aspirin	NOUN
fnp-3395	5	23	,	,	PUNCT
fnp-3395	5	24	thromboxane	thromboxane	NOUN
fnp-3395	5	25	,	,	PUNCT
fnp-3395	5	26	cox-2	cox-2	NOUN
fnp-3395	5	27	,	,	PUNCT
fnp-3395	5	28	adenoviral	adenoviral	ADJ
fnp-3395	5	29	vector	vector	NOUN
fnp-3395	5	30	,	,	PUNCT
fnp-3395	5	31	megakaryocyte	megakaryocyte	NOUN
fnp-3395	5	32	abstract	abstract	ADP
fnp-3395	5	33	the	the	DET
fnp-3395	5	34	covid-19	covid-19	PROPN
fnp-3395	5	35	vaccines	vaccine	NOUN
fnp-3395	5	36	comprised	comprise	VERB
fnp-3395	5	37	of	of	ADP
fnp-3395	5	38	adenoviral	adenoviral	ADJ
fnp-3395	5	39	vectors	vector	NOUN
fnp-3395	5	40	encoding	encode	VERB
fnp-3395	5	41	the	the	DET
fnp-3395	5	42	spike	spike	ADJ
fnp-3395	5	43	(	(	PUNCT
fnp-3395	5	44	s	s	NOUN
fnp-3395	5	45	)	)	PUNCT
fnp-3395	5	46	glycoprotein	glycoprotein	NOUN
fnp-3395	5	47	of	of	ADP
fnp-3395	5	48	sars	sar	NOUN
fnp-3395	5	49	-	-	PUNCT
fnp-3395	5	50	cov-2	cov-2	NOUN
fnp-3395	5	51	are	be	AUX
fnp-3395	5	52	highly	highly	ADV
fnp-3395	5	53	effective	effective	ADJ
fnp-3395	5	54	but	but	CCONJ
fnp-3395	5	55	associated	associate	VERB
fnp-3395	5	56	with	with	ADP
fnp-3395	5	57	rare	rare	ADJ
fnp-3395	5	58	thrombotic	thrombotic	ADJ
fnp-3395	5	59	complications	complication	NOUN
fnp-3395	5	60	.	.	PUNCT
fnp-3395	6	1	the	the	DET
fnp-3395	6	2	adenovirus	adenovirus	NOUN
fnp-3395	6	3	vector	vector	NOUN
fnp-3395	6	4	infects	infect	VERB
fnp-3395	6	5	epithelial	epithelial	ADJ
fnp-3395	6	6	cells	cell	NOUN
fnp-3395	6	7	expressing	express	VERB
fnp-3395	6	8	the	the	DET
fnp-3395	6	9	coxsackievirus	coxsackievirus	NOUN
fnp-3395	6	10	and	and	CCONJ
fnp-3395	6	11	adenovirus	adenovirus	NOUN
fnp-3395	6	12	receptor	receptor	NOUN
fnp-3395	6	13	(	(	PUNCT
fnp-3395	6	14	car	car	NOUN
fnp-3395	6	15	)	)	PUNCT
fnp-3395	6	16	.	.	PUNCT
fnp-3395	7	1	the	the	DET
fnp-3395	7	2	s	s	PART
fnp-3395	7	3	glycoprotein	glycoprotein	NOUN
fnp-3395	7	4	expressed	express	VERB
fnp-3395	7	5	locally	locally	ADV
fnp-3395	7	6	stimulates	stimulate	VERB
fnp-3395	7	7	neutralizing	neutralize	VERB
fnp-3395	7	8	antibody	antibody	NOUN
fnp-3395	7	9	and	and	CCONJ
fnp-3395	7	10	cellular	cellular	ADJ
fnp-3395	7	11	immune	immune	ADJ
fnp-3395	7	12	responses	response	NOUN
fnp-3395	7	13	.	.	PUNCT
fnp-3395	8	1	these	these	DET
fnp-3395	8	2	vaccines	vaccine	NOUN
fnp-3395	8	3	have	have	AUX
fnp-3395	8	4	been	be	AUX
fnp-3395	8	5	associated	associate	VERB
fnp-3395	8	6	with	with	ADP
fnp-3395	8	7	thromboembolic	thromboembolic	ADJ
fnp-3395	8	8	events	event	NOUN
fnp-3395	8	9	including	include	VERB
fnp-3395	8	10	cerebral	cerebral	ADJ
fnp-3395	8	11	venous	venous	ADJ
fnp-3395	8	12	sinus	sinus	NOUN
fnp-3395	8	13	thrombosis	thrombosis	NOUN
fnp-3395	8	14	(	(	PUNCT
fnp-3395	8	15	cvst	cvst	PROPN
fnp-3395	8	16	)	)	PUNCT
fnp-3395	8	17	.	.	PUNCT
fnp-3395	9	1	s	s	PART
fnp-3395	9	2	glycoprotein	glycoprotein	NOUN
fnp-3395	9	3	stimulates	stimulate	VERB
fnp-3395	9	4	the	the	DET
fnp-3395	9	5	expression	expression	NOUN
fnp-3395	9	6	of	of	ADP
fnp-3395	9	7	cyclooxygenase-2	cyclooxygenase-2	NUM
fnp-3395	9	8	(	(	PUNCT
fnp-3395	9	9	cox-2	cox-2	NOUN
fnp-3395	9	10	)	)	PUNCT
fnp-3395	9	11	and	and	CCONJ
fnp-3395	9	12	leads	lead	VERB
fnp-3395	9	13	to	to	ADP
fnp-3395	9	14	massive	massive	ADJ
fnp-3395	9	15	generation	generation	NOUN
fnp-3395	9	16	of	of	ADP
fnp-3395	9	17	thromboxane	thromboxane	NOUN
fnp-3395	9	18	a2	a2	PROPN
fnp-3395	9	19	in	in	ADP
fnp-3395	9	20	covid-19	covid-19	PROPN
fnp-3395	9	21	.	.	PUNCT
fnp-3395	10	1	megakaryocytes	megakaryocyte	NOUN
fnp-3395	10	2	express	express	VERB
fnp-3395	10	3	car	car	NOUN
fnp-3395	10	4	and	and	CCONJ
fnp-3395	10	5	we	we	PRON
fnp-3395	10	6	postulate	postulate	VERB
fnp-3395	10	7	that	that	PRON
fnp-3395	10	8	s	s	VERB
fnp-3395	10	9	glycoprotein	glycoprotein	NOUN
fnp-3395	10	10	stimulated	stimulate	VERB
fnp-3395	10	11	generation	generation	NOUN
fnp-3395	10	12	of	of	ADP
fnp-3395	10	13	thromboxane	thromboxane	NOUN
fnp-3395	10	14	a2	a2	PROPN
fnp-3395	10	15	leads	lead	VERB
fnp-3395	10	16	to	to	ADP
fnp-3395	10	17	megakaryocyte	megakaryocyte	NOUN
fnp-3395	10	18	activation	activation	NOUN
fnp-3395	10	19	,	,	PUNCT
fnp-3395	10	20	biogenesis	biogenesis	NOUN
fnp-3395	10	21	of	of	ADP
fnp-3395	10	22	activated	activate	VERB
fnp-3395	10	23	platelets	platelet	NOUN
fnp-3395	10	24	and	and	CCONJ
fnp-3395	10	25	thereby	thereby	ADV
fnp-3395	10	26	increased	increase	VERB
fnp-3395	10	27	thrombogenicity	thrombogenicity	NOUN
fnp-3395	10	28	.	.	PUNCT
fnp-3395	11	1	cerebral	cerebral	ADJ
fnp-3395	11	2	vein	vein	ADJ
fnp-3395	11	3	sinuses	sinus	NOUN
fnp-3395	11	4	express	express	VERB
fnp-3395	11	5	podoplanin	podoplanin	PROPN
fnp-3395	11	6	,	,	PUNCT
fnp-3395	11	7	a	a	DET
fnp-3395	11	8	natural	natural	ADJ
fnp-3395	11	9	ligand	ligand	NOUN
fnp-3395	11	10	for	for	ADP
fnp-3395	11	11	clec2	clec2	NOUN
fnp-3395	11	12	receptors	receptor	NOUN
fnp-3395	11	13	on	on	ADP
fnp-3395	11	14	platelets	platelet	NOUN
fnp-3395	11	15	.	.	PUNCT
fnp-3395	12	1	platelets	platelet	NOUN
fnp-3395	12	2	traversing	traverse	VERB
fnp-3395	12	3	through	through	ADP
fnp-3395	12	4	the	the	DET
fnp-3395	12	5	cerebral	cerebral	ADJ
fnp-3395	12	6	vein	vein	ADJ
fnp-3395	12	7	sinuses	sinus	NOUN
fnp-3395	12	8	could	could	AUX
fnp-3395	12	9	be	be	AUX
fnp-3395	12	10	further	far	ADV
fnp-3395	12	11	activated	activate	VERB
fnp-3395	12	12	by	by	ADP
fnp-3395	12	13	thromboxane	thromboxane	NOUN
fnp-3395	12	14	a2	a2	PROPN
fnp-3395	12	15	-	-	PUNCT
fnp-3395	12	16	dependent	dependent	ADJ
fnp-3395	12	17	podoplanin	podoplanin	PROPN
fnp-3395	12	18	-	-	PUNCT
fnp-3395	12	19	clec2	clec2	PROPN
fnp-3395	12	20	signaling	signaling	NOUN
fnp-3395	12	21	,	,	PUNCT
fnp-3395	12	22	leading	lead	VERB
fnp-3395	12	23	to	to	ADP
fnp-3395	12	24	cvst	cvst	PROPN
fnp-3395	12	25	.	.	PUNCT
fnp-3395	13	1	a	a	DET
fnp-3395	13	2	prothrombotic	prothrombotic	ADJ
fnp-3395	13	3	hormonal	hormonal	ADJ
fnp-3395	13	4	milieu	milieu	NOUN
fnp-3395	13	5	,	,	PUNCT
fnp-3395	13	6	and	and	CCONJ
fnp-3395	13	7	increased	increase	VERB
fnp-3395	13	8	generation	generation	NOUN
fnp-3395	13	9	of	of	ADP
fnp-3395	13	10	thromboxane	thromboxane	NOUN
fnp-3395	13	11	a2	a2	PROPN
fnp-3395	13	12	and	and	CCONJ
fnp-3395	13	13	platelet	platelet	NOUN
fnp-3395	13	14	activation	activation	NOUN
fnp-3395	13	15	in	in	ADP
fnp-3395	13	16	healthy	healthy	ADJ
fnp-3395	13	17	females	female	NOUN
fnp-3395	13	18	compared	compare	VERB
fnp-3395	13	19	to	to	ADP
fnp-3395	13	20	males	male	NOUN
fnp-3395	13	21	is	be	AUX
fnp-3395	13	22	consistent	consistent	ADJ
fnp-3395	13	23	with	with	ADP
fnp-3395	13	24	increased	increase	VERB
fnp-3395	13	25	risk	risk	NOUN
fnp-3395	13	26	for	for	ADP
fnp-3395	13	27	cvst	cvst	NOUN
fnp-3395	13	28	observed	observe	VERB
fnp-3395	13	29	in	in	ADP
fnp-3395	13	30	women	woman	NOUN
fnp-3395	13	31	.	.	PUNCT
fnp-3395	14	1	we	we	PRON
fnp-3395	14	2	propose	propose	VERB
fnp-3395	14	3	that	that	SCONJ
fnp-3395	14	4	antiplatelet	antiplatelet	NOUN
fnp-3395	14	5	agents	agent	NOUN
fnp-3395	14	6	targeting	target	VERB
fnp-3395	14	7	thromboxane	thromboxane	NOUN
fnp-3395	14	8	a2	a2	PROPN
fnp-3395	14	9	receptor	receptor	NOUN
fnp-3395	14	10	signaling	signal	VERB
fnp-3395	14	11	such	such	ADJ
fnp-3395	14	12	as	as	ADP
fnp-3395	14	13	low	low	ADV
fnp-3395	14	14	-	-	PUNCT
fnp-3395	14	15	dose	dose	NOUN
fnp-3395	14	16	aspirin	aspirin	NOUN
fnp-3395	14	17	merit	merit	NOUN
fnp-3395	14	18	consideration	consideration	NOUN
fnp-3395	14	19	for	for	ADP
fnp-3395	14	20	chemoprophylaxis	chemoprophylaxis	NOUN
fnp-3395	14	21	when	when	SCONJ
fnp-3395	14	22	administering	administer	VERB
fnp-3395	14	23	the	the	DET
fnp-3395	14	24	adenovirus	adenovirus	NOUN
fnp-3395	14	25	based	base	VERB
fnp-3395	14	26	covid-19	covid-19	PROPN
fnp-3395	14	27	vaccines	vaccine	NOUN
fnp-3395	14	28	to	to	ADP
fnp-3395	14	29	young	young	ADJ
fnp-3395	14	30	adults	adult	NOUN
fnp-3395	14	31	at	at	ADP
fnp-3395	14	32	risk	risk	NOUN
fnp-3395	14	33	of	of	ADP
fnp-3395	14	34	thrombosis	thrombosis	NOUN
fnp-3395	14	35	provided	provide	VERB
fnp-3395	14	36	there	there	PRON
fnp-3395	14	37	are	be	VERB
fnp-3395	14	38	no	no	DET
fnp-3395	14	39	contraindications	contraindication	NOUN
fnp-3395	14	40	.	.	PUNCT
fnp-3395	15	1	abbreviations	abbreviation	NOUN
fnp-3395	15	2	txa2	txa2	PROPN
fnp-3395	15	3	thromboxane	thromboxane	NOUN
fnp-3395	15	4	a2	a2	PROPN
fnp-3395	15	5	,	,	PUNCT
fnp-3395	15	6	dic	dic	PROPN
fnp-3395	15	7	disseminated	disseminate	VERB
fnp-3395	15	8	intravascular	intravascular	ADJ
fnp-3395	15	9	coagulopathy	coagulopathy	ADJ
fnp-3395	15	10	,	,	PUNCT
fnp-3395	15	11	cox	cox	PROPN
fnp-3395	15	12	cyclooxygenase	cyclooxygenase	PROPN
fnp-3395	15	13	,	,	PUNCT
fnp-3395	15	14	ttp	ttp	PROPN
fnp-3395	15	15	thrombotic	thrombotic	ADJ
fnp-3395	15	16	thrombocytopenic	thrombocytopenic	ADJ
fnp-3395	15	17	purpura	purpura	NOUN
fnp-3395	15	18	,	,	PUNCT
fnp-3395	15	19	cvst	cvst	PROPN
fnp-3395	15	20	cerebral	cerebral	ADJ
fnp-3395	15	21	venous	venous	ADJ
fnp-3395	15	22	sinus	sinus	NOUN
fnp-3395	15	23	thrombosis	thrombosis	NOUN
fnp-3395	15	24	,	,	PUNCT
fnp-3395	15	25	clec	clec	ADJ
fnp-3395	15	26	c	c	NOUN
fnp-3395	15	27	-	-	PUNCT
fnp-3395	15	28	type	type	NOUN
fnp-3395	15	29	lectin	lectin	NOUN
fnp-3395	15	30	-	-	PUNCT
fnp-3395	15	31	like	like	ADJ
fnp-3395	15	32	receptor	receptor	NOUN
fnp-3395	15	33	tlr	tlr	PROPN
fnp-3395	15	34	,	,	PUNCT
fnp-3395	15	35	toll	toll	NOUN
fnp-3395	15	36	-	-	PUNCT
fnp-3395	15	37	like	like	ADJ
fnp-3395	15	38	receptor	receptor	NOUN
fnp-3395	15	39	,	,	PUNCT
fnp-3395	15	40	car	car	NOUN
fnp-3395	15	41	coxsackievirus	coxsackievirus	NOUN
fnp-3395	15	42	and	and	CCONJ
fnp-3395	15	43	adenovirus	adenovirus	NOUN
fnp-3395	15	44	receptor	receptor	NOUN
fnp-3395	15	45	,	,	PUNCT
fnp-3395	15	46	covid-19	covid-19	PROPN
fnp-3395	15	47	coronavirus	coronavirus	NOUN
fnp-3395	15	48	disease	disease	NOUN
fnp-3395	15	49	2019	2019	NUM
fnp-3395	15	50	,	,	PUNCT
fnp-3395	15	51	sars	sar	NOUN
fnp-3395	15	52	-	-	PUNCT
fnp-3395	15	53	cov-2	cov-2	NOUN
fnp-3395	15	54	severe	severe	ADJ
fnp-3395	15	55	acute	acute	ADJ
fnp-3395	15	56	respiratory	respiratory	ADJ
fnp-3395	15	57	syndrome	syndrome	NOUN
fnp-3395	15	58	coronavirus	coronavirus	NOUN
fnp-3395	15	59	2	2	NUM
fnp-3395	15	60	,	,	PUNCT
fnp-3395	15	61	pf4	pf4	NOUN
fnp-3395	15	62	platelet	platelet	NOUN
fnp-3395	15	63	factor	factor	NOUN
fnp-3395	15	64	4	4	NUM
fnp-3395	15	65	introduction	introduction	NOUN
fnp-3395	15	66	covid-19	covid-19	PROPN
fnp-3395	15	67	disease	disease	NOUN
fnp-3395	15	68	is	be	AUX
fnp-3395	15	69	caused	cause	VERB
fnp-3395	15	70	by	by	ADP
fnp-3395	15	71	a	a	DET
fnp-3395	15	72	novel	novel	ADJ
fnp-3395	15	73	positive	positive	ADJ
fnp-3395	15	74	-	-	PUNCT
fnp-3395	15	75	strand	strand	NOUN
fnp-3395	15	76	rna	rna	NOUN
fnp-3395	15	77	coronavirus	coronavirus	NOUN
fnp-3395	15	78	(	(	PUNCT
fnp-3395	15	79	sars	sar	NOUN
fnp-3395	15	80	-	-	PUNCT
fnp-3395	15	81	cov-2	cov-2	NOUN
fnp-3395	15	82	)	)	PUNCT
fnp-3395	15	83	,	,	PUNCT
fnp-3395	15	84	which	which	PRON
fnp-3395	15	85	belongs	belong	VERB
fnp-3395	15	86	to	to	ADP
fnp-3395	15	87	the	the	DET
fnp-3395	15	88	coronaviridae	coronaviridae	NOUN
fnp-3395	15	89	family	family	NOUN
fnp-3395	15	90	,	,	PUNCT
fnp-3395	15	91	along	along	ADP
fnp-3395	15	92	with	with	ADP
fnp-3395	15	93	the	the	DET
fnp-3395	15	94	severe	severe	ADJ
fnp-3395	15	95	acute	acute	ADJ
fnp-3395	15	96	respiratory	respiratory	ADJ
fnp-3395	15	97	syndrome	syndrome	NOUN
fnp-3395	15	98	(	(	PUNCT
fnp-3395	15	99	sars	sars	PROPN
fnp-3395	15	100	)	)	PUNCT
fnp-3395	15	101	and	and	CCONJ
fnp-3395	15	102	the	the	DET
fnp-3395	15	103	middle	middle	PROPN
fnp-3395	15	104	east	east	PROPN
fnp-3395	15	105	respiratory	respiratory	ADJ
fnp-3395	15	106	syndrome	syndrome	NOUN
fnp-3395	15	107	(	(	PUNCT
fnp-3395	15	108	mers	mer	NOUN
fnp-3395	15	109	)	)	PUNCT
fnp-3395	15	110	coronaviruses.1	coronaviruses.1	PROPN
fnp-3395	15	111	the	the	DET
fnp-3395	15	112	genome	genome	NOUN
fnp-3395	15	113	of	of	ADP
fnp-3395	15	114	these	these	DET
fnp-3395	15	115	viruses	virus	NOUN
fnp-3395	15	116	encodes	encode	VERB
fnp-3395	15	117	several	several	ADJ
fnp-3395	15	118	non	non	ADJ
fnp-3395	15	119	-	-	ADJ
fnp-3395	15	120	structural	structural	ADJ
fnp-3395	15	121	and	and	CCONJ
fnp-3395	15	122	structural	structural	ADJ
fnp-3395	15	123	proteins	protein	NOUN
fnp-3395	15	124	,	,	PUNCT
fnp-3395	15	125	including	include	VERB
fnp-3395	15	126	spike	spike	NOUN
fnp-3395	15	127	,	,	PUNCT
fnp-3395	15	128	envelope	envelope	NOUN
fnp-3395	15	129	,	,	PUNCT
fnp-3395	15	130	membrane	membrane	NOUN
fnp-3395	15	131	,	,	PUNCT
fnp-3395	15	132	and	and	CCONJ
fnp-3395	15	133	nucleocapsid	nucleocapsid	VERB
fnp-3395	15	134	proteins.2	proteins.2	NOUN
fnp-3395	15	135	the	the	DET
fnp-3395	15	136	majority	majority	NOUN
fnp-3395	15	137	of	of	ADP
fnp-3395	15	138	the	the	DET
fnp-3395	15	139	vaccines	vaccine	NOUN
fnp-3395	15	140	for	for	ADP
fnp-3395	15	141	covid-19	covid-19	PROPN
fnp-3395	15	142	that	that	PRON
fnp-3395	15	143	employ	employ	VERB
fnp-3395	15	144	administration	administration	NOUN
fnp-3395	15	145	of	of	ADP
fnp-3395	15	146	viral	viral	ADJ
fnp-3395	15	147	antigens	antigen	NOUN
fnp-3395	15	148	or	or	CCONJ
fnp-3395	15	149	viral	viral	ADJ
fnp-3395	15	150	gene	gene	NOUN
fnp-3395	15	151	sequences	sequence	NOUN
fnp-3395	15	152	aim	aim	VERB
fnp-3395	15	153	to	to	PART
fnp-3395	15	154	induce	induce	VERB
fnp-3395	15	155	neutralizing	neutralize	VERB
fnp-3395	15	156	antibodies	antibody	NOUN
fnp-3395	15	157	against	against	ADP
fnp-3395	15	158	the	the	DET
fnp-3395	15	159	viral	viral	ADJ
fnp-3395	15	160	spike	spike	ADJ
fnp-3395	15	161	protein	protein	NOUN
fnp-3395	15	162	(	(	PUNCT
fnp-3395	15	163	s	s	NOUN
fnp-3395	15	164	)	)	PUNCT
fnp-3395	15	165	,	,	PUNCT
fnp-3395	15	166	preventing	prevent	VERB
fnp-3395	15	167	uptake	uptake	NOUN
fnp-3395	15	168	through	through	ADP
fnp-3395	15	169	the	the	DET
fnp-3395	15	170	ace2	ace2	NOUN
fnp-3395	15	171	receptor	receptor	NOUN
fnp-3395	15	172	,	,	PUNCT
fnp-3395	15	173	and	and	CCONJ
fnp-3395	15	174	thereby	thereby	ADV
fnp-3395	15	175	blocking	block	VERB
fnp-3395	15	176	infection.3	infection.3	PROPN
fnp-3395	15	177	the	the	DET
fnp-3395	15	178	janssen	janssen	PROPN
fnp-3395	15	179	covid-19	covid-19	PROPN
fnp-3395	15	180	vaccine	vaccine	NOUN
fnp-3395	15	181	(	(	PUNCT
fnp-3395	15	182	johnson	johnson	PROPN
fnp-3395	15	183	&	&	CCONJ
fnp-3395	15	184	johnson	johnson	PROPN
fnp-3395	15	185	)	)	PUNCT
fnp-3395	15	186	is	be	AUX
fnp-3395	15	187	comprised	comprise	VERB
fnp-3395	15	188	of	of	ADP
fnp-3395	15	189	a	a	DET
fnp-3395	15	190	recombinant	recombinant	ADJ
fnp-3395	15	191	,	,	PUNCT
fnp-3395	15	192	replicationincompetent	replicationincompetent	NOUN
fnp-3395	15	193	ad26	ad26	PROPN
fnp-3395	15	194	vector	vector	NOUN
fnp-3395	15	195	,	,	PUNCT
fnp-3395	15	196	encoding	encode	VERB
fnp-3395	15	197	a	a	DET
fnp-3395	15	198	stabilized	stabilize	VERB
fnp-3395	15	199	variant	variant	NOUN
fnp-3395	15	200	of	of	ADP
fnp-3395	15	201	the	the	DET
fnp-3395	15	202	sars	sar	NOUN
fnp-3395	15	203	-	-	PUNCT
fnp-3395	15	204	cov-2	cov-2	NOUN
fnp-3395	15	205	spike	spike	ADJ
fnp-3395	15	206	protein	protein	NOUN
fnp-3395	15	207	.	.	PUNCT
fnp-3395	16	1	the	the	DET
fnp-3395	16	2	chadox1	chadox1	ADJ
fnp-3395	16	3	ncov-19	ncov-19	PROPN
fnp-3395	16	4	vaccine	vaccine	NOUN
fnp-3395	16	5	(	(	PUNCT
fnp-3395	16	6	azd1222	azd1222	NOUN
fnp-3395	16	7	,	,	PUNCT
fnp-3395	16	8	vaxzevria	vaxzevria	PROPN
fnp-3395	16	9	®	®	NOUN
fnp-3395	16	10	)	)	PUNCT
fnp-3395	16	11	was	be	AUX
fnp-3395	16	12	developed	develop	VERB
fnp-3395	16	13	at	at	ADP
fnp-3395	16	14	oxford	oxford	PROPN
fnp-3395	16	15	university	university	NOUN
fnp-3395	16	16	and	and	CCONJ
fnp-3395	16	17	consists	consist	VERB
fnp-3395	16	18	of	of	ADP
fnp-3395	16	19	a	a	DET
fnp-3395	16	20	replication	replication	NOUN
fnp-3395	16	21	-	-	PUNCT
fnp-3395	16	22	deficient	deficient	ADJ
fnp-3395	16	23	chimpanzee	chimpanzee	NOUN
fnp-3395	16	24	adenoviral	adenoviral	PROPN
fnp-3395	16	25	vector	vector	PROPN
fnp-3395	16	26	chadox1	chadox1	NOUN
fnp-3395	16	27	,	,	PUNCT
fnp-3395	16	28	encoding	encode	VERB
fnp-3395	16	29	the	the	DET
fnp-3395	16	30	s	s	NOUN
fnp-3395	16	31	protein.4	protein.4	NOUN
fnp-3395	16	32	in	in	ADP
fnp-3395	16	33	us	us	PROPN
fnp-3395	16	34	phase	phase	NOUN
fnp-3395	16	35	iii	iii	NUM
fnp-3395	16	36	trials	trial	NOUN
fnp-3395	16	37	,	,	PUNCT
fnp-3395	16	38	vaxzevria	vaxzevria	NOUN
fnp-3395	16	39	has	have	AUX
fnp-3395	16	40	been	be	AUX
fnp-3395	16	41	demonstrated	demonstrate	VERB
fnp-3395	16	42	to	to	PART
fnp-3395	16	43	have	have	VERB
fnp-3395	16	44	79	79	NUM
fnp-3395	16	45	%	%	NOUN
fnp-3395	16	46	efficacy	efficacy	NOUN
fnp-3395	16	47	at	at	ADP
fnp-3395	16	48	preventing	prevent	VERB
fnp-3395	16	49	symptomatic	symptomatic	ADJ
fnp-3395	16	50	covid-19	covid-19	PROPN
fnp-3395	16	51	,	,	PUNCT
fnp-3395	16	52	and	and	CCONJ
fnp-3395	16	53	100	100	NUM
fnp-3395	16	54	%	%	NOUN
fnp-3395	16	55	efficacy	efficacy	NOUN
fnp-3395	16	56	against	against	ADP
fnp-3395	16	57	severe	severe	ADJ
fnp-3395	16	58	or	or	CCONJ
fnp-3395	16	59	critical	critical	ADJ
fnp-3395	16	60	disease	disease	NOUN
fnp-3395	16	61	and	and	CCONJ
fnp-3395	16	62	hospitalization	hospitalization	NOUN
fnp-3395	16	63	,	,	PUNCT
fnp-3395	16	64	with	with	ADP
fnp-3395	16	65	comparable	comparable	ADJ
fnp-3395	16	66	efficacy	efficacy	NOUN
fnp-3395	16	67	across	across	ADP
fnp-3395	16	68	ethnicity	ethnicity	NOUN
fnp-3395	16	69	,	,	PUNCT
fnp-3395	16	70	gender	gender	NOUN
fnp-3395	16	71	and	and	CCONJ
fnp-3395	16	72	age.5	age.5	NOUN
fnp-3395	16	73	however	however	ADV
fnp-3395	16	74	,	,	PUNCT
fnp-3395	16	75	vaxzevria	vaxzevria	NOUN
fnp-3395	16	76	has	have	AUX
fnp-3395	16	77	been	be	AUX
fnp-3395	16	78	associated	associate	VERB
fnp-3395	16	79	with	with	ADP
fnp-3395	16	80	thrombotic	thrombotic	ADJ
fnp-3395	16	81	and	and	CCONJ
fnp-3395	16	82	embolic	embolic	ADJ
fnp-3395	16	83	events	event	NOUN
fnp-3395	16	84	including	include	VERB
fnp-3395	16	85	disseminated	disseminate	VERB
fnp-3395	16	86	intravascular	intravascular	ADJ
fnp-3395	16	87	coagulation	coagulation	NOUN
fnp-3395	16	88	(	(	PUNCT
fnp-3395	16	89	dic	dic	ADJ
fnp-3395	16	90	)	)	PUNCT
fnp-3395	16	91	and	and	CCONJ
fnp-3395	16	92	cerebral	cerebral	ADJ
fnp-3395	16	93	venous	venous	ADJ
fnp-3395	16	94	sinus	sinus	NOUN
fnp-3395	16	95	thrombosis	thrombosis	NOUN
fnp-3395	16	96	(	(	PUNCT
fnp-3395	16	97	cvst	cvst	PROPN
fnp-3395	16	98	)	)	PUNCT
fnp-3395	16	99	,	,	PUNCT
fnp-3395	16	100	occurring	occur	VERB
fnp-3395	16	101	within	within	ADP
fnp-3395	16	102	14	14	NUM
fnp-3395	16	103	days	day	NOUN
fnp-3395	16	104	after	after	ADP
fnp-3395	16	105	vaccination	vaccination	NOUN
fnp-3395	16	106	,	,	PUNCT
fnp-3395	16	107	mostly	mostly	ADV
fnp-3395	16	108	in	in	ADP
fnp-3395	16	109	people	people	NOUN
fnp-3395	16	110	under	under	ADP
fnp-3395	16	111	55	55	NUM
fnp-3395	16	112	years	year	NOUN
fnp-3395	16	113	of	of	ADP
fnp-3395	16	114	age	age	NOUN
fnp-3395	16	115	,	,	PUNCT
fnp-3395	16	116	the	the	DET
fnp-3395	16	117	majority	majority	NOUN
fnp-3395	16	118	of	of	ADP
fnp-3395	16	119	whom	whom	PRON
fnp-3395	16	120	have	have	AUX
fnp-3395	16	121	been	be	AUX
fnp-3395	16	122	women.6	women.6	NOUN
fnp-3395	16	123	data	datum	NOUN
fnp-3395	16	124	from	from	ADP
fnp-3395	16	125	europe	europe	PROPN
fnp-3395	16	126	suggests	suggest	VERB
fnp-3395	16	127	that	that	SCONJ
fnp-3395	16	128	the	the	DET
fnp-3395	16	129	event	event	NOUN
fnp-3395	16	130	rate	rate	NOUN
fnp-3395	16	131	for	for	ADP
fnp-3395	16	132	thromboembolic	thromboembolic	ADJ
fnp-3395	16	133	events	event	NOUN
fnp-3395	16	134	may	may	AUX
fnp-3395	16	135	be	be	AUX
fnp-3395	16	136	about	about	ADV
fnp-3395	16	137	10	10	NUM
fnp-3395	16	138	per	per	ADP
fnp-3395	16	139	million	million	NUM
fnp-3395	16	140	vaccinated	vaccinated	ADJ
fnp-3395	16	141	.	.	PUNCT
fnp-3395	17	1	antibodies	antibodie	VERB
fnp-3395	17	2	to	to	PART
fnp-3395	17	3	platelet	platelet	NOUN
fnp-3395	17	4	factor	factor	NOUN
fnp-3395	17	5	4	4	NUM
fnp-3395	17	6	(	(	PUNCT
fnp-3395	17	7	pf4)/heparin	pf4)/heparin	ADJ
fnp-3395	17	8	complexes	complex	NOUN
fnp-3395	17	9	have	have	AUX
fnp-3395	17	10	been	be	AUX
fnp-3395	17	11	recently	recently	ADV
fnp-3395	17	12	reported	report	VERB
fnp-3395	17	13	in	in	ADP
fnp-3395	17	14	a	a	DET
fnp-3395	17	15	few	few	ADJ
fnp-3395	17	16	patients.7	patients.7	NOUN
fnp-3395	17	17	however	however	ADV
fnp-3395	17	18	,	,	PUNCT
fnp-3395	17	19	the	the	DET
fnp-3395	17	20	significance	significance	NOUN
fnp-3395	17	21	of	of	ADP
fnp-3395	17	22	this	this	DET
fnp-3395	17	23	finding	finding	NOUN
fnp-3395	17	24	remains	remain	VERB
fnp-3395	17	25	to	to	PART
fnp-3395	17	26	be	be	AUX
fnp-3395	17	27	established	establish	VERB
fnp-3395	17	28	.	.	PUNCT
fnp-3395	18	1	as	as	ADP
fnp-3395	18	2	of	of	ADP
fnp-3395	18	3	april	april	PROPN
fnp-3395	18	4	12	12	NUM
fnp-3395	18	5	,	,	PUNCT
fnp-3395	18	6	2021	2021	NUM
fnp-3395	18	7	,	,	PUNCT
fnp-3395	18	8	about	about	ADP
fnp-3395	18	9	6.8	6.8	NUM
fnp-3395	18	10	million	million	NUM
fnp-3395	18	11	doses	dose	NOUN
fnp-3395	18	12	of	of	ADP
fnp-3395	18	13	the	the	DET
fnp-3395	18	14	janssen	janssen	PROPN
fnp-3395	18	15	vaccine	vaccine	NOUN
fnp-3395	18	16	have	have	AUX
fnp-3395	18	17	been	be	AUX
fnp-3395	18	18	administered	administer	VERB
fnp-3395	18	19	in	in	ADP
fnp-3395	18	20	the	the	DET
fnp-3395	18	21	u.s.8	u.s.8	ADJ
fnp-3395	18	22	cdc	cdc	PROPN
fnp-3395	18	23	and	and	CCONJ
fnp-3395	18	24	fda	fda	PROPN
fnp-3395	18	25	are	be	AUX
fnp-3395	18	26	reviewing	review	VERB
fnp-3395	18	27	data	datum	NOUN
fnp-3395	18	28	involving	involve	VERB
fnp-3395	18	29	six	six	NUM
fnp-3395	18	30	reported	report	VERB
fnp-3395	18	31	u.s	u.s	PROPN
fnp-3395	18	32	.	.	PROPN
fnp-3395	18	33	cases	case	NOUN
fnp-3395	18	34	of	of	ADP
fnp-3395	18	35	cvst	cvst	PROPN
fnp-3395	18	36	in	in	ADP
fnp-3395	18	37	combination	combination	NOUN
fnp-3395	18	38	with	with	ADP
fnp-3395	18	39	thrombocytopenia.8	thrombocytopenia.8	PROPN
fnp-3395	18	40	all	all	DET
fnp-3395	18	41	six	six	NUM
fnp-3395	18	42	cases	case	NOUN
fnp-3395	18	43	occurred	occur	VERB
fnp-3395	18	44	among	among	ADP
fnp-3395	18	45	women	woman	NOUN
fnp-3395	18	46	between	between	ADP
fnp-3395	18	47	the	the	DET
fnp-3395	18	48	ages	age	NOUN
fnp-3395	18	49	of	of	ADP
fnp-3395	18	50	18	18	NUM
fnp-3395	18	51	and	and	CCONJ
fnp-3395	18	52	48	48	NUM
fnp-3395	18	53	,	,	PUNCT
fnp-3395	18	54	and	and	CCONJ
fnp-3395	18	55	symptoms	symptom	NOUN
fnp-3395	18	56	occurred	occur	VERB
fnp-3395	18	57	6	6	NUM
fnp-3395	18	58	to	to	PART
fnp-3395	18	59	13	13	NUM
fnp-3395	18	60	days	day	NOUN
fnp-3395	18	61	after	after	SCONJ
fnp-3395	18	62	vaccination.8	vaccination.8	PROPN
fnp-3395	18	63	sars	sars	PROPN
fnp-3395	18	64	-	-	PUNCT
fnp-3395	18	65	cov-2	cov-2	PART
fnp-3395	18	66	is	be	AUX
fnp-3395	18	67	known	know	VERB
fnp-3395	18	68	to	to	PART
fnp-3395	18	69	cause	cause	VERB
fnp-3395	18	70	thromboinflammation	thromboinflammation	NOUN
fnp-3395	18	71	leading	lead	VERB
fnp-3395	18	72	to	to	ADP
fnp-3395	18	73	thrombotic	thrombotic	ADJ
fnp-3395	18	74	microangiopathy	microangiopathy	ADJ
fnp-3395	18	75	,	,	PUNCT
fnp-3395	18	76	pulmonary	pulmonary	ADJ
fnp-3395	18	77	thrombosis	thrombosis	NOUN
fnp-3395	18	78	,	,	PUNCT
fnp-3395	18	79	pedal	pedal	ADJ
fnp-3395	18	80	acro	acro	PROPN
fnp-3395	18	81	-	-	NOUN
fnp-3395	18	82	ischemia	ischemia	NOUN
fnp-3395	18	83	(	(	PUNCT
fnp-3395	18	84	“	"	PUNCT
fnp-3395	18	85	covid	covid	ADJ
fnp-3395	18	86	-	-	PUNCT
fnp-3395	18	87	toes	toe	NOUN
fnp-3395	18	88	”	"	PUNCT
fnp-3395	18	89	)	)	PUNCT
fnp-3395	18	90	,	,	PUNCT
fnp-3395	18	91	arterial	arterial	NOUN
fnp-3395	18	92	clots	clot	NOUN
fnp-3395	18	93	,	,	PUNCT
fnp-3395	18	94	strokes	stroke	NOUN
fnp-3395	18	95	,	,	PUNCT
fnp-3395	18	96	cardiomyopathy	cardiomyopathy	ADJ
fnp-3395	18	97	,	,	PUNCT
fnp-3395	18	98	coronary	coronary	ADJ
fnp-3395	18	99	and	and	CCONJ
fnp-3395	18	100	systemic	systemic	ADJ
fnp-3395	18	101	vasculitis	vasculitis	NOUN
fnp-3395	18	102	,	,	PUNCT
fnp-3395	18	103	deep	deep	ADJ
fnp-3395	18	104	venous	venous	ADJ
fnp-3395	18	105	thrombosis	thrombosis	NOUN
fnp-3395	18	106	,	,	PUNCT
fnp-3395	18	107	pulmonary	pulmonary	ADJ
fnp-3395	18	108	embolism	embolism	NOUN
fnp-3395	18	109	,	,	PUNCT
fnp-3395	18	110	and	and	CCONJ
fnp-3395	18	111	microvascular	microvascular	ADJ
fnp-3395	18	112	thrombosis	thrombosis	NOUN
fnp-3395	18	113	in	in	ADP
fnp-3395	18	114	renal	renal	ADJ
fnp-3395	18	115	,	,	PUNCT
fnp-3395	18	116	cardiac	cardiac	ADJ
fnp-3395	18	117	and	and	CCONJ
fnp-3395	18	118	brain	brain	NOUN
fnp-3395	18	119	vascularture.9	vascularture.9	PROPN
fnp-3395	18	120	-	-	PUNCT
fnp-3395	18	121	14	14	NUM
fnp-3395	18	122	cerebral	cerebral	ADJ
fnp-3395	18	123	venous	venous	ADJ
fnp-3395	18	124	sinus	sinus	NOUN
fnp-3395	18	125	thrombosis	thrombosis	NOUN
fnp-3395	18	126	(	(	PUNCT
fnp-3395	18	127	cvst	cvst	PROPN
fnp-3395	18	128	)	)	PUNCT
fnp-3395	18	129	has	have	AUX
fnp-3395	18	130	also	also	ADV
fnp-3395	18	131	been	be	AUX
fnp-3395	18	132	reported	report	VERB
fnp-3395	18	133	in	in	ADP
fnp-3395	18	134	covid-19	covid-19	PROPN
fnp-3395	18	135	patients.15	patients.15	NOUN
fnp-3395	18	136	amongst	amongst	ADP
fnp-3395	18	137	34,331	34,331	NUM
fnp-3395	18	138	hospitalized	hospitalize	VERB
fnp-3395	18	139	covid-19	covid-19	PROPN
fnp-3395	18	140	patients	patient	NOUN
fnp-3395	18	141	,	,	PUNCT
fnp-3395	18	142	cvst	cvst	PROPN
fnp-3395	18	143	was	be	AUX
fnp-3395	18	144	diagnosed	diagnose	VERB
fnp-3395	18	145	in	in	ADP
fnp-3395	18	146	28.16	28.16	NUM
fnp-3395	18	147	in	in	ADP
fnp-3395	18	148	a	a	DET
fnp-3395	18	149	multicenter	multicenter	NOUN
fnp-3395	18	150	,	,	PUNCT
fnp-3395	18	151	multinational	multinational	ADJ
fnp-3395	18	152	,	,	PUNCT
fnp-3395	18	153	cross	cross	NOUN
fnp-3395	18	154	sectional	sectional	NOUN
fnp-3395	18	155	,	,	PUNCT
fnp-3395	18	156	retrospective	retrospective	ADJ
fnp-3395	18	157	study	study	NOUN
fnp-3395	18	158	of	of	ADP
fnp-3395	18	159	8	8	NUM
fnp-3395	18	160	patients	patient	NOUN
fnp-3395	18	161	diagnosed	diagnose	VERB
fnp-3395	18	162	with	with	ADP
fnp-3395	18	163	cvst	cvst	PROPN
fnp-3395	18	164	and	and	CCONJ
fnp-3395	18	165	covid-19	covid-19	PROPN
fnp-3395	18	166	,	,	PUNCT
fnp-3395	18	167	seven	seven	NUM
fnp-3395	18	168	were	be	AUX
fnp-3395	18	169	women	woman	NOUN
fnp-3395	18	170	with	with	ADP
fnp-3395	18	171	an	an	DET
fnp-3395	18	172	average	average	ADJ
fnp-3395	18	173	age	age	NOUN
fnp-3395	18	174	of	of	ADP
fnp-3395	18	175	63	63	NUM
fnp-3395	18	176	years.17	years.17	VERB
fnp-3395	18	177	in	in	ADP
fnp-3395	18	178	a	a	DET
fnp-3395	18	179	combined	combine	VERB
fnp-3395	18	180	series	series	NOUN
fnp-3395	18	181	of	of	ADP
fnp-3395	18	182	41	41	NUM
fnp-3395	18	183	patients	patient	NOUN
fnp-3395	18	184	with	with	ADP
fnp-3395	18	185	covid-19	covid-19	PROPN
fnp-3395	18	186	and	and	CCONJ
fnp-3395	18	187	cvst	cvst	PROPN
fnp-3395	18	188	,	,	PUNCT
fnp-3395	18	189	the	the	DET
fnp-3395	18	190	average	average	ADJ
fnp-3395	18	191	age	age	NOUN
fnp-3395	18	192	was	be	AUX
fnp-3395	18	193	about	about	ADV
fnp-3395	18	194	50	50	NUM
fnp-3395	18	195	years	year	NOUN
fnp-3395	18	196	(	(	PUNCT
fnp-3395	18	197	sd	sd	NOUN
fnp-3395	18	198	,	,	PUNCT
fnp-3395	18	199	16.5	16.5	NUM
fnp-3395	18	200	years).17	years).17	NOUN
fnp-3395	18	201	the	the	DET
fnp-3395	18	202	pathobiology	pathobiology	NOUN
fnp-3395	18	203	of	of	ADP
fnp-3395	18	204	thrombotic	thrombotic	ADJ
fnp-3395	18	205	events	event	NOUN
fnp-3395	18	206	associated	associate	VERB
fnp-3395	18	207	with	with	ADP
fnp-3395	18	208	the	the	DET
fnp-3395	18	209	astrazeneca	astrazeneca	NOUN
fnp-3395	18	210	vaccine	vaccine	NOUN
fnp-3395	18	211	should	should	AUX
fnp-3395	18	212	be	be	AUX
fnp-3395	18	213	viewed	view	VERB
fnp-3395	18	214	in	in	ADP
fnp-3395	18	215	the	the	DET
fnp-3395	18	216	context	context	NOUN
fnp-3395	18	217	of	of	ADP
fnp-3395	18	218	mechanisms	mechanism	NOUN
fnp-3395	18	219	underlying	underlie	VERB
fnp-3395	18	220	thromboinflammation	thromboinflammation	NOUN
fnp-3395	18	221	that	that	PRON
fnp-3395	18	222	complicates	complicate	VERB
fnp-3395	18	223	sars	sar	NOUN
fnp-3395	18	224	-	-	PUNCT
fnp-3395	18	225	cov-2	cov-2	PART
fnp-3395	18	226	infection	infection	NOUN
fnp-3395	18	227	and	and	CCONJ
fnp-3395	18	228	covid-19	covid-19	PROPN
fnp-3395	18	229	disease	disease	NOUN
fnp-3395	18	230	.	.	PUNCT
fnp-3395	19	1	a.	a.	NOUN
fnp-3395	19	2	role	role	NOUN
fnp-3395	19	3	of	of	ADP
fnp-3395	19	4	cox-2	cox-2	NOUN
fnp-3395	19	5	and	and	CCONJ
fnp-3395	19	6	thromboxane	thromboxane	NOUN
fnp-3395	19	7	a2	a2	PROPN
fnp-3395	19	8	in	in	ADP
fnp-3395	19	9	thromboinflammation	thromboinflammation	NOUN
fnp-3395	19	10	complicating	complicate	VERB
fnp-3395	19	11	adenovirus	adenovirus	NOUN
fnp-3395	19	12	-	-	PUNCT
fnp-3395	19	13	based	base	VERB
fnp-3395	19	14	covid-19	covid-19	PROPN
fnp-3395	19	15	vaccine	vaccine	NOUN
fnp-3395	19	16	encoding	encode	VERB
fnp-3395	19	17	the	the	DET
fnp-3395	19	18	spike	spike	ADJ
fnp-3395	19	19	protein	protein	NOUN
fnp-3395	19	20	of	of	ADP
fnp-3395	19	21	sars	sar	NOUN
fnp-3395	19	22	-	-	PUNCT
fnp-3395	19	23	cov-2	cov-2	PART
fnp-3395	19	24	thromboinflammation	thromboinflammation	NOUN
fnp-3395	19	25	in	in	ADP
fnp-3395	19	26	covid-19	covid-19	PROPN
fnp-3395	19	27	seems	seem	VERB
fnp-3395	19	28	to	to	PART
fnp-3395	19	29	be	be	AUX
fnp-3395	19	30	primarily	primarily	ADV
fnp-3395	19	31	caused	cause	VERB
fnp-3395	19	32	by	by	ADP
fnp-3395	19	33	endothelial	endothelial	NOUN
fnp-3395	19	34	,	,	PUNCT
fnp-3395	19	35	platelet	platelet	NOUN
fnp-3395	19	36	and	and	CCONJ
fnp-3395	19	37	neutrophil	neutrophil	ADJ
fnp-3395	19	38	activation	activation	NOUN
fnp-3395	19	39	,	,	PUNCT
fnp-3395	19	40	platelet	platelet	ADJ
fnp-3395	19	41	-	-	PUNCT
fnp-3395	19	42	neutrophil	neutrophil	ADJ
fnp-3395	19	43	aggregates	aggregate	NOUN
fnp-3395	19	44	and	and	CCONJ
fnp-3395	19	45	release	release	NOUN
fnp-3395	19	46	of	of	ADP
fnp-3395	19	47	neutrophil	neutrophil	ADJ
fnp-3395	19	48	extracellular	extracellular	ADJ
fnp-3395	19	49	traps	trap	NOUN
fnp-3395	19	50	(	(	PUNCT
fnp-3395	19	51	nets).13,18	nets).13,18	NUM
fnp-3395	19	52	platelet	platelet	NOUN
fnp-3395	19	53	activation	activation	NOUN
fnp-3395	19	54	in	in	ADP
fnp-3395	19	55	covid-19	covid-19	PROPN
fnp-3395	19	56	is	be	AUX
fnp-3395	19	57	fueled	fuel	VERB
fnp-3395	19	58	by	by	ADP
fnp-3395	19	59	a	a	DET
fnp-3395	19	60	lipid	lipid	NOUN
fnp-3395	19	61	storm	storm	NOUN
fnp-3395	19	62	characterized	characterize	VERB
fnp-3395	19	63	by	by	ADP
fnp-3395	19	64	massive	massive	ADJ
fnp-3395	19	65	increases	increase	NOUN
fnp-3395	19	66	in	in	ADP
fnp-3395	19	67	thromboxane	thromboxane	NOUN
fnp-3395	19	68	a2	a2	PROPN
fnp-3395	19	69	(	(	PUNCT
fnp-3395	19	70	txa2	txa2	PROPN
fnp-3395	19	71	)	)	PUNCT
fnp-3395	19	72	levels	level	NOUN
fnp-3395	19	73	in	in	ADP
fnp-3395	19	74	the	the	DET
fnp-3395	19	75	blood	blood	NOUN
fnp-3395	19	76	and	and	CCONJ
fnp-3395	20	1	bronchoalveolar	bronchoalveolar	ADJ
fnp-3395	20	2	lavage	lavage	PROPN
fnp-3395	20	3	fluid.19,20	fluid.19,20	PROPN
fnp-3395	20	4	cyclooxygenase	cyclooxygenase	PROPN
fnp-3395	20	5	(	(	PUNCT
fnp-3395	20	6	cox	cox	PROPN
fnp-3395	20	7	)	)	PUNCT
fnp-3395	20	8	enzymes	enzyme	NOUN
fnp-3395	20	9	catalyze	catalyze	NOUN
fnp-3395	20	10	the	the	DET
fnp-3395	20	11	first	first	ADJ
fnp-3395	20	12	step	step	NOUN
fnp-3395	20	13	in	in	ADP
fnp-3395	20	14	the	the	DET
fnp-3395	20	15	biosynthesis	biosynthesis	NOUN
fnp-3395	20	16	of	of	ADP
fnp-3395	20	17	thromboxane	thromboxane	NOUN
fnp-3395	20	18	a2	a2	PROPN
fnp-3395	20	19	from	from	ADP
fnp-3395	20	20	arachidonic	arachidonic	ADJ
fnp-3395	20	21	acid	acid	NOUN
fnp-3395	20	22	,	,	PUNCT
fnp-3395	20	23	and	and	CCONJ
fnp-3395	20	24	cox-2	cox-2	NOUN
fnp-3395	20	25	expression	expression	NOUN
fnp-3395	20	26	is	be	AUX
fnp-3395	20	27	induced	induce	VERB
fnp-3395	20	28	by	by	ADP
fnp-3395	20	29	the	the	DET
fnp-3395	20	30	spike	spike	ADJ
fnp-3395	20	31	protein	protein	NOUN
fnp-3395	20	32	of	of	ADP
fnp-3395	20	33	coronaviruses.21	coronaviruses.21	NOUN
fnp-3395	20	34	we	we	PRON
fnp-3395	20	35	postulate	postulate	VERB
fnp-3395	20	36	that	that	SCONJ
fnp-3395	20	37	an	an	DET
fnp-3395	20	38	aberrant	aberrant	ADJ
fnp-3395	20	39	increase	increase	NOUN
fnp-3395	20	40	in	in	ADP
fnp-3395	20	41	thromboxane	thromboxane	NOUN
fnp-3395	20	42	a2	a2	PROPN
fnp-3395	20	43	generation	generation	NOUN
fnp-3395	20	44	induced	induce	VERB
fnp-3395	20	45	by	by	ADP
fnp-3395	20	46	the	the	DET
fnp-3395	20	47	spike	spike	ADJ
fnp-3395	20	48	protein	protein	NOUN
fnp-3395	20	49	expression	expression	NOUN
fnp-3395	20	50	from	from	ADP
fnp-3395	20	51	adenovirus	adenovirus	NOUN
fnp-3395	20	52	vaccines	vaccine	NOUN
fnp-3395	20	53	leads	lead	VERB
fnp-3395	20	54	to	to	ADP
fnp-3395	20	55	thromboinflammation	thromboinflammation	NOUN
fnp-3395	20	56	and	and	CCONJ
fnp-3395	20	57	cvst	cvst	PROPN
fnp-3395	20	58	.	.	PUNCT
fnp-3395	21	1	the	the	DET
fnp-3395	21	2	support	support	NOUN
fnp-3395	21	3	for	for	ADP
fnp-3395	21	4	the	the	DET
fnp-3395	21	5	above	above	ADJ
fnp-3395	21	6	proposed	propose	VERB
fnp-3395	21	7	mechanism	mechanism	NOUN
fnp-3395	21	8	comes	come	VERB
fnp-3395	21	9	from	from	ADP
fnp-3395	21	10	the	the	DET
fnp-3395	21	11	following	follow	VERB
fnp-3395	21	12	observations	observation	NOUN
fnp-3395	21	13	.	.	PUNCT
fnp-3395	22	1	first	first	ADV
fnp-3395	22	2	,	,	PUNCT
fnp-3395	22	3	when	when	SCONJ
fnp-3395	22	4	mice	mouse	NOUN
fnp-3395	22	5	of	of	ADP
fnp-3395	22	6	different	different	ADJ
fnp-3395	22	7	age	age	NOUN
fnp-3395	22	8	groups	group	NOUN
fnp-3395	22	9	were	be	AUX
fnp-3395	22	10	infected	infect	VERB
fnp-3395	22	11	with	with	ADP
fnp-3395	22	12	sars	sar	NOUN
fnp-3395	22	13	-	-	PUNCT
fnp-3395	22	14	cov	cov	NOUN
fnp-3395	22	15	virus	virus	NOUN
fnp-3395	22	16	,	,	PUNCT
fnp-3395	22	17	the	the	DET
fnp-3395	22	18	generation	generation	NOUN
fnp-3395	22	19	of	of	ADP
fnp-3395	22	20	txa2	txa2	PROPN
fnp-3395	22	21	was	be	AUX
fnp-3395	22	22	markedly	markedly	ADV
fnp-3395	22	23	increased	increase	VERB
fnp-3395	22	24	in	in	ADP
fnp-3395	22	25	younger	young	ADJ
fnp-3395	22	26	mice	mouse	NOUN
fnp-3395	22	27	compared	compare	VERB
fnp-3395	22	28	to	to	ADP
fnp-3395	22	29	middle	middle	ADJ
fnp-3395	22	30	aged	aged	ADJ
fnp-3395	22	31	mice.22	mice.22	NOUN
fnp-3395	22	32	furthermore	furthermore	ADV
fnp-3395	22	33	,	,	PUNCT
fnp-3395	22	34	in	in	SCONJ
fnp-3395	22	35	children	child	NOUN
fnp-3395	22	36	with	with	ADP
fnp-3395	22	37	asymptomatic	asymptomatic	ADJ
fnp-3395	22	38	or	or	CCONJ
fnp-3395	22	39	mildly	mildly	ADV
fnp-3395	22	40	symptomatic	symptomatic	ADJ
fnp-3395	22	41	sars	sar	NOUN
fnp-3395	22	42	-	-	PUNCT
fnp-3395	22	43	cov-2	cov-2	NOUN
fnp-3395	22	44	infection	infection	NOUN
fnp-3395	22	45	,	,	PUNCT
fnp-3395	22	46	microvascular	microvascular	ADJ
fnp-3395	22	47	thrombosis	thrombosis	NOUN
fnp-3395	22	48	and	and	CCONJ
fnp-3395	22	49	thrombotic	thrombotic	ADJ
fnp-3395	22	50	microangiopathy	microangiopathy	PROPN
fnp-3395	22	51	occur	occur	VERB
fnp-3395	22	52	early	early	ADV
fnp-3395	22	53	in	in	ADP
fnp-3395	22	54	infection.19	infection.19	NOUN
fnp-3395	22	55	these	these	DET
fnp-3395	22	56	observations	observation	NOUN
fnp-3395	22	57	are	be	AUX
fnp-3395	22	58	consistent	consistent	ADJ
fnp-3395	22	59	with	with	ADP
fnp-3395	22	60	the	the	DET
fnp-3395	22	61	higher	high	ADJ
fnp-3395	22	62	risk	risk	NOUN
fnp-3395	22	63	for	for	ADP
fnp-3395	22	64	thrombosis	thrombosis	NOUN
fnp-3395	22	65	in	in	ADP
fnp-3395	22	66	adults	adult	NOUN
fnp-3395	22	67	under	under	ADP
fnp-3395	22	68	60	60	NUM
fnp-3395	22	69	years	year	NOUN
fnp-3395	22	70	of	of	ADP
fnp-3395	22	71	age	age	NOUN
fnp-3395	22	72	,	,	PUNCT
fnp-3395	22	73	compared	compare	VERB
fnp-3395	22	74	with	with	ADP
fnp-3395	22	75	the	the	DET
fnp-3395	22	76	older	old	ADJ
fnp-3395	22	77	age	age	NOUN
fnp-3395	22	78	group.6,7	group.6,7	PROPN
fnp-3395	22	79	second	second	NOUN
fnp-3395	22	80	,	,	PUNCT
fnp-3395	22	81	platelets	platelet	VERB
fnp-3395	22	82	from	from	ADP
fnp-3395	22	83	female	female	ADJ
fnp-3395	22	84	mice	mouse	NOUN
fnp-3395	22	85	are	be	AUX
fnp-3395	22	86	much	much	ADV
fnp-3395	22	87	more	more	ADV
fnp-3395	22	88	reactive	reactive	ADJ
fnp-3395	22	89	than	than	ADP
fnp-3395	22	90	from	from	ADP
fnp-3395	22	91	male	male	ADJ
fnp-3395	22	92	mice.23	mice.23	NOUN
fnp-3395	22	93	furthermore	furthermore	ADV
fnp-3395	22	94	,	,	PUNCT
fnp-3395	22	95	txa2	txa2	NOUN
fnp-3395	22	96	generation	generation	NOUN
fnp-3395	22	97	,	,	PUNCT
fnp-3395	22	98	txa2	txa2	NOUN
fnp-3395	22	99	-	-	PUNCT
fnp-3395	22	100	platelet	platelet	NOUN
fnp-3395	22	101	interaction	interaction	NOUN
fnp-3395	22	102	and	and	CCONJ
fnp-3395	22	103	platelet	platelet	NOUN
fnp-3395	22	104	activation	activation	NOUN
fnp-3395	22	105	is	be	AUX
fnp-3395	22	106	increased	increase	VERB
fnp-3395	22	107	in	in	ADP
fnp-3395	22	108	women	woman	NOUN
fnp-3395	22	109	compared	compare	VERB
fnp-3395	22	110	to	to	ADP
fnp-3395	22	111	men.24,25	men.24,25	VERB
fnp-3395	22	112	these	these	DET
fnp-3395	22	113	observations	observation	NOUN
fnp-3395	22	114	are	be	AUX
fnp-3395	22	115	consistent	consistent	ADJ
fnp-3395	22	116	with	with	ADP
fnp-3395	22	117	disproportionately	disproportionately	ADV
fnp-3395	22	118	increased	increase	VERB
fnp-3395	22	119	risk	risk	NOUN
fnp-3395	22	120	of	of	ADP
fnp-3395	22	121	thrombosis	thrombosis	NOUN
fnp-3395	22	122	in	in	ADP
fnp-3395	22	123	women	woman	NOUN
fnp-3395	22	124	following	follow	VERB
fnp-3395	22	125	astrazeneca	astrazeneca	PROPN
fnp-3395	22	126	and	and	CCONJ
fnp-3395	22	127	janssen	janssen	PROPN
fnp-3395	22	128	covid-19	covid-19	PROPN
fnp-3395	22	129	vaccines	vaccine	NOUN
fnp-3395	22	130	.	.	PUNCT
fnp-3395	23	1	the	the	DET
fnp-3395	23	2	adenoviral	adenoviral	ADJ
fnp-3395	23	3	vector	vector	NOUN
fnp-3395	23	4	chadox1	chadox1	NOUN
fnp-3395	23	5	,	,	PUNCT
fnp-3395	23	6	containing	contain	VERB
fnp-3395	23	7	the	the	DET
fnp-3395	23	8	ncov-19	ncov-19	PROPN
fnp-3395	23	9	spike	spike	ADJ
fnp-3395	23	10	protein	protein	NOUN
fnp-3395	23	11	gene	gene	NOUN
fnp-3395	23	12	,	,	PUNCT
fnp-3395	23	13	infects	infect	VERB
fnp-3395	23	14	host	host	NOUN
fnp-3395	23	15	cells	cell	NOUN
fnp-3395	23	16	through	through	ADP
fnp-3395	23	17	the	the	DET
fnp-3395	23	18	coxsackievirus	coxsackievirus	NOUN
fnp-3395	23	19	and	and	CCONJ
fnp-3395	23	20	adenovirus	adenovirus	NOUN
fnp-3395	23	21	receptor	receptor	NOUN
fnp-3395	23	22	(	(	PUNCT
fnp-3395	23	23	car).26	car).26	VERB
fnp-3395	23	24	car	car	NOUN
fnp-3395	23	25	-	-	PUNCT
fnp-3395	23	26	dependent	dependent	ADJ
fnp-3395	23	27	cell	cell	NOUN
fnp-3395	23	28	entry	entry	NOUN
fnp-3395	23	29	of	of	ADP
fnp-3395	23	30	the	the	DET
fnp-3395	23	31	viral	viral	ADJ
fnp-3395	23	32	vector	vector	NOUN
fnp-3395	23	33	allows	allow	VERB
fnp-3395	23	34	insertion	insertion	NOUN
fnp-3395	23	35	of	of	ADP
fnp-3395	23	36	the	the	DET
fnp-3395	23	37	sars	sar	NOUN
fnp-3395	23	38	-	-	PUNCT
fnp-3395	23	39	cov-2	cov-2	NOUN
fnp-3395	23	40	spike	spike	ADJ
fnp-3395	23	41	protein	protein	NOUN
fnp-3395	23	42	gene	gene	NOUN
fnp-3395	23	43	and	and	CCONJ
fnp-3395	23	44	expression	expression	NOUN
fnp-3395	23	45	of	of	ADP
fnp-3395	23	46	spike	spike	ADJ
fnp-3395	23	47	protein	protein	NOUN
fnp-3395	23	48	by	by	ADP
fnp-3395	23	49	host	host	NOUN
fnp-3395	23	50	cells	cell	NOUN
fnp-3395	23	51	(	(	PUNCT
fnp-3395	23	52	figure	figure	NOUN
fnp-3395	23	53	1	1	NUM
fnp-3395	23	54	)	)	PUNCT
fnp-3395	23	55	.	.	PUNCT
fnp-3395	24	1	car	car	NOUN
fnp-3395	24	2	is	be	AUX
fnp-3395	24	3	primarily	primarily	ADV
fnp-3395	24	4	expressed	express	VERB
fnp-3395	24	5	on	on	ADP
fnp-3395	24	6	epithelial	epithelial	ADJ
fnp-3395	24	7	tight	tight	ADJ
fnp-3395	24	8	junctions	junction	NOUN
fnp-3395	24	9	including	include	VERB
fnp-3395	24	10	on	on	ADP
fnp-3395	24	11	enterocytes.27,28	enterocytes.27,28	NOUN
fnp-3395	24	12	car	car	NOUN
fnp-3395	24	13	expression	expression	NOUN
fnp-3395	24	14	has	have	AUX
fnp-3395	24	15	also	also	ADV
fnp-3395	24	16	been	be	AUX
fnp-3395	24	17	reported	report	VERB
fnp-3395	24	18	in	in	ADP
fnp-3395	24	19	platelets,29	platelets,29	PROPN
fnp-3395	24	20	and	and	CCONJ
fnp-3395	24	21	,	,	PUNCT
fnp-3395	24	22	since	since	SCONJ
fnp-3395	24	23	platelets	platelet	NOUN
fnp-3395	24	24	are	be	AUX
fnp-3395	24	25	anucleate	anucleate	ADJ
fnp-3395	24	26	cells	cell	NOUN
fnp-3395	24	27	,	,	PUNCT
fnp-3395	24	28	car	car	NOUN
fnp-3395	24	29	expression	expression	NOUN
fnp-3395	24	30	by	by	ADP
fnp-3395	24	31	megakaryocytes	megakaryocyte	NOUN
fnp-3395	24	32	can	can	AUX
fnp-3395	24	33	be	be	AUX
fnp-3395	24	34	inferred	infer	VERB
fnp-3395	24	35	.	.	PUNCT
fnp-3395	25	1	therefore	therefore	ADV
fnp-3395	25	2	,	,	PUNCT
fnp-3395	25	3	astrazeneca	astrazeneca	PROPN
fnp-3395	25	4	and	and	CCONJ
fnp-3395	25	5	janssen	janssen	PROPN
fnp-3395	25	6	vaccines	vaccine	NOUN
fnp-3395	25	7	would	would	AUX
fnp-3395	25	8	be	be	AUX
fnp-3395	25	9	expected	expect	VERB
fnp-3395	25	10	to	to	PART
fnp-3395	25	11	induce	induce	VERB
fnp-3395	25	12	expression	expression	NOUN
fnp-3395	25	13	of	of	ADP
fnp-3395	25	14	spike	spike	ADJ
fnp-3395	25	15	protein	protein	NOUN
fnp-3395	25	16	in	in	ADP
fnp-3395	25	17	megakaryocytes	megakaryocyte	NOUN
fnp-3395	25	18	,	,	PUNCT
fnp-3395	25	19	platelets	platelet	NOUN
fnp-3395	25	20	(	(	PUNCT
fnp-3395	25	21	figure	figure	NOUN
fnp-3395	25	22	1	1	NUM
fnp-3395	25	23	)	)	PUNCT
fnp-3395	25	24	and	and	CCONJ
fnp-3395	25	25	enterocytes	enterocyte	NOUN
fnp-3395	25	26	.	.	PUNCT
fnp-3395	26	1	we	we	PRON
fnp-3395	26	2	postulate	postulate	VERB
fnp-3395	26	3	that	that	SCONJ
fnp-3395	26	4	the	the	DET
fnp-3395	26	5	expression	expression	NOUN
fnp-3395	26	6	of	of	ADP
fnp-3395	26	7	car	car	NOUN
fnp-3395	26	8	receptors	receptor	NOUN
fnp-3395	26	9	by	by	ADP
fnp-3395	26	10	basolateral	basolateral	ADJ
fnp-3395	26	11	membrane	membrane	NOUN
fnp-3395	26	12	on	on	ADP
fnp-3395	26	13	enterocytes	enterocyte	NOUN
fnp-3395	26	14	allows	allow	VERB
fnp-3395	26	15	uptake	uptake	ADJ
fnp-3395	26	16	of	of	ADP
fnp-3395	26	17	adenovirus	adenovirus	NOUN
fnp-3395	26	18	vector,28	vector,28	NOUN
fnp-3395	26	19	leading	lead	VERB
fnp-3395	26	20	to	to	ADP
fnp-3395	26	21	spike	spike	ADJ
fnp-3395	26	22	protein	protein	NOUN
fnp-3395	26	23	-	-	PUNCT
fnp-3395	26	24	induced	induce	VERB
fnp-3395	26	25	cox-2	cox-2	ADJ
fnp-3395	26	26	expression	expression	NOUN
fnp-3395	26	27	and	and	CCONJ
fnp-3395	26	28	generation	generation	NOUN
fnp-3395	26	29	of	of	ADP
fnp-3395	26	30	thromboxane	thromboxane	NOUN
fnp-3395	26	31	a2	a2	PROPN
fnp-3395	26	32	.	.	PUNCT
fnp-3395	27	1	delivery	delivery	NOUN
fnp-3395	27	2	of	of	ADP
fnp-3395	27	3	thromboxane	thromboxane	NOUN
fnp-3395	27	4	a2	a2	PROPN
fnp-3395	27	5	into	into	ADP
fnp-3395	27	6	the	the	DET
fnp-3395	27	7	splanchnic	splanchnic	ADJ
fnp-3395	27	8	circulation	circulation	NOUN
fnp-3395	27	9	could	could	AUX
fnp-3395	27	10	activate	activate	VERB
fnp-3395	27	11	platelets	platelet	NOUN
fnp-3395	27	12	locally	locally	ADV
fnp-3395	27	13	,	,	PUNCT
fnp-3395	27	14	leading	lead	VERB
fnp-3395	27	15	to	to	ADP
fnp-3395	27	16	splanchnic	splanchnic	ADJ
fnp-3395	27	17	vein	vein	NOUN
fnp-3395	27	18	thrombosis	thrombosis	NOUN
fnp-3395	27	19	associated	associate	VERB
fnp-3395	27	20	with	with	ADP
fnp-3395	27	21	adenovirus	adenovirus	NOUN
fnp-3395	27	22	vaccines.30	vaccines.30	NOUN
fnp-3395	27	23	figure	figure	VERB
fnp-3395	27	24	1	1	NUM
fnp-3395	27	25	.	.	PUNCT
fnp-3395	28	1	astrazeneca	astrazeneca	NOUN
fnp-3395	28	2	or	or	CCONJ
fnp-3395	28	3	janssen	janssen	PROPN
fnp-3395	28	4	covid-19	covid-19	PROPN
fnp-3395	28	5	vaccine	vaccine	NOUN
fnp-3395	28	6	-	-	PUNCT
fnp-3395	28	7	induced	induce	VERB
fnp-3395	28	8	thromboinflammation	thromboinflammation	NOUN
fnp-3395	28	9	and	and	CCONJ
fnp-3395	28	10	cerebral	cerebral	ADJ
fnp-3395	28	11	venous	venous	ADJ
fnp-3395	28	12	sinus	sinus	NOUN
fnp-3395	28	13	thrombosis	thrombosis	NOUN
fnp-3395	28	14	(	(	PUNCT
fnp-3395	28	15	cvst	cvst	PROPN
fnp-3395	28	16	)	)	PUNCT
fnp-3395	28	17	proposed	propose	VERB
fnp-3395	28	18	mechanisms	mechanism	NOUN
fnp-3395	28	19	:	:	PUNCT
fnp-3395	28	20	adenovirus	adenovirus	NOUN
fnp-3395	28	21	carrier	carrier	NOUN
fnp-3395	28	22	delivers	deliver	VERB
fnp-3395	28	23	sars	sars	PROPN
fnp-3395	28	24	-	-	PUNCT
fnp-3395	28	25	cov-2	cov-2	NOUN
fnp-3395	28	26	dna	dna	NOUN
fnp-3395	28	27	encoding	encode	VERB
fnp-3395	28	28	the	the	DET
fnp-3395	28	29	spike	spike	ADJ
fnp-3395	28	30	(	(	PUNCT
fnp-3395	28	31	s	s	NOUN
fnp-3395	28	32	)	)	PUNCT
fnp-3395	28	33	protein	protein	NOUN
fnp-3395	28	34	to	to	ADP
fnp-3395	28	35	the	the	DET
fnp-3395	28	36	lung	lung	NOUN
fnp-3395	28	37	megakaryocytes	megakaryocyte	NOUN
fnp-3395	28	38	via	via	ADP
fnp-3395	28	39	the	the	DET
fnp-3395	28	40	coxsackie	coxsackie	NOUN
fnp-3395	28	41	-	-	PUNCT
fnp-3395	28	42	adenovirus	adenovirus	NOUN
fnp-3395	28	43	receptor	receptor	NOUN
fnp-3395	28	44	(	(	PUNCT
fnp-3395	28	45	car	car	NOUN
fnp-3395	28	46	)	)	PUNCT
fnp-3395	28	47	.	.	PUNCT
fnp-3395	29	1	spike	spike	ADJ
fnp-3395	29	2	protein	protein	NOUN
fnp-3395	29	3	induces	induce	VERB
fnp-3395	29	4	cox-2	cox-2	ADJ
fnp-3395	29	5	expression	expression	NOUN
fnp-3395	29	6	in	in	ADP
fnp-3395	29	7	megakaryocytes	megakaryocyte	NOUN
fnp-3395	29	8	leading	lead	VERB
fnp-3395	29	9	to	to	ADP
fnp-3395	29	10	megakaryocyte	megakaryocyte	NOUN
fnp-3395	29	11	activation	activation	NOUN
fnp-3395	29	12	,	,	PUNCT
fnp-3395	29	13	biogenesis	biogenesis	NOUN
fnp-3395	29	14	of	of	ADP
fnp-3395	29	15	activated	activate	VERB
fnp-3395	29	16	platelets	platelet	NOUN
fnp-3395	29	17	that	that	PRON
fnp-3395	29	18	express	express	VERB
fnp-3395	29	19	cox-2	cox-2	NOUN
fnp-3395	29	20	and	and	CCONJ
fnp-3395	29	21	generate	generate	VERB
fnp-3395	29	22	thromboxane	thromboxane	NOUN
fnp-3395	29	23	a2	a2	PROPN
fnp-3395	29	24	(	(	PUNCT
fnp-3395	29	25	txa2	txa2	PROPN
fnp-3395	29	26	)	)	PUNCT
fnp-3395	29	27	.	.	PUNCT
fnp-3395	30	1	cerebral	cerebral	ADJ
fnp-3395	30	2	venous	venous	ADJ
fnp-3395	30	3	sinuses	sinus	NOUN
fnp-3395	30	4	express	express	VERB
fnp-3395	30	5	podoplanin	podoplanin	PROPN
fnp-3395	30	6	,	,	PUNCT
fnp-3395	30	7	a	a	DET
fnp-3395	30	8	natural	natural	ADJ
fnp-3395	30	9	ligand	ligand	NOUN
fnp-3395	30	10	for	for	ADP
fnp-3395	30	11	clec2	clec2	NOUN
fnp-3395	30	12	receptors	receptor	NOUN
fnp-3395	30	13	on	on	ADP
fnp-3395	30	14	platelets	platelet	NOUN
fnp-3395	30	15	.	.	PUNCT
fnp-3395	31	1	platelets	platelet	NOUN
fnp-3395	31	2	traversing	traverse	VERB
fnp-3395	31	3	through	through	ADP
fnp-3395	31	4	the	the	DET
fnp-3395	31	5	cerebral	cerebral	ADJ
fnp-3395	31	6	venous	venous	ADJ
fnp-3395	31	7	sinuses	sinus	NOUN
fnp-3395	31	8	would	would	AUX
fnp-3395	31	9	be	be	AUX
fnp-3395	31	10	further	far	ADV
fnp-3395	31	11	activated	activate	VERB
fnp-3395	31	12	by	by	ADP
fnp-3395	31	13	thromboxane	thromboxane	NOUN
fnp-3395	31	14	a2	a2	PROPN
fnp-3395	31	15	-	-	PUNCT
fnp-3395	31	16	dependent	dependent	ADJ
fnp-3395	31	17	podoplanin	podoplanin	PROPN
fnp-3395	31	18	-	-	PUNCT
fnp-3395	31	19	clec2	clec2	PROPN
fnp-3395	31	20	signaling	signaling	NOUN
fnp-3395	31	21	,	,	PUNCT
fnp-3395	31	22	leading	lead	VERB
fnp-3395	31	23	to	to	ADP
fnp-3395	31	24	release	release	NOUN
fnp-3395	31	25	of	of	ADP
fnp-3395	31	26	extracellular	extracellular	ADJ
fnp-3395	31	27	vesicles	vesicle	NOUN
fnp-3395	31	28	,	,	PUNCT
fnp-3395	31	29	thereby	thereby	ADV
fnp-3395	31	30	promoting	promote	VERB
fnp-3395	31	31	clec5aand	clec5aand	NOUN
fnp-3395	31	32	tlr2	tlr2	PROPN
fnp-3395	31	33	-	-	PUNCT
fnp-3395	31	34	mediated	mediate	VERB
fnp-3395	31	35	neutrophil	neutrophil	ADJ
fnp-3395	31	36	activation	activation	NOUN
fnp-3395	31	37	,	,	PUNCT
fnp-3395	31	38	thromboinflammation	thromboinflammation	NOUN
fnp-3395	31	39	and	and	CCONJ
fnp-3395	31	40	cvst	cvst	PROPN
fnp-3395	31	41	.	.	PUNCT
fnp-3395	32	1	young	young	ADJ
fnp-3395	32	2	age	age	NOUN
fnp-3395	32	3	and	and	CCONJ
fnp-3395	32	4	female	female	ADJ
fnp-3395	32	5	gender	gender	NOUN
fnp-3395	32	6	are	be	AUX
fnp-3395	32	7	associated	associate	VERB
fnp-3395	32	8	with	with	ADP
fnp-3395	32	9	increased	increase	VERB
fnp-3395	32	10	txa2	txa2	NOUN
fnp-3395	32	11	generation	generation	NOUN
fnp-3395	32	12	and	and	CCONJ
fnp-3395	32	13	platelet	platelet	NOUN
fnp-3395	32	14	activation	activation	NOUN
fnp-3395	32	15	,	,	PUNCT
fnp-3395	32	16	respectively	respectively	ADV
fnp-3395	32	17	,	,	PUNCT
fnp-3395	32	18	and	and	CCONJ
fnp-3395	32	19	hence	hence	ADV
fnp-3395	32	20	increased	increase	VERB
fnp-3395	32	21	risk	risk	NOUN
fnp-3395	32	22	of	of	ADP
fnp-3395	32	23	thromboembolic	thromboembolic	ADJ
fnp-3395	32	24	complications	complication	NOUN
fnp-3395	32	25	following	follow	VERB
fnp-3395	32	26	sars	sar	NOUN
fnp-3395	32	27	-	-	PUNCT
fnp-3395	32	28	cov-2	cov-2	PART
fnp-3395	32	29	vaccination	vaccination	NOUN
fnp-3395	32	30	with	with	ADP
fnp-3395	32	31	adenovirus	adenovirus	NOUN
fnp-3395	32	32	-	-	PUNCT
fnp-3395	32	33	based	base	VERB
fnp-3395	32	34	vaccines	vaccine	NOUN
fnp-3395	32	35	.	.	PUNCT
fnp-3395	33	1	spike	spike	ADJ
fnp-3395	33	2	protein	protein	NOUN
fnp-3395	33	3	of	of	ADP
fnp-3395	33	4	coronaviruses	coronaviruse	NOUN
fnp-3395	33	5	is	be	AUX
fnp-3395	33	6	known	know	VERB
fnp-3395	33	7	to	to	PART
fnp-3395	33	8	induce	induce	VERB
fnp-3395	33	9	cox-2	cox-2	ADJ
fnp-3395	33	10	gene	gene	NOUN
fnp-3395	33	11	expression.21,31	expression.21,31	NOUN
fnp-3395	33	12	cox-2	cox-2	DET
fnp-3395	33	13	expression	expression	NOUN
fnp-3395	33	14	is	be	AUX
fnp-3395	33	15	induced	induce	VERB
fnp-3395	33	16	during	during	ADP
fnp-3395	33	17	normal	normal	ADJ
fnp-3395	33	18	human	human	ADJ
fnp-3395	33	19	megakaryopoiesis	megakaryopoiesis	NOUN
fnp-3395	33	20	and	and	CCONJ
fnp-3395	33	21	characterizes	characterize	VERB
fnp-3395	33	22	newly	newly	ADV
fnp-3395	33	23	formed	form	VERB
fnp-3395	33	24	platelets.32	platelets.32	VERB
fnp-3395	33	25	while	while	SCONJ
fnp-3395	33	26	in	in	ADP
fnp-3395	33	27	healthy	healthy	ADJ
fnp-3395	33	28	controls	control	NOUN
fnp-3395	33	29	<	<	X
fnp-3395	33	30	10	10	NUM
fnp-3395	33	31	%	%	NOUN
fnp-3395	33	32	of	of	ADP
fnp-3395	33	33	circulating	circulate	VERB
fnp-3395	33	34	platelets	platelet	NOUN
fnp-3395	33	35	express	express	VERB
fnp-3395	33	36	cox-2	cox-2	NOUN
fnp-3395	33	37	,	,	PUNCT
fnp-3395	33	38	in	in	ADP
fnp-3395	33	39	patients	patient	NOUN
fnp-3395	33	40	with	with	ADP
fnp-3395	33	41	high	high	ADJ
fnp-3395	33	42	platelet	platelet	NOUN
fnp-3395	33	43	generation	generation	NOUN
fnp-3395	33	44	,	,	PUNCT
fnp-3395	33	45	up	up	ADV
fnp-3395	33	46	to	to	PART
fnp-3395	33	47	60	60	NUM
fnp-3395	33	48	%	%	NOUN
fnp-3395	33	49	of	of	ADP
fnp-3395	33	50	platelets	platelet	NOUN
fnp-3395	33	51	express	express	VERB
fnp-3395	33	52	cox-2.32	cox-2.32	ADJ
fnp-3395	33	53	generation	generation	NOUN
fnp-3395	33	54	of	of	ADP
fnp-3395	33	55	txa2	txa2	NOUN
fnp-3395	33	56	by	by	ADP
fnp-3395	33	57	platelets	platelet	NOUN
fnp-3395	33	58	is	be	AUX
fnp-3395	33	59	markedly	markedly	ADV
fnp-3395	33	60	suppressed	suppress	VERB
fnp-3395	33	61	by	by	ADP
fnp-3395	33	62	cox-2	cox-2	SYM
fnp-3395	33	63	inhibition	inhibition	NOUN
fnp-3395	33	64	in	in	ADP
fnp-3395	33	65	patients	patient	NOUN
fnp-3395	33	66	with	with	ADP
fnp-3395	33	67	increased	increase	VERB
fnp-3395	33	68	megakaryopoiesis	megakaryopoiesis	NOUN
fnp-3395	33	69	versus	versus	ADP
fnp-3395	33	70	healthy	healthy	ADJ
fnp-3395	33	71	subjects.32	subjects.32	PROPN
fnp-3395	33	72	therefore	therefore	ADV
fnp-3395	33	73	,	,	PUNCT
fnp-3395	33	74	we	we	PRON
fnp-3395	33	75	postulate	postulate	VERB
fnp-3395	33	76	that	that	SCONJ
fnp-3395	33	77	expression	expression	NOUN
fnp-3395	33	78	of	of	ADP
fnp-3395	33	79	spike	spike	ADJ
fnp-3395	33	80	protein	protein	NOUN
fnp-3395	33	81	induces	induce	VERB
fnp-3395	33	82	cox-2	cox-2	ADJ
fnp-3395	33	83	expression	expression	NOUN
fnp-3395	33	84	and	and	CCONJ
fnp-3395	33	85	generation	generation	NOUN
fnp-3395	33	86	of	of	ADP
fnp-3395	33	87	thromboxane	thromboxane	NOUN
fnp-3395	33	88	a2	a2	PROPN
fnp-3395	33	89	by	by	ADP
fnp-3395	33	90	megakaryocytes	megakaryocyte	NOUN
fnp-3395	33	91	.	.	PUNCT
fnp-3395	34	1	txa2	txa2	PROPN
fnp-3395	34	2	promotes	promote	VERB
fnp-3395	34	3	biogenesis	biogenesis	NOUN
fnp-3395	34	4	of	of	ADP
fnp-3395	34	5	activated	activate	VERB
fnp-3395	34	6	platelets	platelet	NOUN
fnp-3395	34	7	expressing	express	VERB
fnp-3395	34	8	cox-2	cox-2	NOUN
fnp-3395	34	9	.	.	PUNCT
fnp-3395	35	1	platelet	platelet	NOUN
fnp-3395	35	2	txa2	txa2	PROPN
fnp-3395	35	3	generation	generation	NOUN
fnp-3395	35	4	leads	lead	VERB
fnp-3395	35	5	to	to	ADP
fnp-3395	35	6	platelet	platelet	NOUN
fnp-3395	35	7	activation	activation	NOUN
fnp-3395	35	8	and	and	CCONJ
fnp-3395	35	9	aggregation	aggregation	NOUN
fnp-3395	35	10	,	,	PUNCT
fnp-3395	35	11	and	and	CCONJ
fnp-3395	35	12	thereby	thereby	ADV
fnp-3395	35	13	thromboinflammation	thromboinflammation	NOUN
fnp-3395	35	14	(	(	PUNCT
fnp-3395	35	15	figure	figure	NOUN
fnp-3395	35	16	1	1	NUM
fnp-3395	35	17	)	)	PUNCT
fnp-3395	35	18	.	.	PUNCT
fnp-3395	36	1	extravascular	extravascular	ADJ
fnp-3395	36	2	spaces	space	NOUN
fnp-3395	36	3	of	of	ADP
fnp-3395	36	4	the	the	DET
fnp-3395	36	5	lungs	lung	NOUN
fnp-3395	36	6	comprise	comprise	VERB
fnp-3395	36	7	populations	population	NOUN
fnp-3395	36	8	of	of	ADP
fnp-3395	36	9	mature	mature	ADJ
fnp-3395	36	10	and	and	CCONJ
fnp-3395	36	11	immature	immature	ADJ
fnp-3395	36	12	megakaryocytes	megakaryocyte	NOUN
fnp-3395	36	13	that	that	PRON
fnp-3395	36	14	originate	originate	VERB
fnp-3395	36	15	from	from	ADP
fnp-3395	36	16	the	the	DET
fnp-3395	36	17	bone	bone	NOUN
fnp-3395	36	18	marrow	marrow	NOUN
fnp-3395	36	19	,	,	PUNCT
fnp-3395	36	20	such	such	ADJ
fnp-3395	36	21	that	that	SCONJ
fnp-3395	36	22	lungs	lung	NOUN
fnp-3395	36	23	are	be	AUX
fnp-3395	36	24	a	a	DET
fnp-3395	36	25	major	major	ADJ
fnp-3395	36	26	site	site	NOUN
fnp-3395	36	27	of	of	ADP
fnp-3395	36	28	platelet	platelet	NOUN
fnp-3395	36	29	biogenesis	biogenesis	NOUN
fnp-3395	36	30	,	,	PUNCT
fnp-3395	36	31	accounting	account	VERB
fnp-3395	36	32	for	for	ADP
fnp-3395	36	33	approximately	approximately	ADV
fnp-3395	36	34	50	50	NUM
fnp-3395	36	35	%	%	NOUN
fnp-3395	36	36	of	of	ADP
fnp-3395	36	37	total	total	ADJ
fnp-3395	36	38	platelet	platelet	NOUN
fnp-3395	36	39	production	production	NOUN
fnp-3395	36	40	or	or	CCONJ
fnp-3395	36	41	about	about	ADV
fnp-3395	36	42	10	10	NUM
fnp-3395	36	43	million	million	NUM
fnp-3395	36	44	platelets	platelet	NOUN
fnp-3395	36	45	per	per	ADP
fnp-3395	36	46	hour.33	hour.33	NOUN
fnp-3395	36	47	more	more	ADJ
fnp-3395	36	48	than	than	ADP
fnp-3395	36	49	1	1	NUM
fnp-3395	36	50	million	million	NUM
fnp-3395	36	51	extravascular	extravascular	ADJ
fnp-3395	36	52	megakaryocytes	megakaryocyte	NOUN
fnp-3395	36	53	have	have	AUX
fnp-3395	36	54	been	be	AUX
fnp-3395	36	55	observed	observe	VERB
fnp-3395	36	56	in	in	ADP
fnp-3395	36	57	each	each	DET
fnp-3395	36	58	lung	lung	NOUN
fnp-3395	36	59	of	of	ADP
fnp-3395	36	60	transplant	transplant	NOUN
fnp-3395	36	61	mice.33	mice.33	NOUN
fnp-3395	36	62	following	follow	VERB
fnp-3395	36	63	intramuscular	intramuscular	ADJ
fnp-3395	36	64	injection	injection	NOUN
fnp-3395	36	65	of	of	ADP
fnp-3395	36	66	the	the	DET
fnp-3395	36	67	astrazeneca	astrazeneca	NOUN
fnp-3395	36	68	and	and	CCONJ
fnp-3395	36	69	janssen	janssen	PROPN
fnp-3395	36	70	vaccines	vaccine	NOUN
fnp-3395	36	71	,	,	PUNCT
fnp-3395	36	72	the	the	DET
fnp-3395	36	73	adenovirus	adenovirus	NOUN
fnp-3395	36	74	vector	vector	NOUN
fnp-3395	36	75	will	will	AUX
fnp-3395	36	76	traverse	traverse	VERB
fnp-3395	36	77	the	the	DET
fnp-3395	36	78	veins	vein	NOUN
fnp-3395	36	79	and	and	CCONJ
fnp-3395	36	80	lymphatics	lymphatic	NOUN
fnp-3395	36	81	to	to	PART
fnp-3395	36	82	be	be	AUX
fnp-3395	36	83	delivered	deliver	VERB
fnp-3395	36	84	to	to	ADP
fnp-3395	36	85	the	the	DET
fnp-3395	36	86	pulmonary	pulmonary	ADJ
fnp-3395	36	87	circulation	circulation	NOUN
fnp-3395	36	88	,	,	PUNCT
fnp-3395	36	89	thereby	thereby	ADV
fnp-3395	36	90	exposing	expose	VERB
fnp-3395	36	91	lung	lung	NOUN
fnp-3395	36	92	megakaryocytes	megakaryocyte	NOUN
fnp-3395	36	93	in	in	ADP
fnp-3395	36	94	the	the	DET
fnp-3395	36	95	first	first	ADJ
fnp-3395	36	96	pass	pass	NOUN
fnp-3395	36	97	.	.	PUNCT
fnp-3395	37	1	interestingly	interestingly	ADV
fnp-3395	37	2	,	,	PUNCT
fnp-3395	37	3	under	under	ADP
fnp-3395	37	4	thrombocytopenic	thrombocytopenic	ADJ
fnp-3395	37	5	conditions	condition	NOUN
fnp-3395	37	6	,	,	PUNCT
fnp-3395	37	7	haematopoietic	haematopoietic	ADJ
fnp-3395	37	8	progenitors	progenitor	NOUN
fnp-3395	37	9	migrate	migrate	VERB
fnp-3395	37	10	out	out	ADP
fnp-3395	37	11	of	of	ADP
fnp-3395	37	12	the	the	DET
fnp-3395	37	13	lung	lung	NOUN
fnp-3395	37	14	to	to	PART
fnp-3395	37	15	repopulate	repopulate	VERB
fnp-3395	37	16	the	the	DET
fnp-3395	37	17	bone	bone	NOUN
fnp-3395	37	18	marrow	marrow	NOUN
fnp-3395	37	19	and	and	CCONJ
fnp-3395	37	20	completely	completely	ADV
fnp-3395	37	21	reconstitute	reconstitute	VERB
fnp-3395	37	22	blood	blood	NOUN
fnp-3395	37	23	platelet	platelet	NOUN
fnp-3395	37	24	count.33	count.33	PROPN
fnp-3395	37	25	since	since	SCONJ
fnp-3395	37	26	thrombocytopenia	thrombocytopenia	PROPN
fnp-3395	37	27	is	be	AUX
fnp-3395	37	28	a	a	DET
fnp-3395	37	29	common	common	ADJ
fnp-3395	37	30	feature	feature	NOUN
fnp-3395	37	31	of	of	ADP
fnp-3395	37	32	cvst	cvst	NOUN
fnp-3395	37	33	associated	associate	VERB
fnp-3395	37	34	with	with	ADP
fnp-3395	37	35	adenovirus	adenovirus	NOUN
fnp-3395	37	36	sars	sar	NOUN
fnp-3395	37	37	-	-	PUNCT
fnp-3395	37	38	cov-2	cov-2	NOUN
fnp-3395	37	39	vaccines	vaccine	NOUN
fnp-3395	37	40	,	,	PUNCT
fnp-3395	37	41	migration	migration	NOUN
fnp-3395	37	42	of	of	ADP
fnp-3395	37	43	megakaryocytes	megakaryocyte	NOUN
fnp-3395	37	44	from	from	ADP
fnp-3395	37	45	the	the	DET
fnp-3395	37	46	lungs	lung	NOUN
fnp-3395	37	47	into	into	ADP
fnp-3395	37	48	the	the	DET
fnp-3395	37	49	systemic	systemic	ADJ
fnp-3395	37	50	circulation	circulation	NOUN
fnp-3395	37	51	including	include	VERB
fnp-3395	37	52	the	the	DET
fnp-3395	37	53	cerebral	cerebral	ADJ
fnp-3395	37	54	circulation	circulation	NOUN
fnp-3395	37	55	could	could	AUX
fnp-3395	37	56	further	far	ADV
fnp-3395	37	57	predispose	predispose	VERB
fnp-3395	37	58	to	to	ADP
fnp-3395	37	59	cvst	cvst	PROPN
fnp-3395	37	60	.	.	PUNCT
fnp-3395	38	1	in	in	ADP
fnp-3395	38	2	this	this	DET
fnp-3395	38	3	regard	regard	NOUN
fnp-3395	38	4	,	,	PUNCT
fnp-3395	38	5	it	it	PRON
fnp-3395	38	6	is	be	AUX
fnp-3395	38	7	relevant	relevant	ADJ
fnp-3395	38	8	that	that	SCONJ
fnp-3395	38	9	megakaryocytes	megakaryocyte	NOUN
fnp-3395	38	10	have	have	AUX
fnp-3395	38	11	been	be	AUX
fnp-3395	38	12	found	find	VERB
fnp-3395	38	13	in	in	ADP
fnp-3395	38	14	the	the	DET
fnp-3395	38	15	cerebral	cerebral	ADJ
fnp-3395	38	16	circulation	circulation	NOUN
fnp-3395	38	17	in	in	ADP
fnp-3395	38	18	patients	patient	NOUN
fnp-3395	38	19	deceased	decease	VERB
fnp-3395	38	20	from	from	ADP
fnp-3395	38	21	severe	severe	ADJ
fnp-3395	38	22	covid-19.34	covid-19.34	NOUN
fnp-3395	38	23	the	the	DET
fnp-3395	38	24	prothrombotic	prothrombotic	ADJ
fnp-3395	38	25	mechanisms	mechanism	NOUN
fnp-3395	38	26	postulated	postulate	VERB
fnp-3395	38	27	above	above	ADV
fnp-3395	38	28	could	could	AUX
fnp-3395	38	29	be	be	AUX
fnp-3395	38	30	operative	operative	ADJ
fnp-3395	38	31	alone	alone	ADJ
fnp-3395	38	32	or	or	CCONJ
fnp-3395	38	33	in	in	ADP
fnp-3395	38	34	conjunction	conjunction	NOUN
fnp-3395	38	35	with	with	ADP
fnp-3395	38	36	other	other	ADJ
fnp-3395	38	37	underlying	underlie	VERB
fnp-3395	38	38	factors	factor	NOUN
fnp-3395	38	39	that	that	PRON
fnp-3395	38	40	have	have	AUX
fnp-3395	38	41	been	be	AUX
fnp-3395	38	42	proposed	propose	VERB
fnp-3395	38	43	including	include	VERB
fnp-3395	38	44	the	the	DET
fnp-3395	38	45	presence	presence	NOUN
fnp-3395	38	46	of	of	ADP
fnp-3395	38	47	anti	anti	ADJ
fnp-3395	38	48	-	-	ADJ
fnp-3395	38	49	platelet	platelet	ADJ
fnp-3395	38	50	factor	factor	NOUN
fnp-3395	38	51	4	4	NUM
fnp-3395	38	52	(	(	PUNCT
fnp-3395	38	53	pf4	pf4	NOUN
fnp-3395	38	54	)	)	PUNCT
fnp-3395	38	55	antibodies	antibody	NOUN
fnp-3395	38	56	as	as	SCONJ
fnp-3395	38	57	reported	report	VERB
fnp-3395	38	58	by	by	ADP
fnp-3395	38	59	greinacher	greinacher	NOUN
fnp-3395	38	60	and	and	CCONJ
fnp-3395	38	61	others.7	others.7	PROPN
fnp-3395	38	62	notably	notably	ADV
fnp-3395	38	63	,	,	PUNCT
fnp-3395	38	64	amongst	amongst	ADP
fnp-3395	38	65	31	31	NUM
fnp-3395	38	66	cases	case	NOUN
fnp-3395	38	67	of	of	ADP
fnp-3395	38	68	cvst	cvst	PROPN
fnp-3395	38	69	in	in	ADP
fnp-3395	38	70	close	close	ADJ
fnp-3395	38	71	temporal	temporal	ADJ
fnp-3395	38	72	relationship	relationship	NOUN
fnp-3395	38	73	with	with	ADP
fnp-3395	38	74	a	a	DET
fnp-3395	38	75	covid-19	covid-19	PROPN
fnp-3395	38	76	vaccination	vaccination	NOUN
fnp-3395	38	77	,	,	PUNCT
fnp-3395	38	78	anti	anti	ADJ
fnp-3395	38	79	-	-	ADJ
fnp-3395	38	80	pf4	pf4	ADJ
fnp-3395	38	81	antibodies	antibody	NOUN
fnp-3395	38	82	were	be	AUX
fnp-3395	38	83	positive	positive	ADJ
fnp-3395	38	84	in	in	ADP
fnp-3395	38	85	22	22	NUM
fnp-3395	38	86	cases	case	NOUN
fnp-3395	38	87	and	and	CCONJ
fnp-3395	38	88	negative	negative	ADJ
fnp-3395	38	89	in	in	ADP
fnp-3395	38	90	9.35	9.35	NUM
fnp-3395	38	91	therefore	therefore	ADV
fnp-3395	38	92	,	,	PUNCT
fnp-3395	38	93	cvst	cvst	NOUN
fnp-3395	38	94	following	follow	VERB
fnp-3395	38	95	covid-19	covid-19	PROPN
fnp-3395	38	96	vaccination	vaccination	NOUN
fnp-3395	38	97	appears	appear	VERB
fnp-3395	38	98	to	to	PART
fnp-3395	38	99	be	be	AUX
fnp-3395	38	100	a	a	DET
fnp-3395	38	101	multifactorial	multifactorial	ADJ
fnp-3395	38	102	disease	disease	NOUN
fnp-3395	38	103	.	.	PUNCT
fnp-3395	39	1	further	further	ADJ
fnp-3395	39	2	studies	study	NOUN
fnp-3395	39	3	using	use	VERB
fnp-3395	39	4	cultured	cultured	ADJ
fnp-3395	39	5	megakaryocytes	megakaryocyte	NOUN
fnp-3395	39	6	and	and	CCONJ
fnp-3395	39	7	animal	animal	NOUN
fnp-3395	39	8	models	model	NOUN
fnp-3395	39	9	are	be	AUX
fnp-3395	39	10	needed	need	VERB
fnp-3395	39	11	to	to	PART
fnp-3395	39	12	define	define	VERB
fnp-3395	39	13	the	the	DET
fnp-3395	39	14	underlying	underlie	VERB
fnp-3395	39	15	mechanisms	mechanism	NOUN
fnp-3395	39	16	.	.	PUNCT
fnp-3395	40	1	even	even	ADV
fnp-3395	40	2	though	though	SCONJ
fnp-3395	40	3	the	the	DET
fnp-3395	40	4	risk	risk	NOUN
fnp-3395	40	5	of	of	ADP
fnp-3395	40	6	cvst	cvst	PROPN
fnp-3395	40	7	is	be	AUX
fnp-3395	40	8	increased	increase	VERB
fnp-3395	40	9	about	about	ADV
fnp-3395	40	10	10	10	NUM
fnp-3395	40	11	-	-	NOUN
fnp-3395	40	12	fold	fold	ADJ
fnp-3395	40	13	by	by	ADP
fnp-3395	40	14	the	the	DET
fnp-3395	40	15	adenovirus	adenovirus	NOUN
fnp-3395	40	16	based	base	VERB
fnp-3395	40	17	covid-19	covid-19	PROPN
fnp-3395	40	18	vaccines,36	vaccines,36	NOUN
fnp-3395	40	19	it	it	PRON
fnp-3395	40	20	remains	remain	VERB
fnp-3395	40	21	unclear	unclear	ADJ
fnp-3395	40	22	why	why	SCONJ
fnp-3395	40	23	cvst	cvst	PROPN
fnp-3395	40	24	remains	remain	VERB
fnp-3395	40	25	a	a	DET
fnp-3395	40	26	rare	rare	ADJ
fnp-3395	40	27	event	event	NOUN
fnp-3395	40	28	.	.	PUNCT
fnp-3395	41	1	to	to	PART
fnp-3395	41	2	further	far	ADV
fnp-3395	41	3	define	define	VERB
fnp-3395	41	4	the	the	DET
fnp-3395	41	5	importance	importance	NOUN
fnp-3395	41	6	of	of	ADP
fnp-3395	41	7	these	these	DET
fnp-3395	41	8	causative	causative	ADJ
fnp-3395	41	9	factors	factor	NOUN
fnp-3395	41	10	,	,	PUNCT
fnp-3395	41	11	biomarkers	biomarker	NOUN
fnp-3395	41	12	such	such	ADJ
fnp-3395	41	13	as	as	ADP
fnp-3395	41	14	plasma	plasma	NOUN
fnp-3395	41	15	thromboxane	thromboxane	NOUN
fnp-3395	41	16	b2	b2	NOUN
fnp-3395	41	17	,	,	PUNCT
fnp-3395	41	18	anti	anti	ADJ
fnp-3395	41	19	-	-	ADJ
fnp-3395	41	20	pf4	pf4	ADJ
fnp-3395	41	21	antibodies	antibody	NOUN
fnp-3395	41	22	and	and	CCONJ
fnp-3395	41	23	anti	anti	ADJ
fnp-3395	41	24	-	-	ADJ
fnp-3395	41	25	phospholipid	phospholipid	ADJ
fnp-3395	41	26	antibodies	antibody	NOUN
fnp-3395	41	27	should	should	AUX
fnp-3395	41	28	be	be	AUX
fnp-3395	41	29	measured	measure	VERB
fnp-3395	41	30	in	in	ADP
fnp-3395	41	31	the	the	DET
fnp-3395	41	32	thrombosis	thrombosis	NOUN
fnp-3395	41	33	-	-	PUNCT
fnp-3395	41	34	free	free	ADJ
fnp-3395	41	35	vaccinated	vaccinated	ADJ
fnp-3395	41	36	population	population	NOUN
fnp-3395	41	37	.	.	PUNCT
fnp-3395	42	1	such	such	ADJ
fnp-3395	42	2	studies	study	NOUN
fnp-3395	42	3	may	may	AUX
fnp-3395	42	4	help	help	VERB
fnp-3395	42	5	define	define	VERB
fnp-3395	42	6	the	the	DET
fnp-3395	42	7	role	role	NOUN
fnp-3395	42	8	of	of	ADP
fnp-3395	42	9	anti	anti	ADJ
fnp-3395	42	10	-	-	ADJ
fnp-3395	42	11	pf4	pf4	ADJ
fnp-3395	42	12	antibodies	antibody	NOUN
fnp-3395	42	13	as	as	ADP
fnp-3395	42	14	causative	causative	ADJ
fnp-3395	42	15	versus	versus	ADP
fnp-3395	42	16	an	an	DET
fnp-3395	42	17	epiphenomenon	epiphenomenon	NOUN
fnp-3395	42	18	.	.	PUNCT
fnp-3395	43	1	interestingly	interestingly	ADV
fnp-3395	43	2	,	,	PUNCT
fnp-3395	43	3	almost	almost	ADV
fnp-3395	43	4	all	all	PRON
fnp-3395	43	5	patients	patient	NOUN
fnp-3395	43	6	with	with	ADP
fnp-3395	43	7	thrombosis	thrombosis	NOUN
fnp-3395	43	8	and	and	CCONJ
fnp-3395	43	9	thrombocytopenia	thrombocytopenia	NOUN
fnp-3395	43	10	were	be	AUX
fnp-3395	43	11	found	find	VERB
fnp-3395	43	12	to	to	PART
fnp-3395	43	13	have	have	VERB
fnp-3395	43	14	anti	anti	ADJ
fnp-3395	43	15	-	-	ADJ
fnp-3395	43	16	pf4	pf4	ADJ
fnp-3395	43	17	antibodies.35	antibodies.35	NOUN
fnp-3395	43	18	on	on	ADP
fnp-3395	43	19	the	the	DET
fnp-3395	43	20	other	other	ADJ
fnp-3395	43	21	hand	hand	NOUN
fnp-3395	43	22	,	,	PUNCT
fnp-3395	43	23	majority	majority	NOUN
fnp-3395	43	24	of	of	ADP
fnp-3395	43	25	patients	patient	NOUN
fnp-3395	43	26	with	with	ADP
fnp-3395	43	27	thrombosis	thrombosis	NOUN
fnp-3395	43	28	without	without	ADP
fnp-3395	43	29	thrombocytopenia	thrombocytopenia	PROPN
fnp-3395	43	30	lacked	lack	VERB
fnp-3395	43	31	anti	anti	ADJ
fnp-3395	43	32	-	-	ADJ
fnp-3395	43	33	pf4	pf4	ADJ
fnp-3395	43	34	antibodies.35	antibodies.35	NOUN
fnp-3395	43	35	the	the	DET
fnp-3395	43	36	postulated	postulate	VERB
fnp-3395	43	37	mechanisms	mechanism	NOUN
fnp-3395	43	38	may	may	AUX
fnp-3395	43	39	be	be	AUX
fnp-3395	43	40	especially	especially	ADV
fnp-3395	43	41	relevant	relevant	ADJ
fnp-3395	43	42	to	to	ADP
fnp-3395	43	43	thrombotic	thrombotic	ADJ
fnp-3395	43	44	events	event	NOUN
fnp-3395	43	45	occurring	occur	VERB
fnp-3395	43	46	in	in	ADP
fnp-3395	43	47	the	the	DET
fnp-3395	43	48	absence	absence	NOUN
fnp-3395	43	49	of	of	ADP
fnp-3395	43	50	thrombocytopenia	thrombocytopenia	NOUN
fnp-3395	43	51	or	or	CCONJ
fnp-3395	43	52	anti	anti	ADJ
fnp-3395	43	53	-	-	ADJ
fnp-3395	43	54	pf4	pf4	ADJ
fnp-3395	43	55	antibodies	antibody	NOUN
fnp-3395	43	56	.	.	PUNCT
fnp-3395	44	1	b.	b.	PROPN
fnp-3395	44	2	predilection	predilection	NOUN
fnp-3395	44	3	of	of	ADP
fnp-3395	44	4	cerebral	cerebral	ADJ
fnp-3395	44	5	venous	venous	ADJ
fnp-3395	44	6	sinuses	sinus	NOUN
fnp-3395	44	7	for	for	ADP
fnp-3395	44	8	thrombosis	thrombosis	NOUN
fnp-3395	44	9	following	follow	VERB
fnp-3395	44	10	vaccination	vaccination	NOUN
fnp-3395	44	11	recent	recent	ADJ
fnp-3395	44	12	studies	study	NOUN
fnp-3395	44	13	have	have	AUX
fnp-3395	44	14	demonstrated	demonstrate	VERB
fnp-3395	44	15	that	that	SCONJ
fnp-3395	44	16	arterial	arterial	NOUN
fnp-3395	44	17	,	,	PUNCT
fnp-3395	44	18	venous	venous	ADJ
fnp-3395	44	19	and	and	CCONJ
fnp-3395	44	20	sinusoidal	sinusoidal	ADJ
fnp-3395	44	21	endothelial	endothelial	ADJ
fnp-3395	44	22	cells	cell	NOUN
fnp-3395	44	23	in	in	ADP
fnp-3395	44	24	the	the	DET
fnp-3395	44	25	brain	brain	NOUN
fnp-3395	44	26	uniquely	uniquely	ADV
fnp-3395	44	27	express	express	VERB
fnp-3395	44	28	markers	marker	NOUN
fnp-3395	44	29	of	of	ADP
fnp-3395	44	30	the	the	DET
fnp-3395	44	31	lymphatic	lymphatic	ADJ
fnp-3395	44	32	endothelium	endothelium	NOUN
fnp-3395	44	33	including	include	VERB
fnp-3395	44	34	podoplanin.37	podoplanin.37	PROPN
fnp-3395	44	35	podoplanin	podoplanin	PROPN
fnp-3395	44	36	(	(	PUNCT
fnp-3395	44	37	d2	d2	PROPN
fnp-3395	44	38	-	-	PUNCT
fnp-3395	44	39	40	40	NUM
fnp-3395	44	40	)	)	PUNCT
fnp-3395	44	41	serves	serve	VERB
fnp-3395	44	42	as	as	ADP
fnp-3395	44	43	a	a	DET
fnp-3395	44	44	ligand	ligand	NOUN
fnp-3395	44	45	for	for	ADP
fnp-3395	44	46	clec2	clec2	NOUN
fnp-3395	44	47	receptors	receptor	NOUN
fnp-3395	44	48	on	on	ADP
fnp-3395	44	49	platelets.38	platelets.38	PROPN
fnp-3395	44	50	thromboxane	thromboxane	NOUN
fnp-3395	44	51	a2	a2	PROPN
fnp-3395	44	52	-	-	PUNCT
fnp-3395	44	53	dependent	dependent	ADJ
fnp-3395	45	1	clec2	clec2	NOUN
fnp-3395	46	1	signaling	signal	VERB
fnp-3395	46	2	leads	lead	VERB
fnp-3395	46	3	to	to	ADP
fnp-3395	46	4	platelet	platelet	NOUN
fnp-3395	46	5	activation	activation	NOUN
fnp-3395	46	6	(	(	PUNCT
fnp-3395	46	7	figure	figure	NOUN
fnp-3395	46	8	1	1	NUM
fnp-3395	46	9	)	)	PUNCT
fnp-3395	46	10	,	,	PUNCT
fnp-3395	46	11	while	while	SCONJ
fnp-3395	46	12	a	a	DET
fnp-3395	46	13	txa2	txa2	NOUN
fnp-3395	46	14	receptor	receptor	NOUN
fnp-3395	46	15	antagonist	antagonist	NOUN
fnp-3395	46	16	nearly	nearly	ADV
fnp-3395	46	17	abolished	abolish	VERB
fnp-3395	46	18	clec2	clec2	PROPN
fnp-3395	46	19	signaling	signaling	NOUN
fnp-3395	46	20	and	and	CCONJ
fnp-3395	46	21	platelet	platelet	NOUN
fnp-3395	46	22	activation.38	activation.38	ADJ
fnp-3395	47	1	txa2	txa2	NOUN
fnp-3395	47	2	-	-	PUNCT
fnp-3395	47	3	dependent	dependent	ADJ
fnp-3395	47	4	clec2	clec2	NOUN
fnp-3395	47	5	signaling	signal	VERB
fnp-3395	47	6	promotes	promote	VERB
fnp-3395	47	7	release	release	NOUN
fnp-3395	47	8	of	of	ADP
fnp-3395	47	9	exosomes	exosome	NOUN
fnp-3395	47	10	and	and	CCONJ
fnp-3395	47	11	microvesicles	microvesicle	NOUN
fnp-3395	47	12	from	from	ADP
fnp-3395	47	13	platelets	platelet	NOUN
fnp-3395	47	14	,	,	PUNCT
fnp-3395	47	15	leading	lead	VERB
fnp-3395	47	16	to	to	ADP
fnp-3395	47	17	activation	activation	NOUN
fnp-3395	47	18	of	of	ADP
fnp-3395	47	19	clec5a	clec5a	PROPN
fnp-3395	47	20	and	and	CCONJ
fnp-3395	47	21	tlr2	tlr2	VERB
fnp-3395	47	22	receptors	receptor	NOUN
fnp-3395	47	23	respectively	respectively	ADV
fnp-3395	47	24	on	on	ADP
fnp-3395	47	25	neutrophils	neutrophil	NOUN
fnp-3395	47	26	,	,	PUNCT
fnp-3395	47	27	neutrophil	neutrophil	ADJ
fnp-3395	47	28	activation	activation	NOUN
fnp-3395	47	29	and	and	CCONJ
fnp-3395	47	30	release	release	NOUN
fnp-3395	47	31	of	of	ADP
fnp-3395	47	32	neutrophil	neutrophil	ADJ
fnp-3395	47	33	extracellular	extracellular	ADJ
fnp-3395	47	34	traps	trap	NOUN
fnp-3395	47	35	(	(	PUNCT
fnp-3395	47	36	nets	net	NOUN
fnp-3395	47	37	)	)	PUNCT
fnp-3395	47	38	(	(	PUNCT
fnp-3395	47	39	figure	figure	VERB
fnp-3395	47	40	1).39	1).39	NUM
fnp-3395	47	41	neutrophil	neutrophil	ADJ
fnp-3395	47	42	activation	activation	NOUN
fnp-3395	47	43	,	,	PUNCT
fnp-3395	47	44	more	more	ADJ
fnp-3395	47	45	than	than	ADP
fnp-3395	47	46	platelet	platelet	NOUN
fnp-3395	47	47	activation	activation	NOUN
fnp-3395	47	48	,	,	PUNCT
fnp-3395	47	49	is	be	AUX
fnp-3395	47	50	associated	associate	VERB
fnp-3395	47	51	with	with	ADP
fnp-3395	47	52	thrombotic	thrombotic	ADJ
fnp-3395	47	53	complications	complication	NOUN
fnp-3395	47	54	in	in	ADP
fnp-3395	47	55	covid-19.13,18,40	covid-19.13,18,40	VERB
fnp-3395	47	56	as	as	ADP
fnp-3395	47	57	proposed	propose	VERB
fnp-3395	47	58	above	above	ADV
fnp-3395	47	59	,	,	PUNCT
fnp-3395	47	60	the	the	DET
fnp-3395	47	61	expression	expression	NOUN
fnp-3395	47	62	of	of	ADP
fnp-3395	47	63	podoplanin	podoplanin	PROPN
fnp-3395	47	64	by	by	ADP
fnp-3395	47	65	cerebral	cerebral	ADJ
fnp-3395	47	66	venous	venous	ADJ
fnp-3395	47	67	sinuses	sinus	NOUN
fnp-3395	47	68	may	may	AUX
fnp-3395	47	69	be	be	AUX
fnp-3395	47	70	responsible	responsible	ADJ
fnp-3395	47	71	for	for	ADP
fnp-3395	47	72	the	the	DET
fnp-3395	47	73	predilection	predilection	NOUN
fnp-3395	47	74	of	of	ADP
fnp-3395	47	75	brain	brain	NOUN
fnp-3395	47	76	vascular	vascular	ADJ
fnp-3395	47	77	bed	bed	NOUN
fnp-3395	47	78	to	to	ADP
fnp-3395	47	79	thromboinflammation	thromboinflammation	NOUN
fnp-3395	47	80	and	and	CCONJ
fnp-3395	47	81	cvst	cvst	PROPN
fnp-3395	47	82	as	as	ADP
fnp-3395	47	83	a	a	DET
fnp-3395	47	84	complication	complication	NOUN
fnp-3395	47	85	of	of	ADP
fnp-3395	47	86	covid-19	covid-19	PROPN
fnp-3395	47	87	vaccines	vaccine	NOUN
fnp-3395	47	88	.	.	PUNCT
fnp-3395	48	1	the	the	DET
fnp-3395	48	2	valves	valve	NOUN
fnp-3395	48	3	at	at	ADP
fnp-3395	48	4	the	the	DET
fnp-3395	48	5	lymphovenous	lymphovenous	ADJ
fnp-3395	48	6	junction	junction	NOUN
fnp-3395	48	7	and	and	CCONJ
fnp-3395	48	8	the	the	DET
fnp-3395	48	9	podoplanin	podoplanin	PROPN
fnp-3395	48	10	-	-	PUNCT
fnp-3395	48	11	clec2	clec2	PROPN
fnp-3395	48	12	lymphovenous	lymphovenous	ADJ
fnp-3395	48	13	hemostasis	hemostasis	NOUN
fnp-3395	48	14	act	act	NOUN
fnp-3395	48	15	as	as	ADP
fnp-3395	48	16	“	"	PUNCT
fnp-3395	48	17	fail	fail	ADJ
fnp-3395	48	18	-	-	PUNCT
fnp-3395	48	19	safe	safe	ADJ
fnp-3395	48	20	”	"	PUNCT
fnp-3395	48	21	mechanisms	mechanism	NOUN
fnp-3395	48	22	to	to	PART
fnp-3395	48	23	prevent	prevent	VERB
fnp-3395	48	24	movement	movement	NOUN
fnp-3395	48	25	of	of	ADP
fnp-3395	48	26	blood	blood	NOUN
fnp-3395	48	27	into	into	ADP
fnp-3395	48	28	the	the	DET
fnp-3395	48	29	lymphatic	lymphatic	ADJ
fnp-3395	48	30	system	system	NOUN
fnp-3395	48	31	,	,	PUNCT
fnp-3395	48	32	thereby	thereby	ADV
fnp-3395	48	33	preventing	prevent	VERB
fnp-3395	48	34	coagulation	coagulation	NOUN
fnp-3395	48	35	in	in	ADP
fnp-3395	48	36	the	the	DET
fnp-3395	48	37	lymphatics	lymphatic	NOUN
fnp-3395	48	38	despite	despite	SCONJ
fnp-3395	48	39	expression	expression	NOUN
fnp-3395	48	40	of	of	ADP
fnp-3395	48	41	podoplanin	podoplanin	PROPN
fnp-3395	48	42	in	in	ADP
fnp-3395	48	43	the	the	DET
fnp-3395	48	44	lymphatic	lymphatic	PROPN
fnp-3395	48	45	endothelium.41	endothelium.41	PROPN
fnp-3395	48	46	c.	c.	PROPN
fnp-3395	48	47	chemoprophylaxis	chemoprophylaxis	PROPN
fnp-3395	48	48	with	with	ADP
fnp-3395	48	49	antiplatelet	antiplatelet	ADJ
fnp-3395	48	50	agents	agent	NOUN
fnp-3395	48	51	in	in	ADP
fnp-3395	48	52	animal	animal	NOUN
fnp-3395	48	53	models	model	NOUN
fnp-3395	48	54	of	of	ADP
fnp-3395	48	55	endotoxin	endotoxin	NOUN
fnp-3395	48	56	-	-	PUNCT
fnp-3395	48	57	mediated	mediate	VERB
fnp-3395	48	58	endothelial	endothelial	ADJ
fnp-3395	48	59	injury	injury	NOUN
fnp-3395	48	60	and	and	CCONJ
fnp-3395	48	61	thromboinflammation	thromboinflammation	NOUN
fnp-3395	48	62	,	,	PUNCT
fnp-3395	48	63	antagonism	antagonism	NOUN
fnp-3395	48	64	of	of	ADP
fnp-3395	48	65	thromboxane	thromboxane	NOUN
fnp-3395	48	66	a2	a2	NOUN
fnp-3395	48	67	signaling	signal	VERB
fnp-3395	48	68	prevents	prevent	NOUN
fnp-3395	48	69	ards	ard	NOUN
fnp-3395	48	70	,	,	PUNCT
fnp-3395	48	71	reduces	reduce	VERB
fnp-3395	48	72	myocardial	myocardial	ADJ
fnp-3395	48	73	damage	damage	NOUN
fnp-3395	48	74	and	and	CCONJ
fnp-3395	48	75	increases	increase	VERB
fnp-3395	48	76	survival.42	survival.42	NOUN
fnp-3395	48	77	-	-	SYM
fnp-3395	48	78	44	44	NUM
fnp-3395	48	79	considering	consider	VERB
fnp-3395	48	80	the	the	DET
fnp-3395	48	81	key	key	ADJ
fnp-3395	48	82	role	role	NOUN
fnp-3395	48	83	played	play	VERB
fnp-3395	48	84	by	by	ADP
fnp-3395	48	85	platelets	platelet	NOUN
fnp-3395	48	86	in	in	ADP
fnp-3395	48	87	thromboinflammation	thromboinflammation	NOUN
fnp-3395	48	88	,	,	PUNCT
fnp-3395	48	89	we	we	PRON
fnp-3395	48	90	propose	propose	VERB
fnp-3395	48	91	consideration	consideration	NOUN
fnp-3395	48	92	of	of	ADP
fnp-3395	48	93	anti	anti	ADJ
fnp-3395	48	94	-	-	ADJ
fnp-3395	48	95	platelet	platelet	ADJ
fnp-3395	48	96	agents	agent	NOUN
fnp-3395	48	97	,	,	PUNCT
fnp-3395	48	98	either	either	CCONJ
fnp-3395	48	99	aspirin	aspirin	NOUN
fnp-3395	48	100	or	or	CCONJ
fnp-3395	48	101	txa2	txa2	NOUN
fnp-3395	48	102	receptor	receptor	NOUN
fnp-3395	48	103	antagonists	antagonist	NOUN
fnp-3395	48	104	,	,	PUNCT
fnp-3395	48	105	as	as	ADP
fnp-3395	48	106	chemoprophylactic	chemoprophylactic	ADJ
fnp-3395	48	107	agents	agent	NOUN
fnp-3395	48	108	when	when	SCONJ
fnp-3395	48	109	the	the	DET
fnp-3395	48	110	astrazeneca	astrazeneca	NOUN
fnp-3395	48	111	vaccine	vaccine	NOUN
fnp-3395	48	112	is	be	AUX
fnp-3395	48	113	administered	administer	VERB
fnp-3395	48	114	to	to	ADP
fnp-3395	48	115	adults	adult	NOUN
fnp-3395	48	116	between	between	ADP
fnp-3395	48	117	18	18	NUM
fnp-3395	48	118	and	and	CCONJ
fnp-3395	48	119	60	60	NUM
fnp-3395	48	120	years	year	NOUN
fnp-3395	48	121	of	of	ADP
fnp-3395	48	122	age.45	age.45	ADJ
fnp-3395	48	123	high	high	ADJ
fnp-3395	48	124	bleeding	bleeding	NOUN
fnp-3395	48	125	risk	risk	NOUN
fnp-3395	48	126	because	because	SCONJ
fnp-3395	48	127	of	of	ADP
fnp-3395	48	128	another	another	DET
fnp-3395	48	129	medical	medical	ADJ
fnp-3395	48	130	condition	condition	NOUN
fnp-3395	48	131	or	or	CCONJ
fnp-3395	48	132	medication	medication	NOUN
fnp-3395	48	133	would	would	AUX
fnp-3395	48	134	be	be	AUX
fnp-3395	48	135	contraindications	contraindication	NOUN
fnp-3395	48	136	to	to	PART
fnp-3395	48	137	use	use	VERB
fnp-3395	48	138	of	of	ADP
fnp-3395	48	139	antiplatelet	antiplatelet	VERB
fnp-3395	48	140	agents.45	agents.45	ADJ
fnp-3395	48	141	medical	medical	ADJ
fnp-3395	48	142	conditions	condition	NOUN
fnp-3395	48	143	that	that	PRON
fnp-3395	48	144	increase	increase	VERB
fnp-3395	48	145	bleeding	bleed	VERB
fnp-3395	48	146	risk	risk	NOUN
fnp-3395	48	147	include	include	VERB
fnp-3395	48	148	previous	previous	ADJ
fnp-3395	48	149	gastrointestinal	gastrointestinal	ADJ
fnp-3395	48	150	bleeding	bleeding	NOUN
fnp-3395	48	151	,	,	PUNCT
fnp-3395	48	152	peptic	peptic	ADJ
fnp-3395	48	153	ulcer	ulcer	NOUN
fnp-3395	48	154	disease	disease	NOUN
fnp-3395	48	155	,	,	PUNCT
fnp-3395	48	156	blood	blood	NOUN
fnp-3395	48	157	clotting	clotting	NOUN
fnp-3395	48	158	problems	problem	NOUN
fnp-3395	48	159	,	,	PUNCT
fnp-3395	48	160	and	and	CCONJ
fnp-3395	48	161	kidney	kidney	NOUN
fnp-3395	48	162	disease.45	disease.45	ADJ
fnp-3395	48	163	medications	medication	NOUN
fnp-3395	48	164	that	that	PRON
fnp-3395	48	165	increase	increase	VERB
fnp-3395	48	166	bleeding	bleed	VERB
fnp-3395	48	167	risk	risk	NOUN
fnp-3395	48	168	include	include	VERB
fnp-3395	48	169	nonsteroidal	nonsteroidal	NOUN
fnp-3395	48	170	anti	anti	ADJ
fnp-3395	48	171	-	-	ADJ
fnp-3395	48	172	inflammatory	inflammatory	ADJ
fnp-3395	48	173	drugs	drug	NOUN
fnp-3395	48	174	,	,	PUNCT
fnp-3395	48	175	steroids	steroid	NOUN
fnp-3395	48	176	,	,	PUNCT
fnp-3395	48	177	and	and	CCONJ
fnp-3395	48	178	other	other	ADJ
fnp-3395	48	179	anticoagulants	anticoagulant	NOUN
fnp-3395	48	180	or	or	CCONJ
fnp-3395	48	181	anti	anti	ADJ
fnp-3395	48	182	-	-	ADJ
fnp-3395	48	183	platelet	platelet	ADJ
fnp-3395	48	184	agents.45	agents.45	ADJ
fnp-3395	48	185	aspirin	aspirin	NOUN
fnp-3395	48	186	appears	appear	VERB
fnp-3395	48	187	to	to	PART
fnp-3395	48	188	be	be	AUX
fnp-3395	48	189	safe	safe	ADJ
fnp-3395	48	190	in	in	ADP
fnp-3395	48	191	covid-19	covid-19	PROPN
fnp-3395	48	192	.	.	PUNCT
fnp-3395	49	1	in	in	ADP
fnp-3395	49	2	a	a	DET
fnp-3395	49	3	retrospective	retrospective	ADJ
fnp-3395	49	4	observational	observational	ADJ
fnp-3395	49	5	study	study	NOUN
fnp-3395	49	6	in	in	ADP
fnp-3395	49	7	hospitalized	hospitalize	VERB
fnp-3395	49	8	patients	patient	NOUN
fnp-3395	49	9	with	with	ADP
fnp-3395	49	10	covid-19	covid-19	PROPN
fnp-3395	49	11	,	,	PUNCT
fnp-3395	49	12	low	low	ADJ
fnp-3395	49	13	-	-	PUNCT
fnp-3395	49	14	dose	dose	NOUN
fnp-3395	49	15	aspirin	aspirin	NOUN
fnp-3395	49	16	was	be	AUX
fnp-3395	49	17	found	find	VERB
fnp-3395	49	18	to	to	PART
fnp-3395	49	19	be	be	AUX
fnp-3395	49	20	effective	effective	ADJ
fnp-3395	49	21	in	in	ADP
fnp-3395	49	22	reducing	reduce	VERB
fnp-3395	49	23	morbidity	morbidity	NOUN
fnp-3395	49	24	and	and	CCONJ
fnp-3395	49	25	mortality	mortality	NOUN
fnp-3395	49	26	and	and	CCONJ
fnp-3395	49	27	was	be	AUX
fnp-3395	49	28	not	not	PART
fnp-3395	49	29	associated	associate	VERB
fnp-3395	49	30	with	with	ADP
fnp-3395	49	31	any	any	DET
fnp-3395	49	32	safety	safety	NOUN
fnp-3395	49	33	issues	issue	NOUN
fnp-3395	49	34	including	include	VERB
fnp-3395	49	35	major	major	ADJ
fnp-3395	49	36	bleeding.46	bleeding.46	NOUN
fnp-3395	49	37	therefore	therefore	ADV
fnp-3395	49	38	,	,	PUNCT
fnp-3395	49	39	aspirin	aspirin	NOUN
fnp-3395	49	40	is	be	AUX
fnp-3395	49	41	likely	likely	ADJ
fnp-3395	49	42	to	to	PART
fnp-3395	49	43	be	be	AUX
fnp-3395	49	44	safe	safe	ADJ
fnp-3395	49	45	as	as	ADP
fnp-3395	49	46	an	an	DET
fnp-3395	49	47	adjunct	adjunct	ADJ
fnp-3395	49	48	to	to	ADP
fnp-3395	49	49	covid-19	covid-19	PROPN
fnp-3395	49	50	vaccines	vaccine	NOUN
fnp-3395	49	51	even	even	ADV
fnp-3395	49	52	in	in	ADP
fnp-3395	49	53	the	the	DET
fnp-3395	49	54	event	event	NOUN
fnp-3395	49	55	of	of	ADP
fnp-3395	49	56	a	a	DET
fnp-3395	49	57	subsequent	subsequent	ADJ
fnp-3395	49	58	infection	infection	NOUN
fnp-3395	49	59	with	with	ADP
fnp-3395	49	60	sars	sar	NOUN
fnp-3395	49	61	-	-	PUNCT
fnp-3395	49	62	cov-2	cov-2	PART
fnp-3395	49	63	virus	virus	NOUN
fnp-3395	49	64	.	.	PUNCT
fnp-3395	50	1	can	can	AUX
fnp-3395	50	2	aspirin	aspirin	VERB
fnp-3395	50	3	influence	influence	VERB
fnp-3395	50	4	the	the	DET
fnp-3395	50	5	host	host	NOUN
fnp-3395	50	6	immune	immune	ADJ
fnp-3395	50	7	response	response	NOUN
fnp-3395	50	8	to	to	ADP
fnp-3395	50	9	the	the	DET
fnp-3395	50	10	covid-19	covid-19	PROPN
fnp-3395	50	11	vaccines	vaccine	NOUN
fnp-3395	50	12	?	?	PUNCT
fnp-3395	51	1	this	this	DET
fnp-3395	51	2	issue	issue	NOUN
fnp-3395	51	3	merits	merit	VERB
fnp-3395	51	4	further	further	ADJ
fnp-3395	51	5	investigation	investigation	NOUN
fnp-3395	51	6	.	.	PUNCT
fnp-3395	52	1	when	when	SCONJ
fnp-3395	52	2	healthy	healthy	ADJ
fnp-3395	52	3	adults	adult	NOUN
fnp-3395	52	4	>	>	X
fnp-3395	52	5	65	65	NUM
fnp-3395	52	6	years	year	NOUN
fnp-3395	52	7	of	of	ADP
fnp-3395	52	8	age	age	NOUN
fnp-3395	52	9	were	be	AUX
fnp-3395	52	10	given	give	VERB
fnp-3395	52	11	influenza	influenza	ADJ
fnp-3395	52	12	vaccine	vaccine	NOUN
fnp-3395	52	13	and	and	CCONJ
fnp-3395	52	14	randomized	randomize	VERB
fnp-3395	52	15	to	to	PART
fnp-3395	52	16	receive	receive	VERB
fnp-3395	52	17	300	300	NUM
fnp-3395	52	18	mg	mg	NOUN
fnp-3395	52	19	aspirin	aspirin	NOUN
fnp-3395	52	20	or	or	CCONJ
fnp-3395	52	21	placebo	placebo	NOUN
fnp-3395	52	22	on	on	ADP
fnp-3395	52	23	days	day	NOUN
fnp-3395	52	24	1	1	NUM
fnp-3395	52	25	,	,	PUNCT
fnp-3395	52	26	2	2	NUM
fnp-3395	52	27	,	,	PUNCT
fnp-3395	52	28	3	3	NUM
fnp-3395	52	29	,	,	PUNCT
fnp-3395	52	30	5	5	NUM
fnp-3395	52	31	and	and	CCONJ
fnp-3395	52	32	7	7	NUM
fnp-3395	52	33	,	,	PUNCT
fnp-3395	52	34	the	the	DET
fnp-3395	52	35	aspirin	aspirin	NOUN
fnp-3395	52	36	group	group	NOUN
fnp-3395	52	37	showed	show	VERB
fnp-3395	52	38	4	4	NUM
fnp-3395	52	39	-	-	NOUN
fnp-3395	52	40	fold	fold	ADJ
fnp-3395	52	41	or	or	CCONJ
fnp-3395	52	42	greater	great	ADJ
fnp-3395	52	43	rise	rise	NOUN
fnp-3395	52	44	in	in	ADP
fnp-3395	52	45	influenza	influenza	NOUN
fnp-3395	52	46	specific	specific	ADJ
fnp-3395	52	47	antibodies.47	antibodies.47	NOUN
fnp-3395	52	48	the	the	DET
fnp-3395	52	49	risk	risk	NOUN
fnp-3395	52	50	-	-	PUNCT
fnp-3395	52	51	benefit	benefit	NOUN
fnp-3395	52	52	analysis	analysis	NOUN
fnp-3395	52	53	,	,	PUNCT
fnp-3395	52	54	based	base	VERB
fnp-3395	52	55	on	on	ADP
fnp-3395	52	56	above	above	ADP
fnp-3395	52	57	information	information	NOUN
fnp-3395	52	58	,	,	PUNCT
fnp-3395	52	59	suggests	suggest	VERB
fnp-3395	52	60	that	that	SCONJ
fnp-3395	52	61	a	a	DET
fnp-3395	52	62	one	one	NUM
fnp-3395	52	63	to	to	PART
fnp-3395	52	64	three	three	NUM
fnp-3395	52	65	week	week	NOUN
fnp-3395	52	66	course	course	NOUN
fnp-3395	52	67	of	of	ADP
fnp-3395	52	68	low	low	ADV
fnp-3395	52	69	-	-	PUNCT
fnp-3395	52	70	dose	dose	NOUN
fnp-3395	52	71	aspirin	aspirin	NOUN
fnp-3395	52	72	merits	merit	VERB
fnp-3395	52	73	consideration	consideration	NOUN
fnp-3395	52	74	in	in	ADP
fnp-3395	52	75	order	order	NOUN
fnp-3395	52	76	to	to	PART
fnp-3395	52	77	prevent	prevent	VERB
fnp-3395	52	78	the	the	DET
fnp-3395	52	79	thromboembolic	thromboembolic	ADJ
fnp-3395	52	80	events	event	NOUN
fnp-3395	52	81	associated	associate	VERB
fnp-3395	52	82	with	with	ADP
fnp-3395	52	83	the	the	DET
fnp-3395	52	84	astrazeneca	astrazeneca	NOUN
fnp-3395	52	85	vaccine	vaccine	NOUN
fnp-3395	52	86	.	.	PUNCT
fnp-3395	53	1	summary	summary	NOUN
fnp-3395	53	2	thromboembolic	thromboembolic	PROPN
fnp-3395	53	3	disease	disease	NOUN
fnp-3395	53	4	,	,	PUNCT
fnp-3395	53	5	cvst	cvst	PROPN
fnp-3395	53	6	and	and	CCONJ
fnp-3395	53	7	thrombocytopenia	thrombocytopenia	NOUN
fnp-3395	53	8	have	have	AUX
fnp-3395	53	9	been	be	AUX
fnp-3395	53	10	reported	report	VERB
fnp-3395	53	11	in	in	ADP
fnp-3395	53	12	association	association	NOUN
fnp-3395	53	13	with	with	ADP
fnp-3395	53	14	astrazeneca	astrazeneca	PROPN
fnp-3395	53	15	and	and	CCONJ
fnp-3395	53	16	janssen	janssen	PROPN
fnp-3395	53	17	covid-19	covid-19	PROPN
fnp-3395	53	18	vaccines	vaccine	NOUN
fnp-3395	53	19	,	,	PUNCT
fnp-3395	53	20	especially	especially	ADV
fnp-3395	53	21	in	in	ADP
fnp-3395	53	22	younger	young	ADJ
fnp-3395	53	23	women	woman	NOUN
fnp-3395	53	24	.	.	PUNCT
fnp-3395	54	1	many	many	ADJ
fnp-3395	54	2	countries	country	NOUN
fnp-3395	54	3	have	have	AUX
fnp-3395	54	4	halted	halt	VERB
fnp-3395	54	5	use	use	NOUN
fnp-3395	54	6	of	of	ADP
fnp-3395	54	7	these	these	DET
fnp-3395	54	8	vaccines	vaccine	NOUN
fnp-3395	54	9	for	for	ADP
fnp-3395	54	10	adults	adult	NOUN
fnp-3395	54	11	under	under	ADP
fnp-3395	54	12	30	30	NUM
fnp-3395	54	13	to	to	PART
fnp-3395	54	14	60	60	NUM
fnp-3395	54	15	years	year	NOUN
fnp-3395	54	16	of	of	ADP
fnp-3395	54	17	age	age	NOUN
fnp-3395	54	18	.	.	PUNCT
fnp-3395	55	1	european	european	ADJ
fnp-3395	55	2	and	and	CCONJ
fnp-3395	55	3	north	north	ADJ
fnp-3395	55	4	american	american	ADJ
fnp-3395	55	5	countries	country	NOUN
fnp-3395	55	6	generally	generally	ADV
fnp-3395	55	7	have	have	VERB
fnp-3395	55	8	access	access	NOUN
fnp-3395	55	9	to	to	ADP
fnp-3395	55	10	mrna	mrna	PROPN
fnp-3395	55	11	vaccines	vaccine	NOUN
fnp-3395	55	12	.	.	PUNCT
fnp-3395	56	1	however	however	ADV
fnp-3395	56	2	,	,	PUNCT
fnp-3395	56	3	in	in	ADP
fnp-3395	56	4	many	many	ADJ
fnp-3395	56	5	asian	asian	ADJ
fnp-3395	56	6	and	and	CCONJ
fnp-3395	56	7	african	african	ADJ
fnp-3395	56	8	countries	country	NOUN
fnp-3395	56	9	the	the	DET
fnp-3395	56	10	choices	choice	NOUN
fnp-3395	56	11	are	be	AUX
fnp-3395	56	12	limited	limit	VERB
fnp-3395	56	13	to	to	ADP
fnp-3395	56	14	adenovirus	adenovirus	NOUN
fnp-3395	56	15	-	-	PUNCT
fnp-3395	56	16	based	base	VERB
fnp-3395	56	17	covid-19	covid-19	PROPN
fnp-3395	56	18	vaccines	vaccine	NOUN
fnp-3395	56	19	.	.	PUNCT
fnp-3395	57	1	the	the	DET
fnp-3395	57	2	governments	government	NOUN
fnp-3395	57	3	in	in	ADP
fnp-3395	57	4	such	such	ADJ
fnp-3395	57	5	countries	country	NOUN
fnp-3395	57	6	are	be	AUX
fnp-3395	57	7	forging	forge	VERB
fnp-3395	57	8	ahead	ahead	ADV
fnp-3395	57	9	with	with	ADP
fnp-3395	57	10	vaccinating	vaccinate	VERB
fnp-3395	57	11	all	all	DET
fnp-3395	57	12	adults	adult	NOUN
fnp-3395	57	13	,	,	PUNCT
fnp-3395	57	14	including	include	VERB
fnp-3395	57	15	those	those	DET
fnp-3395	57	16	under	under	ADP
fnp-3395	57	17	60	60	NUM
fnp-3395	57	18	years	year	NOUN
fnp-3395	57	19	of	of	ADP
fnp-3395	57	20	age	age	NOUN
fnp-3395	57	21	,	,	PUNCT
fnp-3395	57	22	with	with	ADP
fnp-3395	57	23	vaxzevria	vaxzevria	NOUN
fnp-3395	57	24	,	,	PUNCT
fnp-3395	57	25	covishield	covishield	NOUN
fnp-3395	57	26	(	(	PUNCT
fnp-3395	57	27	the	the	DET
fnp-3395	57	28	version	version	NOUN
fnp-3395	57	29	of	of	ADP
fnp-3395	57	30	vaxzevria	vaxzevria	NOUN
fnp-3395	57	31	manufactured	manufacture	VERB
fnp-3395	57	32	by	by	ADP
fnp-3395	57	33	the	the	DET
fnp-3395	57	34	serum	serum	PROPN
fnp-3395	57	35	institute	institute	PROPN
fnp-3395	57	36	of	of	ADP
fnp-3395	57	37	india	india	PROPN
fnp-3395	57	38	)	)	PUNCT
fnp-3395	57	39	or	or	CCONJ
fnp-3395	57	40	the	the	DET
fnp-3395	57	41	janssen	janssen	PROPN
fnp-3395	57	42	vaccines	vaccine	NOUN
fnp-3395	57	43	.	.	PUNCT
fnp-3395	58	1	this	this	PRON
fnp-3395	58	2	has	have	AUX
fnp-3395	58	3	led	lead	VERB
fnp-3395	58	4	to	to	ADP
fnp-3395	58	5	grave	grave	ADJ
fnp-3395	58	6	concern	concern	NOUN
fnp-3395	58	7	and	and	CCONJ
fnp-3395	58	8	anxiety	anxiety	NOUN
fnp-3395	58	9	amongst	amongst	ADP
fnp-3395	58	10	the	the	DET
fnp-3395	58	11	citizens	citizen	NOUN
fnp-3395	58	12	and	and	CCONJ
fnp-3395	58	13	medical	medical	ADJ
fnp-3395	58	14	professionals	professional	NOUN
fnp-3395	58	15	.	.	PUNCT
fnp-3395	59	1	considering	consider	VERB
fnp-3395	59	2	the	the	DET
fnp-3395	59	3	profound	profound	ADJ
fnp-3395	59	4	global	global	ADJ
fnp-3395	59	5	public	public	ADJ
fnp-3395	59	6	health	health	NOUN
fnp-3395	59	7	implications	implication	NOUN
fnp-3395	59	8	of	of	ADP
fnp-3395	59	9	limiting	limit	VERB
fnp-3395	59	10	the	the	DET
fnp-3395	59	11	use	use	NOUN
fnp-3395	59	12	of	of	ADP
fnp-3395	59	13	these	these	DET
fnp-3395	59	14	vaccines	vaccine	NOUN
fnp-3395	59	15	,	,	PUNCT
fnp-3395	59	16	it	it	PRON
fnp-3395	59	17	is	be	AUX
fnp-3395	59	18	critical	critical	ADJ
fnp-3395	59	19	to	to	PART
fnp-3395	59	20	understand	understand	VERB
fnp-3395	59	21	the	the	DET
fnp-3395	59	22	pathobiology	pathobiology	NOUN
fnp-3395	59	23	of	of	ADP
fnp-3395	59	24	vaccination	vaccination	NOUN
fnp-3395	59	25	induced	induce	VERB
fnp-3395	59	26	thrombotic	thrombotic	ADJ
fnp-3395	59	27	events	event	NOUN
fnp-3395	59	28	in	in	ADP
fnp-3395	59	29	order	order	NOUN
fnp-3395	59	30	to	to	PART
fnp-3395	59	31	guide	guide	VERB
fnp-3395	59	32	strategies	strategy	NOUN
fnp-3395	59	33	aimed	aim	VERB
fnp-3395	59	34	at	at	ADP
fnp-3395	59	35	prevention	prevention	NOUN
fnp-3395	59	36	.	.	PUNCT
fnp-3395	60	1	in	in	ADP
fnp-3395	60	2	this	this	DET
fnp-3395	60	3	regard	regard	NOUN
fnp-3395	60	4	,	,	PUNCT
fnp-3395	60	5	studies	study	NOUN
fnp-3395	60	6	are	be	AUX
fnp-3395	60	7	urgently	urgently	ADV
fnp-3395	60	8	needed	need	VERB
fnp-3395	60	9	to	to	PART
fnp-3395	60	10	examine	examine	VERB
fnp-3395	60	11	lipid	lipid	NOUN
fnp-3395	60	12	mediators	mediator	NOUN
fnp-3395	60	13	and	and	CCONJ
fnp-3395	60	14	the	the	DET
fnp-3395	60	15	thromboxane	thromboxane	NOUN
fnp-3395	60	16	a2	a2	PROPN
fnp-3395	60	17	platelet	platelet	VERB
fnp-3395	60	18	axis	axis	NOUN
fnp-3395	60	19	following	follow	VERB
fnp-3395	60	20	vaccination	vaccination	NOUN
fnp-3395	60	21	with	with	ADP
fnp-3395	60	22	these	these	DET
fnp-3395	60	23	vaccines	vaccine	NOUN
fnp-3395	60	24	compared	compare	VERB
fnp-3395	60	25	with	with	ADP
fnp-3395	60	26	mrna	mrna	PROPN
fnp-3395	60	27	vaccines	vaccine	NOUN
fnp-3395	60	28	.	.	PUNCT
fnp-3395	61	1	the	the	DET
fnp-3395	61	2	risk	risk	NOUN
fnp-3395	61	3	-	-	PUNCT
fnp-3395	61	4	benefit	benefit	NOUN
fnp-3395	61	5	analysis	analysis	NOUN
fnp-3395	61	6	based	base	VERB
fnp-3395	61	7	on	on	ADP
fnp-3395	61	8	information	information	NOUN
fnp-3395	61	9	presented	present	VERB
fnp-3395	61	10	here	here	ADV
fnp-3395	61	11	suggests	suggest	VERB
fnp-3395	61	12	that	that	SCONJ
fnp-3395	61	13	chemoprophylaxis	chemoprophylaxis	ADJ
fnp-3395	61	14	using	use	VERB
fnp-3395	61	15	a	a	DET
fnp-3395	61	16	short	short	ADJ
fnp-3395	61	17	course	course	NOUN
fnp-3395	61	18	of	of	ADP
fnp-3395	61	19	low	low	ADV
fnp-3395	61	20	-	-	PUNCT
fnp-3395	61	21	dose	dose	NOUN
fnp-3395	61	22	aspirin	aspirin	NOUN
fnp-3395	61	23	in	in	ADP
fnp-3395	61	24	adults	adult	NOUN
fnp-3395	61	25	under	under	ADP
fnp-3395	61	26	60	60	NUM
fnp-3395	61	27	years	year	NOUN
fnp-3395	61	28	of	of	ADP
fnp-3395	61	29	age	age	NOUN
fnp-3395	61	30	and	and	CCONJ
fnp-3395	61	31	lacking	lack	VERB
fnp-3395	61	32	any	any	DET
fnp-3395	61	33	contraindications	contraindication	NOUN
fnp-3395	61	34	to	to	PART
fnp-3395	61	35	aspirin	aspirin	NOUN
fnp-3395	61	36	may	may	AUX
fnp-3395	61	37	be	be	AUX
fnp-3395	61	38	justified	justify	VERB
fnp-3395	61	39	in	in	ADP
fnp-3395	61	40	conjunction	conjunction	NOUN
fnp-3395	61	41	with	with	ADP
fnp-3395	61	42	adenovirus	adenovirus	NOUN
fnp-3395	61	43	-	-	PUNCT
fnp-3395	61	44	based	base	VERB
fnp-3395	61	45	covid-19	covid-19	PROPN
fnp-3395	61	46	vaccines	vaccine	NOUN
fnp-3395	61	47	in	in	ADP
fnp-3395	61	48	order	order	NOUN
fnp-3395	61	49	to	to	PART
fnp-3395	61	50	prevent	prevent	VERB
fnp-3395	61	51	thromboembolic	thromboembolic	ADJ
fnp-3395	61	52	events	event	NOUN
fnp-3395	61	53	and	and	CCONJ
fnp-3395	61	54	enhance	enhance	VERB
fnp-3395	61	55	safety	safety	NOUN
fnp-3395	61	56	.	.	PUNCT
fnp-3395	62	1	acknowledgment	acknowledgment	NOUN
fnp-3395	62	2	we	we	PRON
fnp-3395	62	3	thank	thank	VERB
fnp-3395	62	4	prof	prof	PROPN
fnp-3395	62	5	.	.	PUNCT
fnp-3395	63	1	andrzej	andrzej	PROPN
fnp-3395	63	2	breborowicz	breborowicz	PROPN
fnp-3395	63	3	,	,	PUNCT
fnp-3395	63	4	md	md	PROPN
fnp-3395	63	5	,	,	PUNCT
fnp-3395	63	6	phd	phd	PROPN
fnp-3395	63	7	,	,	PUNCT
fnp-3395	63	8	department	department	NOUN
fnp-3395	63	9	of	of	ADP
fnp-3395	63	10	pathophysiology	pathophysiology	NOUN
fnp-3395	63	11	,	,	PUNCT
fnp-3395	63	12	poznan	poznan	PROPN
fnp-3395	63	13	university	university	PROPN
fnp-3395	63	14	of	of	ADP
fnp-3395	63	15	medical	medical	PROPN
fnp-3395	63	16	sciences	sciences	PROPN
fnp-3395	63	17	,	,	PUNCT
fnp-3395	63	18	poland	poland	PROPN
fnp-3395	63	19	for	for	ADP
fnp-3395	63	20	a	a	DET
fnp-3395	63	21	careful	careful	ADJ
fnp-3395	63	22	review	review	NOUN
fnp-3395	63	23	and	and	CCONJ
fnp-3395	63	24	critique	critique	NOUN
fnp-3395	63	25	of	of	ADP
fnp-3395	63	26	this	this	DET
fnp-3395	63	27	work	work	NOUN
fnp-3395	63	28	.	.	PUNCT
fnp-3395	64	1	funding	fund	VERB
fnp-3395	64	2	no	no	DET
fnp-3395	64	3	funding	funding	NOUN
fnp-3395	64	4	was	be	AUX
fnp-3395	64	5	required	require	VERB
fnp-3395	64	6	.	.	PUNCT
fnp-3395	65	1	conflict	conflict	NOUN
fnp-3395	65	2	of	of	ADP
fnp-3395	65	3	interest	interest	NOUN
fnp-3395	65	4	ag	ag	PROPN
fnp-3395	65	5	and	and	CCONJ
fnp-3395	65	6	kcc	kcc	PROPN
fnp-3395	65	7	have	have	AUX
fnp-3395	65	8	filed	file	VERB
fnp-3395	65	9	a	a	DET
fnp-3395	65	10	patent	patent	NOUN
fnp-3395	65	11	for	for	ADP
fnp-3395	65	12	use	use	NOUN
fnp-3395	65	13	of	of	ADP
fnp-3395	65	14	ramatroban	ramatroban	NOUN
fnp-3395	65	15	as	as	ADP
fnp-3395	65	16	an	an	DET
fnp-3395	65	17	anti	anti	ADJ
fnp-3395	65	18	-	-	ADJ
fnp-3395	65	19	thrombotic	thrombotic	ADJ
fnp-3395	65	20	and	and	CCONJ
fnp-3395	65	21	immune	immune	ADJ
fnp-3395	65	22	modulator	modulator	NOUN
fnp-3395	65	23	in	in	ADP
fnp-3395	65	24	sars	sar	NOUN
fnp-3395	65	25	-	-	PUNCT
fnp-3395	65	26	cov-2	cov-2	PART
fnp-3395	65	27	infection	infection	NOUN
fnp-3395	65	28	.	.	PUNCT
fnp-3395	66	1	the	the	DET
fnp-3395	66	2	patents	patent	NOUN
fnp-3395	66	3	have	have	AUX
fnp-3395	66	4	been	be	AUX
fnp-3395	66	5	licensed	license	VERB
fnp-3395	66	6	to	to	ADP
fnp-3395	66	7	kare	kare	PROPN
fnp-3395	66	8	biosciences	biosciences	PROPN
fnp-3395	66	9	.	.	PUNCT
fnp-3395	67	1	kcc	kcc	PROPN
fnp-3395	67	2	is	be	AUX
fnp-3395	67	3	an	an	DET
fnp-3395	67	4	employee	employee	NOUN
fnp-3395	67	5	of	of	ADP
fnp-3395	67	6	kare	kare	PROPN
fnp-3395	67	7	biosciences	biosciences	PROPN
fnp-3395	67	8	.	.	PUNCT
fnp-3395	68	1	author	author	PROPN
fnp-3395	68	2	contributions	contribution	NOUN
fnp-3395	68	3	ag	ag	PROPN
fnp-3395	68	4	and	and	CCONJ
fnp-3395	68	5	kcc	kcc	PROPN
fnp-3395	68	6	conceptualized	conceptualize	VERB
fnp-3395	68	7	,	,	PUNCT
fnp-3395	68	8	created	create	VERB
fnp-3395	68	9	the	the	DET
fnp-3395	68	10	framework	framework	NOUN
fnp-3395	68	11	and	and	CCONJ
fnp-3395	68	12	drafted	draft	VERB
fnp-3395	68	13	the	the	DET
fnp-3395	68	14	original	original	ADJ
fnp-3395	68	15	version	version	NOUN
fnp-3395	68	16	.	.	PUNCT
fnp-3395	69	1	all	all	DET
fnp-3395	69	2	authors	author	NOUN
fnp-3395	69	3	reviewed	review	VERB
fnp-3395	69	4	and	and	CCONJ
fnp-3395	69	5	edited	edit	VERB
fnp-3395	69	6	the	the	DET
fnp-3395	69	7	final	final	ADJ
fnp-3395	69	8	version	version	NOUN
fnp-3395	69	9	.	.	PUNCT
fnp-3395	70	1	references	reference	NOUN
fnp-3395	70	2	1	1	NUM
fnp-3395	70	3	.	.	PUNCT
fnp-3395	70	4	ortiz	ortiz	PROPN
fnp-3395	70	5	-	-	PUNCT
fnp-3395	70	6	prado	prado	PROPN
fnp-3395	70	7	e	e	NOUN
fnp-3395	70	8	,	,	PUNCT
fnp-3395	70	9	simbaña	simbaña	NOUN
fnp-3395	70	10	-	-	PUNCT
fnp-3395	70	11	rivera	rivera	PROPN
fnp-3395	70	12	k	k	PROPN
fnp-3395	70	13	,	,	PUNCT
fnp-3395	70	14	gómez	gómez	NOUN
fnp-3395	70	15	-	-	PUNCT
fnp-3395	70	16	barreno	barreno	NOUN
fnp-3395	70	17	l	l	NOUN
fnp-3395	70	18	,	,	PUNCT
fnp-3395	70	19	et	et	PROPN
fnp-3395	70	20	al	al	PROPN
fnp-3395	70	21	.	.	PROPN
fnp-3395	71	1	clinical	clinical	ADJ
fnp-3395	71	2	,	,	PUNCT
fnp-3395	71	3	molecular	molecular	ADJ
fnp-3395	71	4	,	,	PUNCT
fnp-3395	71	5	and	and	CCONJ
fnp-3395	71	6	epidemiological	epidemiological	ADJ
fnp-3395	71	7	characterization	characterization	NOUN
fnp-3395	71	8	of	of	ADP
fnp-3395	71	9	the	the	DET
fnp-3395	71	10	sars	sar	NOUN
fnp-3395	71	11	-	-	PUNCT
fnp-3395	71	12	cov-2	cov-2	PART
fnp-3395	71	13	virus	virus	NOUN
fnp-3395	71	14	and	and	CCONJ
fnp-3395	71	15	the	the	DET
fnp-3395	71	16	coronavirus	coronavirus	NOUN
fnp-3395	71	17	disease	disease	NOUN
fnp-3395	71	18	2019	2019	NUM
fnp-3395	71	19	(	(	PUNCT
fnp-3395	71	20	covid-19	covid-19	PROPN
fnp-3395	71	21	)	)	PUNCT
fnp-3395	71	22	,	,	PUNCT
fnp-3395	71	23	a	a	DET
fnp-3395	71	24	comprehensive	comprehensive	ADJ
fnp-3395	71	25	literature	literature	NOUN
fnp-3395	71	26	review	review	NOUN
fnp-3395	71	27	.	.	PUNCT
fnp-3395	72	1	diagnostic	diagnostic	ADJ
fnp-3395	72	2	microbiology	microbiology	NOUN
fnp-3395	72	3	and	and	CCONJ
fnp-3395	72	4	infectious	infectious	ADJ
fnp-3395	72	5	disease	disease	NOUN
fnp-3395	72	6	.	.	PUNCT
fnp-3395	73	1	2020;98(1):115094	2020;98(1):115094	X
fnp-3395	73	2	.	.	PUNCT
fnp-3395	74	1	2	2	X
fnp-3395	74	2	.	.	X
fnp-3395	74	3	du	du	PROPN
fnp-3395	74	4	l	l	PROPN
fnp-3395	74	5	,	,	PUNCT
fnp-3395	74	6	he	he	PRON
fnp-3395	74	7	y	y	PROPN
fnp-3395	74	8	,	,	PUNCT
fnp-3395	74	9	zhou	zhou	PROPN
fnp-3395	74	10	y	y	PROPN
fnp-3395	74	11	,	,	PUNCT
fnp-3395	74	12	liu	liu	PROPN
fnp-3395	74	13	s	s	PROPN
fnp-3395	74	14	,	,	PUNCT
fnp-3395	74	15	zheng	zheng	PROPN
fnp-3395	74	16	b	b	PROPN
fnp-3395	74	17	-	-	PUNCT
fnp-3395	74	18	j	j	PROPN
fnp-3395	74	19	,	,	PUNCT
fnp-3395	74	20	jiang	jiang	PROPN
fnp-3395	74	21	s.	s.	PROPN
fnp-3395	74	22	the	the	DET
fnp-3395	74	23	spike	spike	ADJ
fnp-3395	74	24	protein	protein	NOUN
fnp-3395	74	25	of	of	ADP
fnp-3395	74	26	sars	sar	NOUN
fnp-3395	74	27	-	-	PUNCT
fnp-3395	74	28	cov	cov	NOUN
fnp-3395	74	29	—	—	PUNCT
fnp-3395	74	30	a	a	DET
fnp-3395	74	31	target	target	NOUN
fnp-3395	74	32	for	for	ADP
fnp-3395	74	33	vaccine	vaccine	NOUN
fnp-3395	74	34	and	and	CCONJ
fnp-3395	74	35	therapeutic	therapeutic	ADJ
fnp-3395	74	36	development	development	NOUN
fnp-3395	74	37	.	.	PUNCT
fnp-3395	75	1	nature	nature	NOUN
fnp-3395	75	2	reviews	review	VERB
fnp-3395	75	3	microbiology	microbiology	NOUN
fnp-3395	75	4	.	.	PUNCT
fnp-3395	76	1	2009;7(3):226	2009;7(3):226	NUM
fnp-3395	76	2	-	-	SYM
fnp-3395	76	3	236	236	NUM
fnp-3395	76	4	.	.	PUNCT
fnp-3395	77	1	3	3	X
fnp-3395	77	2	.	.	X
fnp-3395	77	3	kyriakidis	kyriakidis	PROPN
fnp-3395	77	4	nc	nc	PROPN
fnp-3395	77	5	,	,	PUNCT
fnp-3395	77	6	lópez	lópez	PROPN
fnp-3395	77	7	-	-	PUNCT
fnp-3395	77	8	cortés	cortés	NOUN
fnp-3395	77	9	a	a	PRON
fnp-3395	77	10	,	,	PUNCT
fnp-3395	77	11	gonzález	gonzález	PROPN
fnp-3395	77	12	ev	ev	PROPN
fnp-3395	77	13	,	,	PUNCT
fnp-3395	77	14	grimaldos	grimaldos	PROPN
fnp-3395	77	15	ab	ab	PROPN
fnp-3395	77	16	,	,	PUNCT
fnp-3395	77	17	prado	prado	PROPN
fnp-3395	77	18	eo	eo	PROPN
fnp-3395	77	19	.	.	PROPN
fnp-3395	77	20	sars	sars	PROPN
fnp-3395	77	21	-	-	PUNCT
fnp-3395	77	22	cov-2	cov-2	NOUN
fnp-3395	77	23	vaccines	vaccine	NOUN
fnp-3395	77	24	strategies	strategy	NOUN
fnp-3395	77	25	:	:	PUNCT
fnp-3395	77	26	a	a	DET
fnp-3395	77	27	comprehensive	comprehensive	ADJ
fnp-3395	77	28	review	review	NOUN
fnp-3395	77	29	of	of	ADP
fnp-3395	77	30	phase	phase	NOUN
fnp-3395	77	31	3	3	NUM
fnp-3395	77	32	candidates	candidate	NOUN
fnp-3395	77	33	.	.	PUNCT
fnp-3395	78	1	npj	npj	NOUN
fnp-3395	78	2	vaccines	vaccine	NOUN
fnp-3395	78	3	.	.	PUNCT
fnp-3395	79	1	2021;6(1	2021;6(1	NUM
fnp-3395	79	2	)	)	PUNCT
fnp-3395	79	3	.	.	PUNCT
fnp-3395	80	1	4	4	X
fnp-3395	80	2	.	.	X
fnp-3395	80	3	voysey	voysey	PROPN
fnp-3395	80	4	m	m	PROPN
fnp-3395	80	5	,	,	PUNCT
fnp-3395	80	6	clemens	clemens	PROPN
fnp-3395	80	7	sac	sac	NOUN
fnp-3395	80	8	,	,	PUNCT
fnp-3395	80	9	madhi	madhi	PROPN
fnp-3395	80	10	sa	sa	PROPN
fnp-3395	80	11	,	,	PUNCT
fnp-3395	80	12	et	et	PROPN
fnp-3395	80	13	al	al	PROPN
fnp-3395	80	14	.	.	PROPN
fnp-3395	80	15	safety	safety	NOUN
fnp-3395	80	16	and	and	CCONJ
fnp-3395	80	17	efficacy	efficacy	NOUN
fnp-3395	80	18	of	of	ADP
fnp-3395	80	19	the	the	DET
fnp-3395	80	20	chadox1	chadox1	ADJ
fnp-3395	80	21	ncov-19	ncov-19	ADJ
fnp-3395	80	22	vaccine	vaccine	NOUN
fnp-3395	80	23	(	(	PUNCT
fnp-3395	80	24	azd1222	azd1222	NOUN
fnp-3395	80	25	)	)	PUNCT
fnp-3395	80	26	against	against	ADP
fnp-3395	80	27	sars	sar	NOUN
fnp-3395	80	28	-	-	PUNCT
fnp-3395	80	29	cov-2	cov-2	NOUN
fnp-3395	80	30	:	:	PUNCT
fnp-3395	80	31	an	an	DET
fnp-3395	80	32	interim	interim	ADJ
fnp-3395	80	33	analysis	analysis	NOUN
fnp-3395	80	34	of	of	ADP
fnp-3395	80	35	four	four	NUM
fnp-3395	80	36	randomised	randomised	ADJ
fnp-3395	80	37	controlled	control	VERB
fnp-3395	80	38	trials	trial	NOUN
fnp-3395	80	39	in	in	ADP
fnp-3395	80	40	brazil	brazil	PROPN
fnp-3395	80	41	,	,	PUNCT
fnp-3395	80	42	south	south	PROPN
fnp-3395	80	43	africa	africa	PROPN
fnp-3395	80	44	,	,	PUNCT
fnp-3395	80	45	and	and	CCONJ
fnp-3395	80	46	the	the	DET
fnp-3395	80	47	uk	uk	PROPN
fnp-3395	80	48	.	.	PUNCT
fnp-3395	81	1	the	the	DET
fnp-3395	81	2	lancet	lancet	NOUN
fnp-3395	81	3	.	.	PUNCT
fnp-3395	82	1	2021;397(10269):99	2021;397(10269):99	NUM
fnp-3395	82	2	-	-	PUNCT
fnp-3395	82	3	111	111	NUM
fnp-3395	82	4	.	.	PUNCT
fnp-3395	83	1	5	5	NUM
fnp-3395	83	2	.	.	X
fnp-3395	83	3	astrazeneca	astrazeneca	PROPN
fnp-3395	83	4	.	.	PROPN
fnp-3395	84	1	azd1222	azd1222	PROPN
fnp-3395	84	2	us	us	PROPN
fnp-3395	84	3	phase	phase	NOUN
fnp-3395	84	4	iii	iii	NUM
fnp-3395	84	5	trial	trial	NOUN
fnp-3395	84	6	met	meet	VERB
fnp-3395	84	7	primary	primary	ADJ
fnp-3395	84	8	efficacy	efficacy	NOUN
fnp-3395	84	9	endpoint	endpoint	NOUN
fnp-3395	84	10	in	in	ADP
fnp-3395	84	11	preventing	prevent	VERB
fnp-3395	84	12	covid-19	covid-19	PROPN
fnp-3395	84	13	at	at	ADP
fnp-3395	84	14	interim	interim	ADJ
fnp-3395	84	15	analysis	analysis	NOUN
fnp-3395	84	16	.	.	PUNCT
fnp-3395	85	1	https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-us-vaccine-trial-met-primary-endpoint.html	https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-us-vaccine-trial-met-primary-endpoint.html	PROPN
fnp-3395	85	2	.	.	PUNCT
fnp-3395	85	3	published	publish	VERB
fnp-3395	85	4	2021	2021	NUM
fnp-3395	85	5	.	.	PUNCT
fnp-3395	86	1	accessed	access	VERB
fnp-3395	86	2	april	april	PROPN
fnp-3395	86	3	5	5	NUM
fnp-3395	86	4	,	,	PUNCT
fnp-3395	86	5	2021	2021	NUM
fnp-3395	86	6	.	.	PUNCT
fnp-3395	87	1	6	6	NUM
fnp-3395	87	2	.	.	X
fnp-3395	87	3	european	european	PROPN
fnp-3395	87	4	medicines	medicine	NOUN
fnp-3395	87	5	agency	agency	NOUN
fnp-3395	87	6	.	.	PUNCT
fnp-3395	88	1	covid-19	covid-19	PROPN
fnp-3395	88	2	vaccine	vaccine	NOUN
fnp-3395	88	3	safety	safety	NOUN
fnp-3395	88	4	update	update	NOUN
fnp-3395	88	5	vaxzevria	vaxzevria	NOUN
fnp-3395	88	6	.	.	PUNCT
fnp-3395	89	1	https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-29-march-2021_en.pdf	https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-29-march-2021_en.pdf	PROPN
fnp-3395	89	2	.	.	PUNCT
fnp-3395	90	1	published	publish	VERB
fnp-3395	90	2	2021	2021	NUM
fnp-3395	90	3	.	.	PUNCT
fnp-3395	91	1	accessed	access	VERB
fnp-3395	91	2	april	april	PROPN
fnp-3395	91	3	4	4	NUM
fnp-3395	91	4	,	,	PUNCT
fnp-3395	91	5	2021	2021	NUM
fnp-3395	91	6	.	.	PUNCT
fnp-3395	92	1	7	7	X
fnp-3395	92	2	.	.	X
fnp-3395	92	3	greinacher	greinacher	PROPN
fnp-3395	92	4	a	a	PROPN
fnp-3395	92	5	,	,	PUNCT
fnp-3395	92	6	thiele	thiele	PROPN
fnp-3395	92	7	t	t	PROPN
fnp-3395	92	8	,	,	PUNCT
fnp-3395	92	9	warkentin	warkentin	ADJ
fnp-3395	92	10	te	te	PROPN
fnp-3395	92	11	,	,	PUNCT
fnp-3395	92	12	weisser	weisser	PROPN
fnp-3395	92	13	k	k	NOUN
fnp-3395	92	14	,	,	PUNCT
fnp-3395	92	15	kyrle	kyrle	PROPN
fnp-3395	92	16	pa	pa	PROPN
fnp-3395	92	17	,	,	PUNCT
fnp-3395	92	18	eichinger	eichinger	NOUN
fnp-3395	92	19	s.	s.	PROPN
fnp-3395	92	20	thrombotic	thrombotic	ADJ
fnp-3395	92	21	thrombocytopenia	thrombocytopenia	PROPN
fnp-3395	92	22	after	after	SCONJ
fnp-3395	92	23	chadox1	chadox1	VERB
fnp-3395	92	24	ncov-19	ncov-19	PROPN
fnp-3395	92	25	vaccination	vaccination	NOUN
fnp-3395	92	26	.	.	PUNCT
fnp-3395	93	1	new	new	PROPN
fnp-3395	93	2	england	england	PROPN
fnp-3395	93	3	journal	journal	PROPN
fnp-3395	93	4	of	of	ADP
fnp-3395	93	5	medicine	medicine	NOUN
fnp-3395	93	6	.	.	PUNCT
fnp-3395	94	1	2021;384(22):2092	2021;384(22):2092	NUM
fnp-3395	94	2	-	-	SYM
fnp-3395	94	3	2101	2101	NUM
fnp-3395	94	4	.	.	PUNCT
fnp-3395	95	1	8	8	X
fnp-3395	95	2	.	.	PUNCT
fnp-3395	96	1	cdc	cdc	PROPN
fnp-3395	96	2	.	.	PUNCT
fnp-3395	97	1	joint	joint	PROPN
fnp-3395	97	2	cdc	cdc	PROPN
fnp-3395	97	3	and	and	CCONJ
fnp-3395	97	4	fda	fda	PROPN
fnp-3395	97	5	statement	statement	NOUN
fnp-3395	97	6	on	on	ADP
fnp-3395	97	7	johnson	johnson	PROPN
fnp-3395	97	8	&	&	CCONJ
fnp-3395	97	9	johnson	johnson	PROPN
fnp-3395	97	10	covid-19	covid-19	PROPN
fnp-3395	97	11	vaccine	vaccine	NOUN
fnp-3395	97	12	.	.	PUNCT
fnp-3395	98	1	https://www.cdc.gov/media/releases/2021/s0413-jj-vaccine.html	https://www.cdc.gov/media/releases/2021/s0413-jj-vaccine.html	PROPN
fnp-3395	98	2	.	.	PROPN
fnp-3395	98	3	published	publish	VERB
fnp-3395	98	4	2021	2021	NUM
fnp-3395	98	5	.	.	PUNCT
fnp-3395	99	1	accessed	access	VERB
fnp-3395	99	2	april	april	PROPN
fnp-3395	99	3	13	13	NUM
fnp-3395	99	4	,	,	PUNCT
fnp-3395	99	5	2021	2021	NUM
fnp-3395	99	6	.	.	PUNCT
fnp-3395	100	1	9	9	X
fnp-3395	100	2	.	.	X
fnp-3395	100	3	ackermann	ackermann	PROPN
fnp-3395	100	4	m	m	PROPN
fnp-3395	100	5	,	,	PUNCT
fnp-3395	100	6	verleden	verleden	PROPN
fnp-3395	100	7	se	se	X
fnp-3395	100	8	,	,	PUNCT
fnp-3395	100	9	kuehnel	kuehnel	PROPN
fnp-3395	100	10	m	m	PROPN
fnp-3395	100	11	,	,	PUNCT
fnp-3395	100	12	et	et	PROPN
fnp-3395	100	13	al	al	PROPN
fnp-3395	100	14	.	.	PUNCT
fnp-3395	100	15	pulmonary	pulmonary	ADJ
fnp-3395	100	16	vascular	vascular	ADJ
fnp-3395	100	17	endothelialitis	endothelialitis	NOUN
fnp-3395	100	18	,	,	PUNCT
fnp-3395	100	19	thrombosis	thrombosis	NOUN
fnp-3395	100	20	,	,	PUNCT
fnp-3395	100	21	and	and	CCONJ
fnp-3395	100	22	angiogenesis	angiogenesis	NOUN
fnp-3395	100	23	in	in	ADP
fnp-3395	100	24	covid-19	covid-19	PROPN
fnp-3395	100	25	.	.	PUNCT
fnp-3395	100	26	new	new	PROPN
fnp-3395	100	27	england	england	PROPN
fnp-3395	100	28	journal	journal	PROPN
fnp-3395	100	29	of	of	ADP
fnp-3395	100	30	medicine	medicine	NOUN
fnp-3395	100	31	.	.	PUNCT
fnp-3395	101	1	2020;383(2):120	2020;383(2):120	NUM
fnp-3395	101	2	-	-	SYM
fnp-3395	101	3	128	128	NUM
fnp-3395	101	4	.	.	PUNCT
fnp-3395	102	1	10	10	NUM
fnp-3395	102	2	.	.	PUNCT
fnp-3395	103	1	goyal	goyal	PROPN
fnp-3395	103	2	p	p	NOUN
fnp-3395	103	3	,	,	PUNCT
fnp-3395	103	4	choi	choi	PROPN
fnp-3395	103	5	jj	jj	PROPN
fnp-3395	103	6	,	,	PUNCT
fnp-3395	103	7	pinheiro	pinheiro	PROPN
fnp-3395	103	8	lc	lc	PROPN
fnp-3395	103	9	,	,	PUNCT
fnp-3395	103	10	et	et	PROPN
fnp-3395	103	11	al	al	PROPN
fnp-3395	103	12	.	.	PROPN
fnp-3395	104	1	clinical	clinical	ADJ
fnp-3395	104	2	characteristics	characteristic	NOUN
fnp-3395	104	3	of	of	ADP
fnp-3395	104	4	covid-19	covid-19	PROPN
fnp-3395	104	5	in	in	ADP
fnp-3395	104	6	new	new	PROPN
fnp-3395	104	7	york	york	PROPN
fnp-3395	104	8	city	city	PROPN
fnp-3395	104	9	.	.	PUNCT
fnp-3395	105	1	new	new	PROPN
fnp-3395	105	2	england	england	PROPN
fnp-3395	105	3	journal	journal	PROPN
fnp-3395	105	4	of	of	ADP
fnp-3395	105	5	medicine	medicine	NOUN
fnp-3395	105	6	.	.	PUNCT
fnp-3395	106	1	2020;382(24):2372	2020;382(24):2372	NUM
fnp-3395	106	2	-	-	SYM
fnp-3395	106	3	2374	2374	NUM
fnp-3395	106	4	.	.	PUNCT
fnp-3395	107	1	11	11	NUM
fnp-3395	107	2	.	.	X
fnp-3395	108	1	guan	guan	PROPN
fnp-3395	108	2	w	w	PROPN
fnp-3395	108	3	-	-	PROPN
fnp-3395	108	4	j	j	PROPN
fnp-3395	108	5	,	,	PUNCT
fnp-3395	108	6	ni	ni	PROPN
fnp-3395	108	7	z	z	PROPN
fnp-3395	108	8	-	-	PROPN
fnp-3395	108	9	y	y	PROPN
fnp-3395	108	10	,	,	PUNCT
fnp-3395	108	11	hu	hu	PROPN
fnp-3395	108	12	y	y	PROPN
fnp-3395	108	13	,	,	PUNCT
fnp-3395	108	14	et	et	PROPN
fnp-3395	108	15	al	al	PROPN
fnp-3395	108	16	.	.	PROPN
fnp-3395	109	1	clinical	clinical	ADJ
fnp-3395	109	2	characteristics	characteristic	NOUN
fnp-3395	109	3	of	of	ADP
fnp-3395	109	4	coronavirus	coronavirus	NOUN
fnp-3395	109	5	disease	disease	NOUN
fnp-3395	109	6	2019	2019	NUM
fnp-3395	109	7	in	in	ADP
fnp-3395	109	8	china	china	PROPN
fnp-3395	109	9	.	.	PUNCT
fnp-3395	110	1	new	new	PROPN
fnp-3395	110	2	england	england	PROPN
fnp-3395	110	3	journal	journal	PROPN
fnp-3395	110	4	of	of	ADP
fnp-3395	110	5	medicine	medicine	NOUN
fnp-3395	110	6	.	.	PUNCT
fnp-3395	111	1	2020;382(18):1708	2020;382(18):1708	NUM
fnp-3395	111	2	-	-	SYM
fnp-3395	111	3	1720	1720	NUM
fnp-3395	111	4	.	.	PUNCT
fnp-3395	112	1	12	12	NUM
fnp-3395	112	2	.	.	PUNCT
fnp-3395	113	1	hottz	hottz	PROPN
fnp-3395	113	2	ed	ed	PROPN
fnp-3395	113	3	,	,	PUNCT
fnp-3395	113	4	azevedo	azevedo	PROPN
fnp-3395	113	5	-	-	PUNCT
fnp-3395	113	6	quintanilha	quintanilha	NOUN
fnp-3395	113	7	ig	ig	PROPN
fnp-3395	113	8	,	,	PUNCT
fnp-3395	113	9	palhinha	palhinha	VERB
fnp-3395	113	10	l	l	PROPN
fnp-3395	113	11	,	,	PUNCT
fnp-3395	113	12	et	et	PROPN
fnp-3395	113	13	al	al	PROPN
fnp-3395	113	14	.	.	PUNCT
fnp-3395	114	1	platelet	platelet	NOUN
fnp-3395	114	2	activation	activation	NOUN
fnp-3395	114	3	and	and	CCONJ
fnp-3395	114	4	platelet	platelet	ADJ
fnp-3395	114	5	-	-	PUNCT
fnp-3395	114	6	monocyte	monocyte	NOUN
fnp-3395	114	7	aggregates	aggregate	NOUN
fnp-3395	114	8	formation	formation	NOUN
fnp-3395	114	9	trigger	trigger	NOUN
fnp-3395	114	10	tissue	tissue	NOUN
fnp-3395	114	11	factor	factor	NOUN
fnp-3395	114	12	expression	expression	NOUN
fnp-3395	114	13	in	in	ADP
fnp-3395	114	14	severe	severe	ADJ
fnp-3395	114	15	covid-19	covid-19	PROPN
fnp-3395	114	16	patients	patient	NOUN
fnp-3395	114	17	.	.	PUNCT
fnp-3395	115	1	blood	blood	NOUN
fnp-3395	115	2	.	.	PUNCT
fnp-3395	116	1	2020;136(11):1330	2020;136(11):1330	NUM
fnp-3395	116	2	-	-	SYM
fnp-3395	116	3	1341	1341	NUM
fnp-3395	116	4	.	.	PUNCT
fnp-3395	117	1	13	13	NUM
fnp-3395	117	2	.	.	PUNCT
fnp-3395	118	1	nicolai	nicolai	PROPN
fnp-3395	118	2	l	l	PROPN
fnp-3395	118	3	,	,	PUNCT
fnp-3395	118	4	leunig	leunig	NOUN
fnp-3395	118	5	a	a	PRON
fnp-3395	118	6	,	,	PUNCT
fnp-3395	118	7	brambs	brambs	NOUN
fnp-3395	118	8	s	s	PROPN
fnp-3395	118	9	,	,	PUNCT
fnp-3395	118	10	et	et	PROPN
fnp-3395	118	11	al	al	PROPN
fnp-3395	118	12	.	.	PROPN
fnp-3395	119	1	immunothrombotic	immunothrombotic	ADJ
fnp-3395	119	2	dysregulation	dysregulation	NOUN
fnp-3395	119	3	in	in	ADP
fnp-3395	119	4	covid-19	covid-19	PROPN
fnp-3395	119	5	pneumonia	pneumonia	NOUN
fnp-3395	119	6	is	be	AUX
fnp-3395	119	7	associated	associate	VERB
fnp-3395	119	8	with	with	ADP
fnp-3395	119	9	respiratory	respiratory	ADJ
fnp-3395	119	10	failure	failure	NOUN
fnp-3395	119	11	and	and	CCONJ
fnp-3395	119	12	coagulopathy	coagulopathy	ADJ
fnp-3395	119	13	.	.	PUNCT
fnp-3395	120	1	circulation	circulation	NOUN
fnp-3395	120	2	.	.	PUNCT
fnp-3395	121	1	2020;142(12):1176	2020;142(12):1176	X
fnp-3395	121	2	-	-	PUNCT
fnp-3395	121	3	1189	1189	NUM
fnp-3395	121	4	.	.	PUNCT
fnp-3395	122	1	14	14	NUM
fnp-3395	122	2	.	.	PUNCT
fnp-3395	123	1	song	song	PROPN
fnp-3395	123	2	w	w	PROPN
fnp-3395	123	3	-	-	PUNCT
fnp-3395	123	4	c	c	PROPN
fnp-3395	123	5	,	,	PUNCT
fnp-3395	123	6	fitzgerald	fitzgerald	PROPN
fnp-3395	123	7	ga	ga	PROPN
fnp-3395	123	8	.	.	PUNCT
fnp-3395	123	9	covid-19	covid-19	PROPN
fnp-3395	123	10	,	,	PUNCT
fnp-3395	123	11	microangiopathy	microangiopathy	ADJ
fnp-3395	123	12	,	,	PUNCT
fnp-3395	123	13	hemostatic	hemostatic	ADJ
fnp-3395	123	14	activation	activation	NOUN
fnp-3395	123	15	,	,	PUNCT
fnp-3395	123	16	and	and	CCONJ
fnp-3395	123	17	complement	complement	NOUN
fnp-3395	123	18	.	.	PUNCT
fnp-3395	124	1	journal	journal	NOUN
fnp-3395	124	2	of	of	ADP
fnp-3395	124	3	clinical	clinical	ADJ
fnp-3395	124	4	investigation	investigation	NOUN
fnp-3395	124	5	.	.	PUNCT
fnp-3395	125	1	2020;130(8):3950	2020;130(8):3950	NUM
fnp-3395	125	2	-	-	SYM
fnp-3395	125	3	3953	3953	NUM
fnp-3395	125	4	.	.	PUNCT
fnp-3395	126	1	15	15	NUM
fnp-3395	126	2	.	.	X
fnp-3395	126	3	mowla	mowla	PROPN
fnp-3395	126	4	a	a	PRON
fnp-3395	126	5	,	,	PUNCT
fnp-3395	126	6	shakibajahromi	shakibajahromi	NOUN
fnp-3395	126	7	b	b	PROPN
fnp-3395	126	8	,	,	PUNCT
fnp-3395	126	9	shahjouei	shahjouei	PROPN
fnp-3395	126	10	s	s	PROPN
fnp-3395	126	11	,	,	PUNCT
fnp-3395	126	12	et	et	PROPN
fnp-3395	126	13	al	al	PROPN
fnp-3395	126	14	.	.	PROPN
fnp-3395	126	15	cerebral	cerebral	ADJ
fnp-3395	126	16	venous	venous	ADJ
fnp-3395	126	17	sinus	sinus	NOUN
fnp-3395	126	18	thrombosis	thrombosis	NOUN
fnp-3395	126	19	associated	associate	VERB
fnp-3395	126	20	with	with	ADP
fnp-3395	126	21	sars	sar	NOUN
fnp-3395	126	22	-	-	PUNCT
fnp-3395	126	23	cov-2	cov-2	NUM
fnp-3395	126	24	;	;	PUNCT
fnp-3395	126	25	a	a	DET
fnp-3395	126	26	multinational	multinational	ADJ
fnp-3395	126	27	case	case	NOUN
fnp-3395	126	28	series	series	NOUN
fnp-3395	126	29	.	.	PUNCT
fnp-3395	127	1	journal	journal	PROPN
fnp-3395	127	2	of	of	ADP
fnp-3395	127	3	neurological	neurological	ADJ
fnp-3395	127	4	sciences	science	NOUN
fnp-3395	127	5	.	.	PUNCT
fnp-3395	128	1	2020;419:117183	2020;419:117183	NUM
fnp-3395	128	2	.	.	PUNCT
fnp-3395	129	1	16	16	NUM
fnp-3395	129	2	.	.	PUNCT
fnp-3395	130	1	baldini	baldini	PROPN
fnp-3395	130	2	t	t	PROPN
fnp-3395	130	3	,	,	PUNCT
fnp-3395	130	4	asioli	asioli	PROPN
fnp-3395	130	5	gm	gm	PROPN
fnp-3395	130	6	,	,	PUNCT
fnp-3395	130	7	romoli	romoli	PROPN
fnp-3395	130	8	m	m	PROPN
fnp-3395	130	9	,	,	PUNCT
fnp-3395	130	10	et	et	PROPN
fnp-3395	130	11	al	al	PROPN
fnp-3395	130	12	.	.	PROPN
fnp-3395	130	13	cerebral	cerebral	ADJ
fnp-3395	130	14	venous	venous	ADJ
fnp-3395	130	15	thrombosis	thrombosis	NOUN
fnp-3395	130	16	and	and	CCONJ
fnp-3395	130	17	severe	severe	ADJ
fnp-3395	130	18	acute	acute	ADJ
fnp-3395	130	19	respiratory	respiratory	ADJ
fnp-3395	130	20	syndrome	syndrome	NOUN
fnp-3395	130	21	coronavirus-2	coronavirus-2	NUM
fnp-3395	130	22	infection	infection	NOUN
fnp-3395	130	23	:	:	PUNCT
fnp-3395	130	24	a	a	DET
fnp-3395	130	25	systematic	systematic	ADJ
fnp-3395	130	26	review	review	NOUN
fnp-3395	130	27	and	and	CCONJ
fnp-3395	130	28	meta	meta	ADJ
fnp-3395	130	29	-	-	PUNCT
fnp-3395	130	30	analysis	analysis	NOUN
fnp-3395	130	31	.	.	PUNCT
fnp-3395	131	1	european	european	ADJ
fnp-3395	131	2	journal	journal	PROPN
fnp-3395	131	3	of	of	ADP
fnp-3395	131	4	neurology	neurology	NOUN
fnp-3395	131	5	.	.	PUNCT
fnp-3395	132	1	2021;10.1111	2021;10.1111	X
fnp-3395	132	2	/	/	SYM
fnp-3395	132	3	ene.14727	ene.14727	NOUN
fnp-3395	132	4	.	.	PUNCT
fnp-3395	133	1	17	17	NUM
fnp-3395	133	2	.	.	PUNCT
fnp-3395	134	1	abdalkader	abdalkader	PROPN
fnp-3395	134	2	m	m	PROPN
fnp-3395	134	3	,	,	PUNCT
fnp-3395	134	4	shaikh	shaikh	PROPN
fnp-3395	134	5	sp	sp	PROPN
fnp-3395	134	6	,	,	PUNCT
fnp-3395	134	7	siegler	siegler	PROPN
fnp-3395	134	8	je	je	PROPN
fnp-3395	134	9	,	,	PUNCT
fnp-3395	134	10	et	et	PROPN
fnp-3395	134	11	al	al	PROPN
fnp-3395	134	12	.	.	PROPN
fnp-3395	134	13	cerebral	cerebral	ADJ
fnp-3395	134	14	venous	venous	ADJ
fnp-3395	134	15	sinus	sinus	NOUN
fnp-3395	134	16	thrombosis	thrombosis	NOUN
fnp-3395	134	17	in	in	ADP
fnp-3395	134	18	covid-19	covid-19	PROPN
fnp-3395	134	19	patients	patient	NOUN
fnp-3395	134	20	:	:	PUNCT
fnp-3395	134	21	a	a	DET
fnp-3395	134	22	multicenter	multicenter	ADJ
fnp-3395	134	23	study	study	NOUN
fnp-3395	134	24	and	and	CCONJ
fnp-3395	134	25	review	review	NOUN
fnp-3395	134	26	of	of	ADP
fnp-3395	134	27	literature	literature	NOUN
fnp-3395	134	28	.	.	PUNCT
fnp-3395	135	1	journal	journal	PROPN
fnp-3395	135	2	of	of	ADP
fnp-3395	135	3	stroke	stroke	NOUN
fnp-3395	135	4	and	and	CCONJ
fnp-3395	135	5	cerebrovascular	cerebrovascular	ADJ
fnp-3395	135	6	diseases	disease	NOUN
fnp-3395	135	7	.	.	PUNCT
fnp-3395	136	1	2021;30(6):105733	2021;30(6):105733	NUM
fnp-3395	136	2	.	.	PUNCT
fnp-3395	137	1	18	18	NUM
fnp-3395	137	2	.	.	X
fnp-3395	137	3	petito	petito	PROPN
fnp-3395	137	4	e	e	PROPN
fnp-3395	137	5	,	,	PUNCT
fnp-3395	137	6	falcinelli	falcinelli	PROPN
fnp-3395	137	7	e	e	PROPN
fnp-3395	137	8	,	,	PUNCT
fnp-3395	137	9	paliani	paliani	PROPN
fnp-3395	137	10	u	u	PROPN
fnp-3395	137	11	,	,	PUNCT
fnp-3395	137	12	et	et	PROPN
fnp-3395	137	13	al	al	PROPN
fnp-3395	137	14	.	.	PROPN
fnp-3395	137	15	association	association	PROPN
fnp-3395	137	16	of	of	ADP
fnp-3395	137	17	neutrophil	neutrophil	ADJ
fnp-3395	137	18	activation	activation	NOUN
fnp-3395	137	19	,	,	PUNCT
fnp-3395	137	20	more	more	ADJ
fnp-3395	137	21	than	than	ADP
fnp-3395	137	22	platelet	platelet	NOUN
fnp-3395	137	23	activation	activation	NOUN
fnp-3395	137	24	,	,	PUNCT
fnp-3395	137	25	with	with	ADP
fnp-3395	137	26	thrombotic	thrombotic	ADJ
fnp-3395	137	27	complications	complication	NOUN
fnp-3395	137	28	in	in	ADP
fnp-3395	137	29	coronavirus	coronavirus	NOUN
fnp-3395	137	30	disease	disease	NOUN
fnp-3395	137	31	2019	2019	NUM
fnp-3395	137	32	.	.	PUNCT
fnp-3395	138	1	the	the	DET
fnp-3395	138	2	journal	journal	NOUN
fnp-3395	138	3	of	of	ADP
fnp-3395	138	4	infectious	infectious	ADJ
fnp-3395	138	5	diseases	disease	NOUN
fnp-3395	138	6	.	.	PUNCT
fnp-3395	139	1	2021;223(6):933	2021;223(6):933	NUM
fnp-3395	139	2	-	-	SYM
fnp-3395	139	3	944	944	NUM
fnp-3395	139	4	.	.	NOUN
fnp-3395	140	1	19	19	NUM
fnp-3395	140	2	.	.	NOUN
fnp-3395	140	3	diorio	diorio	PROPN
fnp-3395	140	4	c	c	PROPN
fnp-3395	140	5	,	,	PUNCT
fnp-3395	140	6	mcnerney	mcnerney	PROPN
fnp-3395	140	7	ko	ko	PROPN
fnp-3395	140	8	,	,	PUNCT
fnp-3395	140	9	lambert	lambert	PROPN
fnp-3395	140	10	m	m	PROPN
fnp-3395	140	11	,	,	PUNCT
fnp-3395	140	12	et	et	PROPN
fnp-3395	140	13	al	al	PROPN
fnp-3395	140	14	.	.	PROPN
fnp-3395	140	15	evidence	evidence	NOUN
fnp-3395	140	16	of	of	ADP
fnp-3395	140	17	thrombotic	thrombotic	ADJ
fnp-3395	140	18	microangiopathy	microangiopathy	NOUN
fnp-3395	140	19	in	in	ADP
fnp-3395	140	20	children	child	NOUN
fnp-3395	140	21	with	with	ADP
fnp-3395	140	22	sars	sar	NOUN
fnp-3395	140	23	-	-	PUNCT
fnp-3395	140	24	cov-2	cov-2	NOUN
fnp-3395	140	25	across	across	ADP
fnp-3395	140	26	the	the	DET
fnp-3395	140	27	spectrum	spectrum	NOUN
fnp-3395	140	28	of	of	ADP
fnp-3395	140	29	clinical	clinical	ADJ
fnp-3395	140	30	presentations	presentation	NOUN
fnp-3395	140	31	.	.	PUNCT
fnp-3395	141	1	blood	blood	NOUN
fnp-3395	141	2	advances	advance	NOUN
fnp-3395	141	3	.	.	PUNCT
fnp-3395	142	1	2020;4(23):6051	2020;4(23):6051	NUM
fnp-3395	142	2	-	-	SYM
fnp-3395	142	3	6063	6063	NUM
fnp-3395	142	4	.	.	PUNCT
fnp-3395	143	1	20	20	NUM
fnp-3395	143	2	.	.	PUNCT
fnp-3395	143	3	archambault	archambault	PROPN
fnp-3395	143	4	as	as	ADP
fnp-3395	143	5	,	,	PUNCT
fnp-3395	143	6	zaid	zaid	PROPN
fnp-3395	143	7	y	y	PROPN
fnp-3395	143	8	,	,	PUNCT
fnp-3395	143	9	rakotoarivelo	rakotoarivelo	ADV
fnp-3395	143	10	v	v	NOUN
fnp-3395	143	11	,	,	PUNCT
fnp-3395	143	12	et	et	PROPN
fnp-3395	143	13	al	al	PROPN
fnp-3395	143	14	.	.	PROPN
fnp-3395	143	15	high	high	ADJ
fnp-3395	143	16	levels	level	NOUN
fnp-3395	143	17	of	of	ADP
fnp-3395	143	18	eicosanoids	eicosanoid	NOUN
fnp-3395	143	19	and	and	CCONJ
fnp-3395	143	20	docosanoids	docosanoid	NOUN
fnp-3395	143	21	in	in	ADP
fnp-3395	143	22	the	the	DET
fnp-3395	143	23	lungs	lung	NOUN
fnp-3395	143	24	of	of	ADP
fnp-3395	143	25	intubated	intubate	VERB
fnp-3395	143	26	covid‐19	covid‐19	PROPN
fnp-3395	143	27	patients	patient	NOUN
fnp-3395	143	28	.	.	PUNCT
fnp-3395	144	1	the	the	DET
fnp-3395	144	2	faseb	faseb	PROPN
fnp-3395	144	3	journal	journal	PROPN
fnp-3395	144	4	.	.	PUNCT
fnp-3395	145	1	2021;35(6	2021;35(6	NUM
fnp-3395	145	2	)	)	PUNCT
fnp-3395	145	3	.	.	PUNCT
fnp-3395	146	1	21	21	NUM
fnp-3395	146	2	.	.	PUNCT
fnp-3395	147	1	liu	liu	PROPN
fnp-3395	147	2	m	m	PROPN
fnp-3395	147	3	,	,	PUNCT
fnp-3395	147	4	gu	gu	PROPN
fnp-3395	147	5	c	c	PROPN
fnp-3395	147	6	,	,	PUNCT
fnp-3395	147	7	wu	wu	PROPN
fnp-3395	147	8	j	j	PROPN
fnp-3395	147	9	,	,	PUNCT
fnp-3395	147	10	zhu	zhu	PROPN
fnp-3395	147	11	y.	y.	PROPN
fnp-3395	147	12	amino	amino	PROPN
fnp-3395	147	13	acids	acid	NOUN
fnp-3395	147	14	1	1	NUM
fnp-3395	147	15	to	to	ADP
fnp-3395	147	16	422	422	NUM
fnp-3395	147	17	of	of	ADP
fnp-3395	147	18	the	the	DET
fnp-3395	147	19	spike	spike	ADJ
fnp-3395	147	20	protein	protein	NOUN
fnp-3395	147	21	of	of	ADP
fnp-3395	147	22	sars	sars	PROPN
fnp-3395	147	23	associated	associate	VERB
fnp-3395	147	24	coronavirus	coronavirus	PROPN
fnp-3395	147	25	are	be	AUX
fnp-3395	147	26	required	require	VERB
fnp-3395	147	27	for	for	ADP
fnp-3395	147	28	induction	induction	NOUN
fnp-3395	147	29	of	of	ADP
fnp-3395	147	30	cyclooxygenase-2	cyclooxygenase-2	PROPN
fnp-3395	147	31	.	.	PUNCT
fnp-3395	148	1	virus	virus	NOUN
fnp-3395	148	2	genes	gene	NOUN
fnp-3395	148	3	.	.	PUNCT
fnp-3395	149	1	2006;33(3):309	2006;33(3):309	NUM
fnp-3395	149	2	-	-	PUNCT
fnp-3395	149	3	317	317	NUM
fnp-3395	149	4	.	.	PUNCT
fnp-3395	150	1	22	22	NUM
fnp-3395	150	2	.	.	PUNCT
fnp-3395	151	1	vijay	vijay	NOUN
fnp-3395	151	2	r	r	PROPN
fnp-3395	151	3	,	,	PUNCT
fnp-3395	151	4	hua	hua	PROPN
fnp-3395	151	5	x	x	PROPN
fnp-3395	151	6	,	,	PUNCT
fnp-3395	151	7	meyerholz	meyerholz	PROPN
fnp-3395	151	8	dk	dk	PROPN
fnp-3395	151	9	,	,	PUNCT
fnp-3395	151	10	et	et	PROPN
fnp-3395	151	11	al	al	PROPN
fnp-3395	151	12	.	.	PROPN
fnp-3395	151	13	critical	critical	ADJ
fnp-3395	151	14	role	role	NOUN
fnp-3395	151	15	of	of	ADP
fnp-3395	151	16	phospholipase	phospholipase	PROPN
fnp-3395	151	17	a2	a2	PROPN
fnp-3395	151	18	group	group	PROPN
fnp-3395	151	19	iid	iid	NOUN
fnp-3395	151	20	in	in	ADP
fnp-3395	151	21	age	age	NOUN
fnp-3395	151	22	-	-	PUNCT
fnp-3395	151	23	related	relate	VERB
fnp-3395	151	24	susceptibility	susceptibility	NOUN
fnp-3395	151	25	to	to	ADP
fnp-3395	151	26	severe	severe	ADJ
fnp-3395	151	27	acute	acute	ADJ
fnp-3395	151	28	respiratory	respiratory	ADJ
fnp-3395	151	29	syndrome	syndrome	NOUN
fnp-3395	151	30	-	-	PUNCT
fnp-3395	151	31	cov	cov	NOUN
fnp-3395	151	32	infection	infection	NOUN
fnp-3395	151	33	.	.	PUNCT
fnp-3395	152	1	journal	journal	NOUN
fnp-3395	152	2	of	of	ADP
fnp-3395	152	3	experimental	experimental	ADJ
fnp-3395	152	4	medicine	medicine	NOUN
fnp-3395	152	5	.	.	PUNCT
fnp-3395	153	1	2015;212(11):1851	2015;212(11):1851	NOUN
fnp-3395	153	2	-	-	SYM
fnp-3395	153	3	1868	1868	NUM
fnp-3395	153	4	.	.	PUNCT
fnp-3395	154	1	23	23	NUM
fnp-3395	154	2	.	.	PUNCT
fnp-3395	155	1	leng	leng	PROPN
fnp-3395	155	2	x	x	PROPN
fnp-3395	155	3	-	-	PROPN
fnp-3395	155	4	h	h	PROPN
fnp-3395	155	5	,	,	PUNCT
fnp-3395	155	6	hong	hong	PROPN
fnp-3395	155	7	sy	sy	PROPN
fnp-3395	155	8	,	,	PUNCT
fnp-3395	155	9	larrucea	larrucea	PROPN
fnp-3395	155	10	s	s	PROPN
fnp-3395	155	11	,	,	PUNCT
fnp-3395	155	12	et	et	PROPN
fnp-3395	155	13	al	al	PROPN
fnp-3395	155	14	.	.	PUNCT
fnp-3395	156	1	platelets	platelet	NOUN
fnp-3395	156	2	of	of	ADP
fnp-3395	156	3	female	female	ADJ
fnp-3395	156	4	mice	mouse	NOUN
fnp-3395	156	5	are	be	AUX
fnp-3395	156	6	intrinsically	intrinsically	ADV
fnp-3395	156	7	more	more	ADV
fnp-3395	156	8	sensitive	sensitive	ADJ
fnp-3395	156	9	to	to	ADP
fnp-3395	156	10	agonists	agonist	NOUN
fnp-3395	156	11	than	than	SCONJ
fnp-3395	156	12	are	be	AUX
fnp-3395	156	13	platelets	platelet	NOUN
fnp-3395	156	14	of	of	ADP
fnp-3395	156	15	males	male	NOUN
fnp-3395	156	16	.	.	PUNCT
fnp-3395	157	1	arteriosclerosis	arteriosclerosis	NOUN
fnp-3395	157	2	,	,	PUNCT
fnp-3395	157	3	thrombosis	thrombosis	NOUN
fnp-3395	157	4	,	,	PUNCT
fnp-3395	157	5	and	and	CCONJ
fnp-3395	157	6	vascular	vascular	ADJ
fnp-3395	157	7	biology	biology	NOUN
fnp-3395	157	8	.	.	PUNCT
fnp-3395	158	1	2004;24(2):376	2004;24(2):376	NUM
fnp-3395	158	2	-	-	SYM
fnp-3395	158	3	381	381	NUM
fnp-3395	158	4	.	.	NOUN
fnp-3395	158	5	24	24	NUM
fnp-3395	158	6	.	.	PUNCT
fnp-3395	159	1	kim	kim	PROPN
fnp-3395	159	2	bs	bs	PROPN
fnp-3395	159	3	,	,	PUNCT
fnp-3395	159	4	auerbach	auerbach	PROPN
fnp-3395	159	5	da	da	PROPN
fnp-3395	159	6	,	,	PUNCT
fnp-3395	159	7	sadhra	sadhra	PROPN
fnp-3395	159	8	h	h	NOUN
fnp-3395	159	9	,	,	PUNCT
fnp-3395	159	10	et	et	PROPN
fnp-3395	159	11	al	al	PROPN
fnp-3395	159	12	.	.	PUNCT
fnp-3395	160	1	a	a	DET
fnp-3395	160	2	sex	sex	NOUN
fnp-3395	160	3	-	-	PUNCT
fnp-3395	160	4	specific	specific	ADJ
fnp-3395	160	5	switch	switch	NOUN
fnp-3395	160	6	in	in	ADP
fnp-3395	160	7	platelet	platelet	NOUN
fnp-3395	160	8	receptor	receptor	NOUN
fnp-3395	160	9	signaling	signal	VERB
fnp-3395	160	10	following	follow	VERB
fnp-3395	160	11	myocardial	myocardial	ADJ
fnp-3395	160	12	infarction	infarction	NOUN
fnp-3395	160	13	.	.	PUNCT
fnp-3395	161	1	in	in	ADP
fnp-3395	161	2	:	:	PUNCT
fnp-3395	161	3	cold	cold	ADJ
fnp-3395	161	4	spring	spring	NOUN
fnp-3395	161	5	harbor	harbor	NOUN
fnp-3395	161	6	laboratory	laboratory	NOUN
fnp-3395	161	7	;	;	PUNCT
fnp-3395	161	8	2019	2019	NUM
fnp-3395	161	9	.	.	X
fnp-3395	162	1	25	25	NUM
fnp-3395	162	2	.	.	PUNCT
fnp-3395	162	3	eikelboom	eikelboom	PROPN
fnp-3395	162	4	jw	jw	PROPN
fnp-3395	162	5	,	,	PUNCT
fnp-3395	162	6	hirsh	hirsh	PROPN
fnp-3395	162	7	j	j	PROPN
fnp-3395	162	8	,	,	PUNCT
fnp-3395	162	9	weitz	weitz	PROPN
fnp-3395	162	10	ji	ji	PROPN
fnp-3395	162	11	,	,	PUNCT
fnp-3395	162	12	johnston	johnston	PROPN
fnp-3395	162	13	m	m	PROPN
fnp-3395	162	14	,	,	PUNCT
fnp-3395	162	15	yi	yi	PROPN
fnp-3395	162	16	q	q	PROPN
fnp-3395	162	17	,	,	PUNCT
fnp-3395	162	18	yusuf	yusuf	PROPN
fnp-3395	162	19	s.	s.	PROPN
fnp-3395	162	20	aspirin	aspirin	PROPN
fnp-3395	162	21	-	-	PUNCT
fnp-3395	162	22	resistant	resistant	ADJ
fnp-3395	162	23	thromboxane	thromboxane	NOUN
fnp-3395	162	24	biosynthesis	biosynthesis	NOUN
fnp-3395	162	25	and	and	CCONJ
fnp-3395	162	26	the	the	DET
fnp-3395	162	27	risk	risk	NOUN
fnp-3395	162	28	of	of	ADP
fnp-3395	162	29	myocardial	myocardial	ADJ
fnp-3395	162	30	infarction	infarction	NOUN
fnp-3395	162	31	,	,	PUNCT
fnp-3395	162	32	stroke	stroke	NOUN
fnp-3395	162	33	,	,	PUNCT
fnp-3395	162	34	or	or	CCONJ
fnp-3395	162	35	cardiovascular	cardiovascular	ADJ
fnp-3395	162	36	death	death	NOUN
fnp-3395	162	37	in	in	ADP
fnp-3395	162	38	patients	patient	NOUN
fnp-3395	162	39	at	at	ADP
fnp-3395	162	40	high	high	ADJ
fnp-3395	162	41	risk	risk	NOUN
fnp-3395	162	42	for	for	ADP
fnp-3395	162	43	cardiovascular	cardiovascular	ADJ
fnp-3395	162	44	events	event	NOUN
fnp-3395	162	45	.	.	PUNCT
fnp-3395	163	1	circulation	circulation	NOUN
fnp-3395	163	2	.	.	PUNCT
fnp-3395	164	1	2002;105(14):1650	2002;105(14):1650	NUM
fnp-3395	164	2	-	-	SYM
fnp-3395	164	3	1655	1655	NUM
fnp-3395	164	4	.	.	PUNCT
fnp-3395	165	1	26	26	NUM
fnp-3395	165	2	.	.	PUNCT
fnp-3395	166	1	cohen	cohen	PROPN
fnp-3395	166	2	cj	cj	PROPN
fnp-3395	166	3	,	,	PUNCT
fnp-3395	166	4	xiang	xiang	PROPN
fnp-3395	166	5	zq	zq	PROPN
fnp-3395	166	6	,	,	PUNCT
fnp-3395	166	7	gao	gao	PROPN
fnp-3395	166	8	g	g	PROPN
fnp-3395	166	9	-	-	PUNCT
fnp-3395	166	10	p	p	X
fnp-3395	166	11	,	,	PUNCT
fnp-3395	166	12	ertl	ertl	PROPN
fnp-3395	166	13	hcj	hcj	PROPN
fnp-3395	166	14	,	,	PUNCT
fnp-3395	166	15	wilson	wilson	PROPN
fnp-3395	166	16	jm	jm	PROPN
fnp-3395	166	17	,	,	PUNCT
fnp-3395	166	18	bergelson	bergelson	PROPN
fnp-3395	166	19	jm	jm	PROPN
fnp-3395	166	20	.	.	PROPN
fnp-3395	166	21	chimpanzee	chimpanzee	PROPN
fnp-3395	166	22	adenovirus	adenovirus	PROPN
fnp-3395	166	23	cv-68	cv-68	PART
fnp-3395	166	24	adapted	adapt	VERB
fnp-3395	166	25	as	as	SCONJ
fnp-3395	166	26	a	a	DET
fnp-3395	166	27	gene	gene	NOUN
fnp-3395	166	28	delivery	delivery	NOUN
fnp-3395	166	29	vector	vector	NOUN
fnp-3395	166	30	interacts	interact	VERB
fnp-3395	166	31	with	with	ADP
fnp-3395	166	32	the	the	DET
fnp-3395	166	33	coxsackievirus	coxsackievirus	NOUN
fnp-3395	166	34	and	and	CCONJ
fnp-3395	166	35	adenovirus	adenovirus	NOUN
fnp-3395	166	36	receptor	receptor	NOUN
fnp-3395	166	37	.	.	PUNCT
fnp-3395	167	1	journal	journal	PROPN
fnp-3395	167	2	of	of	ADP
fnp-3395	167	3	general	general	ADJ
fnp-3395	167	4	virology	virology	NOUN
fnp-3395	167	5	.	.	PUNCT
fnp-3395	168	1	2002;83(1):151	2002;83(1):151	NUM
fnp-3395	168	2	-	-	SYM
fnp-3395	168	3	155	155	NUM
fnp-3395	168	4	.	.	PUNCT
fnp-3395	168	5	27	27	NUM
fnp-3395	168	6	.	.	PUNCT
fnp-3395	169	1	cohen	cohen	PROPN
fnp-3395	169	2	cj	cj	PROPN
fnp-3395	169	3	,	,	PUNCT
fnp-3395	169	4	shieh	shieh	PROPN
fnp-3395	169	5	jt	jt	PROPN
fnp-3395	169	6	,	,	PUNCT
fnp-3395	169	7	pickles	pickles	PROPN
fnp-3395	169	8	rj	rj	PROPN
fnp-3395	169	9	,	,	PUNCT
fnp-3395	169	10	okegawa	okegawa	PROPN
fnp-3395	169	11	t	t	PROPN
fnp-3395	169	12	,	,	PUNCT
fnp-3395	169	13	hsieh	hsieh	PROPN
fnp-3395	169	14	jt	jt	PROPN
fnp-3395	169	15	,	,	PUNCT
fnp-3395	169	16	bergelson	bergelson	PROPN
fnp-3395	169	17	jm	jm	PROPN
fnp-3395	169	18	.	.	PUNCT
fnp-3395	170	1	the	the	DET
fnp-3395	170	2	coxsackievirus	coxsackievirus	NOUN
fnp-3395	170	3	and	and	CCONJ
fnp-3395	170	4	adenovirus	adenovirus	NOUN
fnp-3395	170	5	receptor	receptor	NOUN
fnp-3395	170	6	is	be	AUX
fnp-3395	170	7	a	a	DET
fnp-3395	170	8	transmembrane	transmembrane	ADJ
fnp-3395	170	9	component	component	NOUN
fnp-3395	170	10	of	of	ADP
fnp-3395	170	11	the	the	DET
fnp-3395	170	12	tight	tight	ADJ
fnp-3395	170	13	junction	junction	NOUN
fnp-3395	170	14	.	.	PUNCT
fnp-3395	171	1	proceedings	proceeding	NOUN
fnp-3395	171	2	of	of	ADP
fnp-3395	171	3	the	the	DET
fnp-3395	171	4	national	national	PROPN
fnp-3395	171	5	academy	academy	PROPN
fnp-3395	171	6	of	of	ADP
fnp-3395	171	7	sciences	sciences	PROPN
fnp-3395	171	8	.	.	PUNCT
fnp-3395	172	1	2001;98(26):15191	2001;98(26):15191	NUM
fnp-3395	172	2	-	-	SYM
fnp-3395	172	3	15196	15196	NUM
fnp-3395	172	4	.	.	PUNCT
fnp-3395	173	1	28	28	NUM
fnp-3395	173	2	.	.	PUNCT
fnp-3395	174	1	kesisoglou	kesisoglou	PROPN
fnp-3395	174	2	f	f	PROPN
fnp-3395	174	3	,	,	PUNCT
fnp-3395	174	4	schmiedlin	schmiedlin	PROPN
fnp-3395	174	5	-	-	PROPN
fnp-3395	174	6	ren	ren	PROPN
fnp-3395	174	7	p	p	NOUN
fnp-3395	174	8	,	,	PUNCT
fnp-3395	174	9	fleisher	fleisher	PROPN
fnp-3395	174	10	d	d	PROPN
fnp-3395	174	11	,	,	PUNCT
fnp-3395	174	12	zimmermann	zimmermann	PROPN
fnp-3395	174	13	em	em	PRON
fnp-3395	174	14	.	.	PUNCT
fnp-3395	175	1	adenoviral	adenoviral	ADJ
fnp-3395	175	2	transduction	transduction	NOUN
fnp-3395	175	3	of	of	ADP
fnp-3395	175	4	enterocytes	enterocyte	NOUN
fnp-3395	175	5	and	and	CCONJ
fnp-3395	175	6	m	m	NOUN
fnp-3395	175	7	-	-	NOUN
fnp-3395	175	8	cells	cell	NOUN
fnp-3395	175	9	using	use	VERB
fnp-3395	175	10	in	in	ADP
fnp-3395	175	11	vitro	vitro	X
fnp-3395	175	12	models	model	NOUN
fnp-3395	175	13	based	base	VERB
fnp-3395	175	14	on	on	ADP
fnp-3395	175	15	caco-2	caco-2	NUM
fnp-3395	175	16	cells	cell	NOUN
fnp-3395	175	17	:	:	PUNCT
fnp-3395	175	18	the	the	DET
fnp-3395	175	19	coxsackievirus	coxsackievirus	NOUN
fnp-3395	175	20	and	and	CCONJ
fnp-3395	175	21	adenovirus	adenovirus	NOUN
fnp-3395	175	22	receptor	receptor	NOUN
fnp-3395	175	23	(	(	PUNCT
fnp-3395	175	24	car	car	NOUN
fnp-3395	175	25	)	)	PUNCT
fnp-3395	175	26	mediates	mediate	VERB
fnp-3395	175	27	both	both	CCONJ
fnp-3395	175	28	apical	apical	ADJ
fnp-3395	175	29	and	and	CCONJ
fnp-3395	175	30	basolateral	basolateral	ADJ
fnp-3395	175	31	transduction	transduction	NOUN
fnp-3395	175	32	.	.	PUNCT
fnp-3395	176	1	molecular	molecular	ADJ
fnp-3395	176	2	pharmaceutics	pharmaceutic	NOUN
fnp-3395	176	3	.	.	PUNCT
fnp-3395	177	1	2010;7(3):619	2010;7(3):619	X
fnp-3395	177	2	-	-	SYM
fnp-3395	177	3	629	629	NUM
fnp-3395	177	4	.	.	NOUN
fnp-3395	177	5	29	29	NUM
fnp-3395	177	6	.	.	PUNCT
fnp-3395	178	1	assinger	assing	ADJ
fnp-3395	178	2	a.	a.	NOUN
fnp-3395	178	3	platelets	platelet	NOUN
fnp-3395	178	4	and	and	CCONJ
fnp-3395	178	5	infection	infection	NOUN
fnp-3395	178	6	an	an	DET
fnp-3395	178	7	emerging	emerge	VERB
fnp-3395	178	8	role	role	NOUN
fnp-3395	178	9	of	of	ADP
fnp-3395	178	10	platelets	platelet	NOUN
fnp-3395	178	11	in	in	ADP
fnp-3395	178	12	viral	viral	ADJ
fnp-3395	178	13	infection	infection	NOUN
fnp-3395	178	14	.	.	PUNCT
fnp-3395	179	1	frontiers	frontier	NOUN
fnp-3395	179	2	in	in	ADP
fnp-3395	179	3	immunology	immunology	NOUN
fnp-3395	179	4	.	.	PUNCT
fnp-3395	180	1	2014;5:649	2014;5:649	X
fnp-3395	180	2	.	.	NOUN
fnp-3395	180	3	30	30	NUM
fnp-3395	180	4	.	.	PUNCT
fnp-3395	181	1	porres	porre	NOUN
fnp-3395	181	2	-	-	PUNCT
fnp-3395	181	3	aguilar	aguilar	PROPN
fnp-3395	181	4	m	m	PROPN
fnp-3395	181	5	,	,	PUNCT
fnp-3395	181	6	lazo	lazo	NOUN
fnp-3395	181	7	-	-	PUNCT
fnp-3395	181	8	langner	langner	NOUN
fnp-3395	181	9	a	a	NOUN
fnp-3395	181	10	,	,	PUNCT
fnp-3395	181	11	panduro	panduro	VERB
fnp-3395	181	12	a	a	PRON
fnp-3395	181	13	,	,	PUNCT
fnp-3395	181	14	uribe	uribe	PROPN
fnp-3395	181	15	m.	m.	PROPN
fnp-3395	181	16	covid-19	covid-19	PROPN
fnp-3395	181	17	vaccine	vaccine	NOUN
fnp-3395	181	18	-	-	PUNCT
fnp-3395	181	19	induced	induce	VERB
fnp-3395	181	20	immune	immune	ADJ
fnp-3395	181	21	thrombotic	thrombotic	ADJ
fnp-3395	181	22	thrombocytopenia	thrombocytopenia	PROPN
fnp-3395	181	23	:	:	PUNCT
fnp-3395	181	24	an	an	DET
fnp-3395	181	25	emerging	emerge	VERB
fnp-3395	181	26	cause	cause	NOUN
fnp-3395	181	27	of	of	ADP
fnp-3395	181	28	splanchnic	splanchnic	ADJ
fnp-3395	181	29	vein	vein	NOUN
fnp-3395	181	30	thrombosis	thrombosis	NOUN
fnp-3395	181	31	.	.	PUNCT
fnp-3395	182	1	annals	annal	NOUN
fnp-3395	182	2	of	of	ADP
fnp-3395	182	3	hepatology	hepatology	NOUN
fnp-3395	182	4	.	.	PUNCT
fnp-3395	183	1	2021;23:100356	2021;23:100356	NUM
fnp-3395	183	2	.	.	PUNCT
fnp-3395	184	1	31	31	NUM
fnp-3395	184	2	.	.	PUNCT
fnp-3395	184	3	yan	yan	PROPN
fnp-3395	185	1	x	x	X
fnp-3395	185	2	,	,	PUNCT
fnp-3395	185	3	hao	hao	PROPN
fnp-3395	185	4	q	q	PROPN
fnp-3395	185	5	,	,	PUNCT
fnp-3395	185	6	mu	mu	PROPN
fnp-3395	185	7	y	y	PROPN
fnp-3395	185	8	,	,	PUNCT
fnp-3395	185	9	et	et	PROPN
fnp-3395	185	10	al	al	PROPN
fnp-3395	185	11	.	.	PUNCT
fnp-3395	185	12	nucleocapsid	nucleocapsid	ADJ
fnp-3395	185	13	protein	protein	NOUN
fnp-3395	185	14	of	of	ADP
fnp-3395	185	15	sars	sar	NOUN
fnp-3395	185	16	-	-	PUNCT
fnp-3395	185	17	cov	cov	NOUN
fnp-3395	185	18	activates	activate	VERB
fnp-3395	185	19	the	the	DET
fnp-3395	185	20	expression	expression	NOUN
fnp-3395	185	21	of	of	ADP
fnp-3395	185	22	cyclooxygenase-2	cyclooxygenase-2	NUM
fnp-3395	185	23	by	by	ADP
fnp-3395	185	24	binding	bind	VERB
fnp-3395	185	25	directly	directly	ADV
fnp-3395	185	26	to	to	ADP
fnp-3395	185	27	regulatory	regulatory	ADJ
fnp-3395	185	28	elements	element	NOUN
fnp-3395	185	29	for	for	ADP
fnp-3395	185	30	nuclear	nuclear	ADJ
fnp-3395	185	31	factor	factor	NOUN
fnp-3395	185	32	-	-	PUNCT
fnp-3395	185	33	kappa	kappa	PROPN
fnp-3395	185	34	b	b	PROPN
fnp-3395	185	35	and	and	CCONJ
fnp-3395	185	36	ccaat	ccaat	PROPN
fnp-3395	185	37	/	/	SYM
fnp-3395	185	38	enhancer	enhancer	NOUN
fnp-3395	185	39	binding	bind	VERB
fnp-3395	185	40	protein	protein	NOUN
fnp-3395	185	41	.	.	PUNCT
fnp-3395	186	1	the	the	DET
fnp-3395	186	2	international	international	ADJ
fnp-3395	186	3	journal	journal	NOUN
fnp-3395	186	4	of	of	ADP
fnp-3395	186	5	biochemistry	biochemistry	PROPN
fnp-3395	186	6	&	&	CCONJ
fnp-3395	186	7	cell	cell	NOUN
fnp-3395	186	8	biology	biology	NOUN
fnp-3395	186	9	.	.	PUNCT
fnp-3395	187	1	2006;38(8):1417	2006;38(8):1417	NUM
fnp-3395	187	2	-	-	SYM
fnp-3395	187	3	1428	1428	NUM
fnp-3395	187	4	.	.	PUNCT
fnp-3395	188	1	32	32	NUM
fnp-3395	188	2	.	.	PUNCT
fnp-3395	189	1	rocca	rocca	PROPN
fnp-3395	189	2	b	b	PROPN
fnp-3395	189	3	,	,	PUNCT
fnp-3395	189	4	secchiero	secchiero	ADJ
fnp-3395	189	5	p	p	NOUN
fnp-3395	189	6	,	,	PUNCT
fnp-3395	189	7	ciabattoni	ciabattoni	ADJ
fnp-3395	189	8	g	g	NOUN
fnp-3395	189	9	,	,	PUNCT
fnp-3395	189	10	et	et	PROPN
fnp-3395	189	11	al	al	PROPN
fnp-3395	189	12	.	.	PUNCT
fnp-3395	189	13	cyclooxygenase-2	cyclooxygenase-2	NUM
fnp-3395	189	14	expression	expression	NOUN
fnp-3395	189	15	is	be	AUX
fnp-3395	189	16	induced	induce	VERB
fnp-3395	189	17	during	during	ADP
fnp-3395	189	18	human	human	ADJ
fnp-3395	189	19	megakaryopoiesis	megakaryopoiesis	NOUN
fnp-3395	189	20	and	and	CCONJ
fnp-3395	189	21	characterizes	characterize	VERB
fnp-3395	189	22	newly	newly	ADV
fnp-3395	189	23	formed	form	VERB
fnp-3395	189	24	platelets	platelet	NOUN
fnp-3395	189	25	.	.	PUNCT
fnp-3395	190	1	proceedings	proceeding	NOUN
fnp-3395	190	2	of	of	ADP
fnp-3395	190	3	the	the	DET
fnp-3395	190	4	national	national	PROPN
fnp-3395	190	5	academy	academy	PROPN
fnp-3395	190	6	of	of	ADP
fnp-3395	190	7	sciences	sciences	PROPN
fnp-3395	190	8	.	.	PUNCT
fnp-3395	191	1	2002;99(11):7634	2002;99(11):7634	X
fnp-3395	191	2	-	-	SYM
fnp-3395	191	3	7639	7639	NUM
fnp-3395	191	4	.	.	PUNCT
fnp-3395	192	1	33	33	NUM
fnp-3395	192	2	.	.	X
fnp-3395	192	3	lefrançais	lefrançais	PROPN
fnp-3395	192	4	e	e	PROPN
fnp-3395	192	5	,	,	PUNCT
fnp-3395	192	6	ortiz	ortiz	PROPN
fnp-3395	192	7	-	-	PUNCT
fnp-3395	192	8	muñoz	muñoz	PROPN
fnp-3395	192	9	g	g	PROPN
fnp-3395	192	10	,	,	PUNCT
fnp-3395	192	11	caudrillier	caudrillier	NOUN
fnp-3395	192	12	a	a	X
fnp-3395	192	13	,	,	PUNCT
fnp-3395	192	14	et	et	PROPN
fnp-3395	192	15	al	al	PROPN
fnp-3395	192	16	.	.	PUNCT
fnp-3395	193	1	the	the	DET
fnp-3395	193	2	lung	lung	NOUN
fnp-3395	193	3	is	be	AUX
fnp-3395	193	4	a	a	DET
fnp-3395	193	5	site	site	NOUN
fnp-3395	193	6	of	of	ADP
fnp-3395	193	7	platelet	platelet	NOUN
fnp-3395	193	8	biogenesis	biogenesis	NOUN
fnp-3395	193	9	and	and	CCONJ
fnp-3395	193	10	a	a	DET
fnp-3395	193	11	reservoir	reservoir	NOUN
fnp-3395	193	12	for	for	ADP
fnp-3395	193	13	haematopoietic	haematopoietic	ADJ
fnp-3395	193	14	progenitors	progenitor	NOUN
fnp-3395	193	15	.	.	PUNCT
fnp-3395	194	1	nature	nature	NOUN
fnp-3395	194	2	.	.	PUNCT
fnp-3395	195	1	2017;544(7648):105	2017;544(7648):105	NUM
fnp-3395	195	2	-	-	SYM
fnp-3395	195	3	109	109	NUM
fnp-3395	195	4	.	.	PUNCT
fnp-3395	196	1	34	34	NUM
fnp-3395	196	2	.	.	PUNCT
fnp-3395	196	3	nauen	nauen	PROPN
fnp-3395	196	4	dw	dw	PROPN
fnp-3395	196	5	,	,	PUNCT
fnp-3395	196	6	hooper	hooper	PROPN
fnp-3395	196	7	je	je	PROPN
fnp-3395	196	8	,	,	PUNCT
fnp-3395	196	9	stewart	stewart	PROPN
fnp-3395	196	10	cm	cm	PROPN
fnp-3395	196	11	,	,	PUNCT
fnp-3395	196	12	solomon	solomon	PROPN
fnp-3395	196	13	ih	ih	PROPN
fnp-3395	196	14	.	.	PUNCT
fnp-3395	197	1	assessing	assess	VERB
fnp-3395	197	2	brain	brain	NOUN
fnp-3395	197	3	capillaries	capillary	NOUN
fnp-3395	197	4	in	in	ADP
fnp-3395	197	5	coronavirus	coronavirus	NOUN
fnp-3395	197	6	disease	disease	NOUN
fnp-3395	197	7	2019	2019	NUM
fnp-3395	197	8	.	.	PUNCT
fnp-3395	198	1	jama	jama	PROPN
fnp-3395	198	2	neurology	neurology	NOUN
fnp-3395	198	3	.	.	PUNCT
fnp-3395	199	1	2021;78(6):760	2021;78(6):760	NUM
fnp-3395	199	2	-	-	SYM
fnp-3395	199	3	762	762	NUM
fnp-3395	199	4	35	35	NUM
fnp-3395	199	5	.	.	PUNCT
fnp-3395	200	1	schultz	schultz	PROPN
fnp-3395	200	2	nh	nh	PROPN
fnp-3395	200	3	,	,	PUNCT
fnp-3395	200	4	sørvoll	sørvoll	PROPN
fnp-3395	200	5	ih	ih	NOUN
fnp-3395	200	6	,	,	PUNCT
fnp-3395	200	7	michelsen	michelsen	PROPN
fnp-3395	200	8	ae	ae	PROPN
fnp-3395	200	9	,	,	PUNCT
fnp-3395	200	10	et	et	PROPN
fnp-3395	200	11	al	al	PROPN
fnp-3395	200	12	.	.	PROPN
fnp-3395	200	13	thrombosis	thrombosis	NOUN
fnp-3395	200	14	and	and	CCONJ
fnp-3395	200	15	thrombocytopenia	thrombocytopenia	NOUN
fnp-3395	200	16	after	after	ADP
fnp-3395	200	17	chadox1	chadox1	VERB
fnp-3395	200	18	ncov-19	ncov-19	PROPN
fnp-3395	200	19	vaccination	vaccination	NOUN
fnp-3395	200	20	.	.	PUNCT
fnp-3395	201	1	new	new	PROPN
fnp-3395	201	2	england	england	PROPN
fnp-3395	201	3	journal	journal	PROPN
fnp-3395	201	4	of	of	ADP
fnp-3395	201	5	medicine	medicine	NOUN
fnp-3395	201	6	.	.	PUNCT
fnp-3395	202	1	2021;384(22):2124	2021;384(22):2124	NUM
fnp-3395	202	2	-	-	SYM
fnp-3395	202	3	2130	2130	NUM
fnp-3395	202	4	.	.	PUNCT
fnp-3395	203	1	36	36	NUM
fnp-3395	203	2	.	.	PUNCT
fnp-3395	203	3	torjesen	torjesen	PROPN
fnp-3395	203	4	i.	i.	PROPN
fnp-3395	203	5	covid-19	covid-19	PROPN
fnp-3395	203	6	:	:	PUNCT
fnp-3395	203	7	risk	risk	NOUN
fnp-3395	203	8	of	of	ADP
fnp-3395	203	9	cerebral	cerebral	ADJ
fnp-3395	203	10	blood	blood	NOUN
fnp-3395	203	11	clots	clot	NOUN
fnp-3395	203	12	from	from	ADP
fnp-3395	203	13	disease	disease	NOUN
fnp-3395	203	14	is	be	AUX
fnp-3395	203	15	10	10	NUM
fnp-3395	203	16	times	time	NOUN
fnp-3395	203	17	that	that	SCONJ
fnp-3395	203	18	from	from	ADP
fnp-3395	203	19	vaccination	vaccination	NOUN
fnp-3395	203	20	,	,	PUNCT
fnp-3395	203	21	study	study	NOUN
fnp-3395	203	22	finds	find	VERB
fnp-3395	203	23	.	.	PUNCT
fnp-3395	204	1	bmj	bmj	PROPN
fnp-3395	204	2	.	.	PUNCT
fnp-3395	205	1	2021;373	2021;373	NUM
fnp-3395	205	2	:	:	PUNCT
fnp-3395	205	3	n1005	n1005	NOUN
fnp-3395	205	4	.	.	PUNCT
fnp-3395	206	1	37	37	NUM
fnp-3395	206	2	.	.	PUNCT
fnp-3395	207	1	mezey	mezey	PROPN
fnp-3395	207	2	é	é	PROPN
fnp-3395	207	3	,	,	PUNCT
fnp-3395	207	4	szalayova	szalayova	PROPN
fnp-3395	207	5	i	i	PRON
fnp-3395	207	6	,	,	PUNCT
fnp-3395	207	7	hogden	hogden	PROPN
fnp-3395	207	8	ct	ct	PROPN
fnp-3395	207	9	,	,	PUNCT
fnp-3395	207	10	et	et	PROPN
fnp-3395	207	11	al	al	PROPN
fnp-3395	207	12	.	.	PUNCT
fnp-3395	208	1	an	an	DET
fnp-3395	208	2	immunohistochemical	immunohistochemical	ADJ
fnp-3395	208	3	study	study	NOUN
fnp-3395	208	4	of	of	ADP
fnp-3395	208	5	lymphatic	lymphatic	ADJ
fnp-3395	208	6	elements	element	NOUN
fnp-3395	208	7	in	in	ADP
fnp-3395	208	8	the	the	DET
fnp-3395	208	9	human	human	ADJ
fnp-3395	208	10	brain	brain	NOUN
fnp-3395	208	11	.	.	PUNCT
fnp-3395	209	1	proceedings	proceeding	NOUN
fnp-3395	209	2	of	of	ADP
fnp-3395	209	3	the	the	DET
fnp-3395	209	4	national	national	PROPN
fnp-3395	209	5	academy	academy	PROPN
fnp-3395	209	6	of	of	ADP
fnp-3395	209	7	sciences	sciences	PROPN
fnp-3395	209	8	.	.	PUNCT
fnp-3395	210	1	2021;118(3):e2002574118	2021;118(3):e2002574118	NUM
fnp-3395	210	2	.	.	NOUN
fnp-3395	210	3	38	38	NUM
fnp-3395	210	4	.	.	PUNCT
fnp-3395	211	1	badolia	badolia	PROPN
fnp-3395	211	2	r	r	NOUN
fnp-3395	211	3	,	,	PUNCT
fnp-3395	211	4	inamdar	inamdar	NOUN
fnp-3395	211	5	v	v	NOUN
fnp-3395	211	6	,	,	PUNCT
fnp-3395	211	7	manne	manne	PROPN
fnp-3395	211	8	bk	bk	PROPN
fnp-3395	211	9	,	,	PUNCT
fnp-3395	211	10	dangelmaier	dangelmaier	PROPN
fnp-3395	211	11	c	c	NOUN
fnp-3395	211	12	,	,	PUNCT
fnp-3395	211	13	eble	eble	ADJ
fnp-3395	211	14	ja	ja	PROPN
fnp-3395	211	15	,	,	PUNCT
fnp-3395	211	16	kunapuli	kunapuli	PROPN
fnp-3395	211	17	sp	sp	PROPN
fnp-3395	211	18	.	.	PUNCT
fnp-3395	211	19	g(q	g(q	NOUN
fnp-3395	211	20	)	)	PUNCT
fnp-3395	211	21	pathway	pathway	NOUN
fnp-3395	211	22	regulates	regulate	VERB
fnp-3395	211	23	proximal	proximal	ADJ
fnp-3395	211	24	c	c	NOUN
fnp-3395	211	25	-	-	PUNCT
fnp-3395	211	26	type	type	NOUN
fnp-3395	211	27	lectin	lectin	NOUN
fnp-3395	211	28	-	-	PUNCT
fnp-3395	211	29	like	like	ADJ
fnp-3395	211	30	receptor-2	receptor-2	PROPN
fnp-3395	211	31	(	(	PUNCT
fnp-3395	211	32	clec-2	clec-2	NOUN
fnp-3395	211	33	)	)	PUNCT
fnp-3395	211	34	signaling	signal	VERB
fnp-3395	211	35	in	in	ADP
fnp-3395	211	36	platelets	platelet	NOUN
fnp-3395	211	37	.	.	PUNCT
fnp-3395	212	1	journal	journal	NOUN
fnp-3395	212	2	of	of	ADP
fnp-3395	212	3	biological	biological	ADJ
fnp-3395	212	4	chemistry	chemistry	NOUN
fnp-3395	212	5	.	.	PUNCT
fnp-3395	213	1	2017;292(35):14516	2017;292(35):14516	NUM
fnp-3395	213	2	-	-	SYM
fnp-3395	213	3	14531	14531	NUM
fnp-3395	213	4	.	.	PUNCT
fnp-3395	214	1	39	39	NUM
fnp-3395	214	2	.	.	PUNCT
fnp-3395	215	1	sung	sing	VERB
fnp-3395	215	2	p	p	PROPN
fnp-3395	215	3	-	-	PUNCT
fnp-3395	215	4	s	s	PROPN
fnp-3395	215	5	,	,	PUNCT
fnp-3395	215	6	huang	huang	PROPN
fnp-3395	215	7	t	t	PROPN
fnp-3395	215	8	-	-	PUNCT
fnp-3395	215	9	f	f	PROPN
fnp-3395	215	10	,	,	PUNCT
fnp-3395	215	11	hsieh	hsieh	PROPN
fnp-3395	215	12	s	s	PROPN
fnp-3395	215	13	-	-	PUNCT
fnp-3395	215	14	l.	l.	ADJ
fnp-3395	215	15	extracellular	extracellular	ADJ
fnp-3395	215	16	vesicles	vesicle	NOUN
fnp-3395	215	17	from	from	ADP
fnp-3395	215	18	clec2	clec2	NOUN
fnp-3395	215	19	-	-	PUNCT
fnp-3395	215	20	activated	activate	VERB
fnp-3395	215	21	platelets	platelet	NOUN
fnp-3395	215	22	enhance	enhance	VERB
fnp-3395	215	23	dengue	dengue	PROPN
fnp-3395	215	24	virus	virus	NOUN
fnp-3395	215	25	-	-	PUNCT
fnp-3395	215	26	induced	induce	VERB
fnp-3395	215	27	lethality	lethality	NOUN
fnp-3395	215	28	via	via	ADP
fnp-3395	215	29	clec5a	clec5a	PROPN
fnp-3395	215	30	/	/	SYM
fnp-3395	215	31	tlr2	tlr2	PROPN
fnp-3395	215	32	.	.	PUNCT
fnp-3395	216	1	nature	nature	NOUN
fnp-3395	216	2	communications	communication	NOUN
fnp-3395	216	3	.	.	PUNCT
fnp-3395	217	1	2019;10(1	2019;10(1	NUM
fnp-3395	217	2	)	)	PUNCT
fnp-3395	217	3	.	.	PUNCT
fnp-3395	218	1	40	40	NUM
fnp-3395	218	2	.	.	PUNCT
fnp-3395	219	1	ng	ng	PROPN
fnp-3395	219	2	h	h	PROPN
fnp-3395	219	3	,	,	PUNCT
fnp-3395	219	4	havervall	havervall	NOUN
fnp-3395	219	5	s	s	PROPN
fnp-3395	219	6	,	,	PUNCT
fnp-3395	219	7	rosell	rosell	VERB
fnp-3395	219	8	a	a	PRON
fnp-3395	219	9	,	,	PUNCT
fnp-3395	219	10	et	et	PROPN
fnp-3395	219	11	al	al	PROPN
fnp-3395	219	12	.	.	PUNCT
fnp-3395	220	1	circulating	circulate	VERB
fnp-3395	220	2	markers	marker	NOUN
fnp-3395	220	3	of	of	ADP
fnp-3395	220	4	neutrophil	neutrophil	ADJ
fnp-3395	220	5	extracellular	extracellular	ADJ
fnp-3395	220	6	traps	trap	NOUN
fnp-3395	220	7	are	be	AUX
fnp-3395	220	8	of	of	ADP
fnp-3395	220	9	prognostic	prognostic	ADJ
fnp-3395	220	10	value	value	NOUN
fnp-3395	220	11	in	in	ADP
fnp-3395	220	12	patients	patient	NOUN
fnp-3395	220	13	with	with	ADP
fnp-3395	220	14	covid-19	covid-19	PROPN
fnp-3395	220	15	.	.	PUNCT
fnp-3395	220	16	arteriosclerosis	arteriosclerosis	NOUN
fnp-3395	220	17	,	,	PUNCT
fnp-3395	220	18	thrombosis	thrombosis	NOUN
fnp-3395	220	19	,	,	PUNCT
fnp-3395	220	20	and	and	CCONJ
fnp-3395	220	21	vascular	vascular	ADJ
fnp-3395	220	22	biology	biology	NOUN
fnp-3395	220	23	.	.	PUNCT
fnp-3395	221	1	2021;41(2):988	2021;41(2):988	NUM
fnp-3395	221	2	-	-	SYM
fnp-3395	221	3	994	994	NUM
fnp-3395	221	4	.	.	PUNCT
fnp-3395	221	5	41	41	NUM
fnp-3395	221	6	.	.	PUNCT
fnp-3395	222	1	welsh	welsh	PROPN
fnp-3395	222	2	jd	jd	PROPN
fnp-3395	222	3	,	,	PUNCT
fnp-3395	222	4	kahn	kahn	PROPN
fnp-3395	222	5	ml	ml	PROPN
fnp-3395	222	6	,	,	PUNCT
fnp-3395	222	7	sweet	sweet	ADJ
fnp-3395	222	8	dt	dt	X
fnp-3395	222	9	.	.	PUNCT
fnp-3395	223	1	lymphovenous	lymphovenous	ADJ
fnp-3395	223	2	hemostasis	hemostasis	NOUN
fnp-3395	223	3	and	and	CCONJ
fnp-3395	223	4	the	the	DET
fnp-3395	223	5	role	role	NOUN
fnp-3395	223	6	of	of	ADP
fnp-3395	223	7	platelets	platelet	NOUN
fnp-3395	223	8	in	in	ADP
fnp-3395	223	9	regulating	regulate	VERB
fnp-3395	223	10	lymphatic	lymphatic	ADJ
fnp-3395	223	11	flow	flow	NOUN
fnp-3395	223	12	and	and	CCONJ
fnp-3395	223	13	lymphatic	lymphatic	ADJ
fnp-3395	223	14	vessel	vessel	NOUN
fnp-3395	223	15	maturation	maturation	NOUN
fnp-3395	223	16	.	.	PUNCT
fnp-3395	224	1	blood	blood	NOUN
fnp-3395	224	2	.	.	PUNCT
fnp-3395	225	1	2016;128(9):1169	2016;128(9):1169	PROPN
fnp-3395	225	2	-	-	SYM
fnp-3395	225	3	1173	1173	NUM
fnp-3395	225	4	.	.	PUNCT
fnp-3395	226	1	42	42	NUM
fnp-3395	226	2	.	.	PUNCT
fnp-3395	227	1	carey	carey	PROPN
fnp-3395	227	2	ma	ma	PROPN
fnp-3395	227	3	,	,	PUNCT
fnp-3395	227	4	bradbury	bradbury	PROPN
fnp-3395	227	5	ja	ja	PROPN
fnp-3395	227	6	,	,	PUNCT
fnp-3395	227	7	seubert	seubert	PROPN
fnp-3395	227	8	jm	jm	PROPN
fnp-3395	227	9	,	,	PUNCT
fnp-3395	227	10	langenbach	langenbach	NOUN
fnp-3395	227	11	r	r	NOUN
fnp-3395	227	12	,	,	PUNCT
fnp-3395	227	13	zeldin	zeldin	PROPN
fnp-3395	227	14	dc	dc	PROPN
fnp-3395	227	15	,	,	PUNCT
fnp-3395	227	16	germolec	germolec	PROPN
fnp-3395	227	17	dr	dr	PROPN
fnp-3395	227	18	.	.	PROPN
fnp-3395	227	19	contrasting	contrast	VERB
fnp-3395	227	20	effects	effect	NOUN
fnp-3395	227	21	of	of	ADP
fnp-3395	227	22	cyclooxygenase-1	cyclooxygenase-1	PROPN
fnp-3395	227	23	(	(	PUNCT
fnp-3395	227	24	cox-1	cox-1	X
fnp-3395	227	25	)	)	PUNCT
fnp-3395	227	26	and	and	CCONJ
fnp-3395	227	27	cox-2	cox-2	VERB
fnp-3395	227	28	deficiency	deficiency	NOUN
fnp-3395	227	29	on	on	ADP
fnp-3395	227	30	the	the	DET
fnp-3395	227	31	host	host	NOUN
fnp-3395	227	32	response	response	NOUN
fnp-3395	227	33	to	to	ADP
fnp-3395	227	34	influenza	influenza	NOUN
fnp-3395	227	35	a	a	DET
fnp-3395	227	36	viral	viral	ADJ
fnp-3395	227	37	infection	infection	NOUN
fnp-3395	227	38	.	.	PUNCT
fnp-3395	228	1	the	the	DET
fnp-3395	228	2	journal	journal	NOUN
fnp-3395	228	3	of	of	ADP
fnp-3395	228	4	immunology	immunology	NOUN
fnp-3395	228	5	.	.	PUNCT
fnp-3395	229	1	2005;175(10):6878	2005;175(10):6878	NUM
fnp-3395	229	2	-	-	SYM
fnp-3395	229	3	6884	6884	NUM
fnp-3395	229	4	.	.	PUNCT
fnp-3395	230	1	43	43	NUM
fnp-3395	230	2	.	.	PUNCT
fnp-3395	231	1	kuhl	kuhl	PROPN
fnp-3395	231	2	pg	pg	PROPN
fnp-3395	231	3	,	,	PUNCT
fnp-3395	231	4	bolds	bolds	PROPN
fnp-3395	231	5	jm	jm	PROPN
fnp-3395	231	6	,	,	PUNCT
fnp-3395	231	7	loyd	loyd	PROPN
fnp-3395	231	8	je	je	PROPN
fnp-3395	231	9	,	,	PUNCT
fnp-3395	231	10	snapper	snapper	PROPN
fnp-3395	231	11	jr	jr	PROPN
fnp-3395	231	12	,	,	PUNCT
fnp-3395	231	13	fitzgerald	fitzgerald	PROPN
fnp-3395	231	14	ga	ga	PROPN
fnp-3395	231	15	.	.	PROPN
fnp-3395	231	16	thromboxane	thromboxane	PROPN
fnp-3395	231	17	receptor	receptor	NOUN
fnp-3395	231	18	-	-	PUNCT
fnp-3395	231	19	mediated	mediate	VERB
fnp-3395	231	20	bronchial	bronchial	ADJ
fnp-3395	231	21	and	and	CCONJ
fnp-3395	231	22	hemodynamic	hemodynamic	ADJ
fnp-3395	231	23	responses	response	NOUN
fnp-3395	231	24	in	in	ADP
fnp-3395	231	25	ovine	ovine	ADJ
fnp-3395	231	26	endotoxemia	endotoxemia	NOUN
fnp-3395	231	27	.	.	PUNCT
fnp-3395	232	1	american	american	PROPN
fnp-3395	232	2	journal	journal	PROPN
fnp-3395	232	3	of	of	ADP
fnp-3395	232	4	physiology	physiology	NOUN
fnp-3395	232	5	.	.	PUNCT
fnp-3395	233	1	1988;254(2	1988;254(2	NUM
fnp-3395	233	2	pt	pt	PROPN
fnp-3395	233	3	2):r310	2):r310	NUM
fnp-3395	233	4	-	-	SYM
fnp-3395	233	5	319	319	NUM
fnp-3395	233	6	.	.	PUNCT
fnp-3395	234	1	44	44	NUM
fnp-3395	234	2	.	.	PUNCT
fnp-3395	235	1	altavilla	altavilla	PROPN
fnp-3395	235	2	d	d	PROPN
fnp-3395	235	3	,	,	PUNCT
fnp-3395	235	4	canale	canale	ADJ
fnp-3395	235	5	p	p	NOUN
fnp-3395	235	6	,	,	PUNCT
fnp-3395	235	7	squadrito	squadrito	PROPN
fnp-3395	235	8	f	f	AUX
fnp-3395	235	9	,	,	PUNCT
fnp-3395	235	10	et	et	PROPN
fnp-3395	235	11	al	al	PROPN
fnp-3395	235	12	.	.	PUNCT
fnp-3395	236	1	protective	protective	ADJ
fnp-3395	236	2	effects	effect	NOUN
fnp-3395	236	3	of	of	ADP
fnp-3395	236	4	bay	bay	NOUN
fnp-3395	236	5	u	u	PROPN
fnp-3395	236	6	3405	3405	PROPN
fnp-3395	236	7	,	,	PUNCT
fnp-3395	236	8	a	a	DET
fnp-3395	236	9	thromboxane	thromboxane	NOUN
fnp-3395	236	10	a2	a2	NOUN
fnp-3395	236	11	receptor	receptor	NOUN
fnp-3395	236	12	antagonist	antagonist	NOUN
fnp-3395	236	13	,	,	PUNCT
fnp-3395	236	14	in	in	ADP
fnp-3395	236	15	endotoxin	endotoxin	ADJ
fnp-3395	236	16	shock	shock	NOUN
fnp-3395	236	17	.	.	PUNCT
fnp-3395	237	1	pharmacological	pharmacological	ADJ
fnp-3395	237	2	research	research	NOUN
fnp-3395	237	3	.	.	PUNCT
fnp-3395	238	1	1994;30(2):137	1994;30(2):137	NUM
fnp-3395	238	2	-	-	SYM
fnp-3395	238	3	151	151	NUM
fnp-3395	238	4	.	.	PUNCT
fnp-3395	239	1	45	45	NUM
fnp-3395	239	2	.	.	PUNCT
fnp-3395	240	1	peters	peters	PROPN
fnp-3395	240	2	at	at	ADP
fnp-3395	240	3	,	,	PUNCT
fnp-3395	240	4	mutharasan	mutharasan	ADJ
fnp-3395	240	5	rk	rk	NOUN
fnp-3395	240	6	.	.	PROPN
fnp-3395	240	7	aspirin	aspirin	PROPN
fnp-3395	240	8	for	for	ADP
fnp-3395	240	9	prevention	prevention	NOUN
fnp-3395	240	10	of	of	ADP
fnp-3395	240	11	cardiovascular	cardiovascular	ADJ
fnp-3395	240	12	disease	disease	NOUN
fnp-3395	240	13	.	.	PUNCT
fnp-3395	241	1	jama	jama	PROPN
fnp-3395	241	2	.	.	PUNCT
fnp-3395	242	1	2020;323(7):676	2020;323(7):676	NUM
fnp-3395	242	2	.	.	NOUN
fnp-3395	243	1	46	46	NUM
fnp-3395	243	2	.	.	PUNCT
fnp-3395	244	1	chow	chow	PROPN
fnp-3395	244	2	jh	jh	PROPN
fnp-3395	244	3	,	,	PUNCT
fnp-3395	244	4	khanna	khanna	PROPN
fnp-3395	244	5	ak	ak	PROPN
fnp-3395	244	6	,	,	PUNCT
fnp-3395	244	7	kethireddy	kethireddy	PROPN
fnp-3395	244	8	s	s	PROPN
fnp-3395	244	9	,	,	PUNCT
fnp-3395	244	10	et	et	PROPN
fnp-3395	244	11	al	al	PROPN
fnp-3395	244	12	.	.	PROPN
fnp-3395	244	13	aspirin	aspirin	PROPN
fnp-3395	244	14	use	use	NOUN
fnp-3395	244	15	is	be	AUX
fnp-3395	244	16	associated	associate	VERB
fnp-3395	244	17	with	with	ADP
fnp-3395	244	18	decreased	decrease	VERB
fnp-3395	244	19	mechanical	mechanical	ADJ
fnp-3395	244	20	ventilation	ventilation	NOUN
fnp-3395	244	21	,	,	PUNCT
fnp-3395	244	22	intensive	intensive	ADJ
fnp-3395	244	23	care	care	NOUN
fnp-3395	244	24	unit	unit	NOUN
fnp-3395	244	25	admission	admission	NOUN
fnp-3395	244	26	,	,	PUNCT
fnp-3395	244	27	and	and	CCONJ
fnp-3395	244	28	in	in	ADP
fnp-3395	244	29	-	-	PUNCT
fnp-3395	244	30	hospital	hospital	NOUN
fnp-3395	244	31	mortality	mortality	NOUN
fnp-3395	244	32	in	in	ADP
fnp-3395	244	33	hospitalized	hospitalize	VERB
fnp-3395	244	34	patients	patient	NOUN
fnp-3395	244	35	with	with	ADP
fnp-3395	244	36	coronavirus	coronavirus	NOUN
fnp-3395	244	37	disease	disease	NOUN
fnp-3395	244	38	2019	2019	NUM
fnp-3395	244	39	.	.	PUNCT
fnp-3395	245	1	anesthesia	anesthesia	PROPN
fnp-3395	245	2	&	&	CCONJ
fnp-3395	245	3	analgesia	analgesia	PROPN
fnp-3395	245	4	.	.	PUNCT
fnp-3395	246	1	2021;132(4	2021;132(4	NUM
fnp-3395	246	2	)	)	PUNCT
fnp-3395	246	3	.	.	PUNCT
fnp-3395	247	1	47	47	NUM
fnp-3395	247	2	.	.	PUNCT
fnp-3395	248	1	saleh	saleh	PROPN
fnp-3395	248	2	e	e	NOUN
fnp-3395	248	3	,	,	PUNCT
fnp-3395	248	4	moody	moody	PROPN
fnp-3395	248	5	ma	ma	PROPN
fnp-3395	248	6	,	,	PUNCT
fnp-3395	248	7	walter	walter	PROPN
fnp-3395	248	8	eb	eb	PROPN
fnp-3395	248	9	.	.	PROPN
fnp-3395	249	1	effect	effect	NOUN
fnp-3395	249	2	of	of	ADP
fnp-3395	249	3	antipyretic	antipyretic	ADJ
fnp-3395	249	4	analgesics	analgesic	NOUN
fnp-3395	249	5	on	on	ADP
fnp-3395	249	6	immune	immune	ADJ
fnp-3395	249	7	responses	response	NOUN
fnp-3395	249	8	to	to	ADP
fnp-3395	249	9	vaccination	vaccination	NOUN
fnp-3395	249	10	.	.	PUNCT
fnp-3395	250	1	human	human	ADJ
fnp-3395	250	2	vaccines	vaccine	NOUN
fnp-3395	250	3	&	&	CCONJ
fnp-3395	250	4	immunotherapeutics	immunotherapeutic	NOUN
fnp-3395	250	5	.	.	PUNCT
fnp-3395	251	1	2016;12(9):2391	2016;12(9):2391	NUM
fnp-3395	251	2	-	-	SYM
fnp-3395	251	3	2402	2402	NUM
fnp-3395	251	4	.	.	PUNCT
fnp-3395	252	1	copyright	copyright	NOUN
fnp-3395	252	2	:	:	PUNCT
fnp-3395	252	3	©	©	PROPN
fnp-3395	252	4	2021	2021	NUM
fnp-3395	252	5	the	the	DET
fnp-3395	252	6	author(s	author(s	NOUN
fnp-3395	252	7	)	)	PUNCT
fnp-3395	252	8	.	.	PUNCT
fnp-3395	253	1	this	this	PRON
fnp-3395	253	2	is	be	AUX
fnp-3395	253	3	an	an	DET
fnp-3395	253	4	open	open	ADJ
fnp-3395	253	5	access	access	NOUN
fnp-3395	253	6	article	article	NOUN
fnp-3395	253	7	distributed	distribute	VERB
fnp-3395	253	8	under	under	ADP
fnp-3395	253	9	the	the	DET
fnp-3395	253	10	terms	term	NOUN
fnp-3395	253	11	of	of	ADP
fnp-3395	253	12	the	the	DET
fnp-3395	253	13	creative	creative	ADJ
fnp-3395	253	14	commons	common	NOUN
fnp-3395	253	15	attribution	attribution	NOUN
fnp-3395	253	16	4.0	4.0	NUM
fnp-3395	253	17	international	international	ADJ
fnp-3395	253	18	license	license	NOUN
fnp-3395	253	19	(	(	PUNCT
fnp-3395	253	20	https://creativecommons.org/licenses/by/4.0/	https://creativecommons.org/licenses/by/4.0/	PROPN
fnp-3395	253	21	)	)	PUNCT
fnp-3395	253	22	,	,	PUNCT
fnp-3395	253	23	which	which	PRON
fnp-3395	253	24	permits	permit	VERB
fnp-3395	253	25	unrestricted	unrestricted	ADJ
fnp-3395	253	26	use	use	NOUN
fnp-3395	253	27	,	,	PUNCT
fnp-3395	253	28	distribution	distribution	NOUN
fnp-3395	253	29	,	,	PUNCT
fnp-3395	253	30	and	and	CCONJ
fnp-3395	253	31	reproduction	reproduction	NOUN
fnp-3395	253	32	in	in	ADP
fnp-3395	253	33	any	any	DET
fnp-3395	253	34	medium	medium	NOUN
fnp-3395	253	35	,	,	PUNCT
fnp-3395	253	36	provided	provide	VERB
fnp-3395	253	37	the	the	DET
fnp-3395	253	38	original	original	ADJ
fnp-3395	253	39	author	author	NOUN
fnp-3395	253	40	and	and	CCONJ
fnp-3395	253	41	source	source	NOUN
fnp-3395	253	42	are	be	AUX
fnp-3395	253	43	credited	credit	VERB
fnp-3395	253	44	,	,	PUNCT
fnp-3395	253	45	a	a	DET
fnp-3395	253	46	link	link	NOUN
fnp-3395	253	47	to	to	ADP
fnp-3395	253	48	the	the	DET
fnp-3395	253	49	creative	creative	ADJ
fnp-3395	253	50	commons	common	NOUN
fnp-3395	253	51	license	license	NOUN
fnp-3395	253	52	is	be	AUX
fnp-3395	253	53	provided	provide	VERB
fnp-3395	253	54	,	,	PUNCT
fnp-3395	253	55	and	and	CCONJ
fnp-3395	253	56	any	any	DET
fnp-3395	253	57	changes	change	NOUN
fnp-3395	253	58	are	be	AUX
fnp-3395	253	59	indicated	indicate	VERB
fnp-3395	253	60	.	.	PUNCT
fnp-3395	254	1	the	the	DET
fnp-3395	254	2	creative	creative	ADJ
fnp-3395	254	3	commons	common	NOUN
fnp-3395	254	4	public	public	ADJ
fnp-3395	254	5	domain	domain	NOUN
fnp-3395	254	6	dedication	dedication	NOUN
fnp-3395	254	7	waiver	waiver	NOUN
fnp-3395	254	8	(	(	PUNCT
fnp-3395	254	9	https://creativecommons.org/publicdomain/zero/1.0/	https://creativecommons.org/publicdomain/zero/1.0/	PROPN
fnp-3395	254	10	)	)	PUNCT
fnp-3395	254	11	applies	apply	VERB
fnp-3395	254	12	to	to	ADP
fnp-3395	254	13	the	the	DET
fnp-3395	254	14	data	datum	NOUN
fnp-3395	254	15	made	make	VERB
fnp-3395	254	16	available	available	ADJ
fnp-3395	254	17	in	in	ADP
fnp-3395	254	18	this	this	DET
fnp-3395	254	19	article	article	NOUN
fnp-3395	254	20	,	,	PUNCT
fnp-3395	254	21	unless	unless	SCONJ
fnp-3395	254	22	otherwise	otherwise	ADV
fnp-3395	254	23	stated	state	VERB
fnp-3395	254	24	.	.	PUNCT